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Liver fibrosis has a range of aetiologies and is a global cause of mortality.  A 
critical effect of liver fibrosis which also increases mortality is portal 
hypertension. The hepatic stellate cell is accepted as a major progenitor of liver 
myofibroblasts, which have been shown to be a major source of collagen and 
extracellular matrix proteins that disrupt liver architecture and function.  Relaxin 
is a hormone involved in remodelling of extracellular matrix in the uterus and 
cervix and is known to increase renal blood flow in pregnancy.  It has been 
implicated in the regulation of fibrosis in animal models and to modify the cell 
biology of hepatic stellate cells in vitro.  I have demonstrated the profile of 
expression of relaxin receptors in primary human stellate cells (HSC), showing 
them to express RXFP-1, 3 and 4. Using a cAMP assay I confirm these receptors 
to be functional, with RXFP-1 positively and RXFP-3 and 4 negatively coupling 
to cAMP.  The expression of RXFP-1 is coupled with the level of activation, 
demonstrating a possible role for H2-relaxin in the regulation of HSC.  I have 
established a dynamic regulation of fibrotic mediators and HSC activation 
markers, including a reduction in α-SMA, TIMP-1 and TGF-β with increases in 
MMP-1 and MMP-2, consistent with H2-relaxin having potentially therapeutic 
antifibrotic effects by increasing the fibrolytic phenotype.  In addition through 
the use of gel contraction assays I demonstrate that H2-relaxin reduces serum or 
endothelin-1 induced HSC contraction.  Through the use of siRNA I have 
confirmed that H2-relaxin mediates its regulation of fibrotic mediators and HSC 
activation markers as well as the inhibition of gel contraction through the relaxin 
receptor RXFP-1.  I have evidence to suggest that the inhibition of contraction 
may in part be via nitric oxide release in HSC.  In conclusion I propose that 
RXFP-1 is a potential therapeutic target in end stage human liver disease, 
targeting fibrosis and portal blood hypertension via both resolution of the 
phenotypic collagen deposition and vascular constriction associated with the 
human hepatic stellate cell. 
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Chapter 1  
 
Introduction 
 
 
 
 
 
                                                                                            Chapter 1: Introduction 
  2
1.1 The burden of chronic liver disease, a worldwide ‘epidemic’ 
 
Chronic Liver disease (CLD) is a worldwide public health problem. In the UK 
deaths from CLD have increased eight times in men and seven times in women 
over the last three decades (Chief medical officer’s report, 2001).  The disease 
burden of CLD in the UK, encompassing a number of aspects including 
frequency, longevity, morbidity, mortality, quality of life and finance, is likely to 
be underestimated at the present time and is only set to increase in the coming 
decades. CLD is characterised by chronic damage to the liver, which can lead to 
irreversible scarring eventually impairing its normal function.  The extent of 
injury increases over time with the persistence of injurious stimuli and ultimately 
leads to liver failure and the need to transplant if left untreated.  This is 
associated with serious physical and psychological morbidity and mortality and 
cost to the National Health Service. CLD has many different aetiologies ranging 
from viral hepatitis to autoimmune diseases.  
 
In the UK mortality rates from CLD are eleven per one hundred thousand and 
rising.  In the year 2000 over seventeen percent of deaths due to CLD were from 
alcoholic liver disease (ALD) but increasingly non-alcoholic fatty liver disease 
(NAFLD), as a result of the relatively recent epidemic of obesity and increasing 
levels of type 2 diabetes, is fast becoming a major problem.  The group with the 
poorest outcome also represent the patients with alcoholic liver disease (ALD), 
especially if this is combined with hepatitis C infection and obesity, and 
consequently these patients are more likely to have secondary complications.  
The five year survival rate for patients without complications given a transplant 
is 75% but if they develop secondary complications it is reduced to less then 
50% (Roderick, 2004). In the US between 1997 and 2002, seventy two people 
per one hundred thousand were diagnosed with CLD which made it the tenth 
leading cause of death. Hepatitis C and alcoholic cirrhosis made up over 80% of 
the diagnosed cases (Kim, 2002). 
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The scale of the problem is almost certainly being underplayed by these statistics 
as the number of cases that are not diagnosed is still relatively high.  Many 
people are asymptomatic for many years due to the time it takes from initial 
injury, e.g. Hepatitis C infection, to evolution to cirrhosis leaving the disease 
undetected for many years.  Many patients only present at clinic with advanced 
fibrosis or cirrhosis when much of the function and regenerative capacity of the 
liver has been lost.  The largest groups of people that develop end stage chronic 
liver disease are traditionally the ‘hard to reach patients’ such as intravenous 
drug users and may go undiagnosed even after death (Roderick et al., 2004). 
 
There is clear evidence that better diagnostics and treatments that can slow the 
progression of the disease are urgently needed, as there is already a shortage of 
donor organs and this treatment does not come without its own risks and 
complications. 
 
1.2 The causes of liver disease 
 
 
 
Figure 1.1. Flow diagram outlining the main causes of liver disease which will be 
discussed in further detail below. 
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1.2.1 Persistent Viral Infection 
 
The term viral hepatitis is used to encompass the infection of the liver by a group 
of viruses that have particular affinity for the liver. At present there are six 
hepatitis viruses known to infect humans and they have been classed A-G.  
Hepatitis B and C are the most common cause of chronic liver disease and 
cirrhosis worldwide.  There are other systemic viral infections that can affect the 
liver, for example yellow fever and the Epstein Barr virus, but these do not carry 
a chronic risk of liver damage (Kumar et al., 2005).   
 
Hepatitis A virus (HVA) is self limiting disease with an incubation period of 2-6 
weeks.  It is spread by ingesting contaminated food or water and outbreaks are 
usually in areas where people live in close contact and in unsanitary conditions.  
The HVA infectious agent is a small non-enveloped single stranded RNA 
picornavirus that occupies its own genus, ultrastructurally it is a icosahedral 
capsid around 27 nm in diameter and does not cause chronic hepatitis (Cuthbert, 
2001). Hepatitis E virus (HEV) is similar to HAV due to transmission being 
through water-borne infection.  A characteristic of HEV is a high mortality rate 
among pregnant women, which approaches 20%.  HEV is an un-enveloped 
single stranded RNA virus with an average incubation period of around 6 weeks. 
The RNA genome is around 7.6 kb and the active infection can cause acute 
hepatitis but is not persistent or chronic (Mast and Krawczynski, 1996).  
Hepatitis D virus (HDV) is a unique single stranded RNA virus that is 
replication defective and will only cause infection if co-infected with HBV.  The 
virus is then encapsulated by the hepatitis B surface antigen and is then 
dependent on the genetic information provided by the HBV virus for 
multiplication and infectivity.  The co-infection can increase the risk of 
developing fulminant disease then with HBV alone.  The co-infection can also 
cause acute severe hepatitis in previously healthy carriers of HBV and chronic 
progressive disease culminating in cirrhosis develops in 80% of patients 
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It is a single stranded RNA virus that is transmitted through contaminated blood 
or possibly sexual contact.  In 75% of infection HGV is cleared from the plasma, 
the remaining cases become chronic.  The site of replication is more likely to be 
the mononuclear cells and therefore has been inappropriately named.  Infection 
does not cause damage to the liver and in fact to date no pathological effects of 
the virus have been found.  It is commonly co-infected with HIV and 
surprisingly can show some protective affects against the HIV disease 
(Pomerantz and Nunnari, 2004). 
 
Hepatitis B virus (HBV) is a particular problem when considering liver fibrosis.  
A member of the hepadanavirus family containing semi-double stranded circular 
DNA, the mature HBV is a 42 nm spherical double layered Dane particle that 
has an outer surface envelope of protein, lipid and carbohydrate which encloses 
an electron dense core.  The DNA molecule comprises 3200 nucleotides and all 
of the HBV genome encodes protein (Ganem and Prince, 2004).  HBV is a 
major global problem, there are around 350 million chronic hepatitis B carriers 
worldwide and it is estimated that the virus has infected over 2 billion 
individuals alive today at some point in their life.  In the UK the rate of infection 
is around 1 in 1000.  75% of all chronic carriers live in Asia and the Pacific Rim 
but in the United States there are an estimated 185,000 new infections per year 
(Kim, 2002).  HBV has a prolonged incubation of 4-26 weeks and the virus 
remains in the blood during all active episodes of acute or chronic hepatitis.  
HBV is a hardy virus and can be transmitted not only through blood and body 
fluids but also secretions such as semen, saliva, sweat, tears and breast milk.  
There is an effective vaccination against the virus due to the circulating host 
antibodies effectively neutralising HBV.  The vaccine has been effective at 
reducing prevalence in endemic areas and in people at risk such as health care 
professionals.  HBV can cause acute hepatitis with resolution, chronic hepatitis 
that may go on to develop cirrohsis and/or hepatocellular carcinoma (HCC), 
fulminant hepatitis with massive hepatocyte necrosis and is also the backdrop for 
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through two phases.  The proliferative phase, when the virus is actively 
replicating inside the hepatocyte, causes a massive influx of lymphocytes (CD8 
+ cytotoxic T cells), activation of the immune response and increase 
necrosis/destruction of the hepatocytes.  The next phase is the integrative phase 
where hepatocytes that were infected but not destroyed by the cytotoxic T cells 
incorporate the viral DNA into the host genome.  This reduces the immune 
response due to the cessation of viral replication and the damage to the liver 
subsides, but now there is an increased risk of developing HCC (Chisari, 2000).  
 
Hepatitis C virus (HCV) is also a major cause of fibrosis, it is an enveloped virus 
carrying a positive strand RNA genome, an estimated 3% of the worlds 
population carry the virus around 200 million (70%) of these chronically (Mast 
et al., 1999).  It is transferred via blood-blood contact, around 60-90% of 
intravenous drug users carry the virus. There is no vaccination available for 
HCV unlike HBV (Fabris et al., 1999).  These statistics make HCV the most 
common of all blood-borne infections and accounts for around half of all chronic 
liver disease patients in the United States (Kim et al., 2002).  HCV is closely 
related to the Hepatitis G virus (HGV), they are both hepacivirus in the 
flaviviradae family.  HCV is an RNA virus with a genome of 9kb that encodes 
for a single poly-protein of about 3010 amino acids in one single open reading 
frame.  This single protein then undergoes post translational processing to 
produce functional highly conserved proteins and six less conserved proteins 
with unknown function.  The HCV virus genome is inherently unstable which 
enables mutations to take place and this gives rise to many different subtypes of 
the virus. This is why there is no vaccine to the HCV virus unlike the HBV virus 
which is a more stable DNA virus (Farci P, 2008).  The initial incubation period 
for HCV is 2-26 weeks.  The initial infection is usually less severe then HBV 
infection but due to the HCV ability to evade the hosts immune system, 
persistent reinfection and chronic hepatitis is more common in HCV affected 
patients and cirrhosis may develop 5-20 years after the initial acute infection.  
Over the next decade HCV may become the leading cause of chronic liver                                                                                            Chapter 1: Introduction 
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disease in the western world (Farci P, 2008).  Hepatitis, particularly HCV, can 
lead to chronic liver injury resulting in fibrosis.  Regardless of aetiology fibrosis 
can become progressive and lead to cirrhosis.  Therefore combining viral 
therapies with antifibrotic therapies such as H2-relaxin, may augment the benefit 
previously observed from removing the cause of liver damage. 
 
1.2.2 Alcohol and Toxic Damage 
 
Excessive alcohol consumption is currently the number one cause of liver 
disease in the western world.  This highlights the major differences in lifestyle 
between westernised society and the rest of the world, when considering liver 
disease.  There are three forms of alcoholic liver disease, hepatic steatosis (fatty 
liver), alcoholic hepatitis and alcoholic cirrhosis.  Steatosis and hepatitis can be 
independent from one another but cirrhosis represents the end stage of either of 
the first two conditions.  Ethanol and its metabolites can cause fatty change 
through the increased catabolism of fat by peripheral tissues causing increased 
delivery of free fatty acids to the liver causing massive enlargement.  Ethanol 
and its metabolites are also believed to be directly toxic to hepatocytes 
(Tsukamoto and Lu, 2001;Lands, 1995b).  This toxicity is understood to be 
mediated by glutathione depletion, mitochondrial injury, altered metabolism of 
methionine and cytokine release from Kupffer cells, which then activates HSC.   
Ethanol is believed to cause damage at the site of metabolism from ethanol to 
acetylaldehyde.  This metabolism is performed by nicotinamide adenine 
dinucleotide (NAD+) dependent enzyme, alcohol dehydrogenase (Zakhari and 
Li, 2007).  This reaction is performed by alchohol dehydrogenase in the cytosol 
of the gastric mucosa but can also be performed by cytochrome P-450 
(CYP2E1) in liver microsomes and catalase in the liver peroxisomes.  Induction 
of cytochrome P-450 and in particular CYP2E1, increases the catabolism of 
ethanol and other drugs such as paracetamol in the endoplasmic reticulum, 
increasing the levels of toxic metabolites and reactive oxygen species in the liver 
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toxic acetylaldehyde to acetic acid in the mitochondria and this process also 
requires NAD+.  The consumption of large amounts of alcohol depletes the 
oxidised NAD+ and causes an excess of the reduced NADH in the liver causing 
a build up of toxic acetylaldehyde within the cytosol of the hepatocytes (Zakhari 
and Li, 2007).  An excess of NADH over NAD not only reduces the conversion 
of ethanol to acetic acid but can also stimulate lipid biosynthesis and the 
oxidation of fatty acids by the mitochondria is decreased.  Alcohol induced 
impaired metabolism of methionine leads to decreased intrahepatic levels of 
glutathione (GSH) which sensitises the liver to oxidative injury.  Acetylaldehyde 
is toxic due to the formation of adducts with tubulin, this impairs the function of 
microtubules which results in the decreased transport of lipoproteins from the 
liver.  Antibodies to these adducts have been detected in alcoholics suggesting 
an autoimmune component causing inflammation of the liver and immune 
mediated hepatocellular injury. (Adducts are the parts of a metabolised protein 
that may retain an electrophilic carbonyl group or neutrophilic groups that then 
attenuate the toxicity of the toxic stimuli within the hepatocytes) (Viitala et al., 
2000;Rolla et al., 2000).  
 
 
 
Figure 1.2. Adapted from (Zakhari and Li, 2007).  Schematic showing the four 
compartments peroxisomes, cytosol, endoplasmic reticulum and the mitochondria as 
sites of ethanol metabolism in the liver.  The liver has a limited capacity to oxidise 
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during high exposure to ethanol the acetate is released into the circulation and 
transported to organs such as the heart, skeletal muscle and the brain, that have a high 
capacity to utilize the TCA cycle for this function.   
 
Alcohol increases the permeability of the intestine to bacterial endotoxin, 
increasing the content in the portal circulation and therefore increasing 
inflammation within the liver.  The inflammation is caused by the activation of 
Kupffer cells (liver macrophages).  The activation of Kupffer cells will initiate 
the activation of HSC from a quiescent to myofibroblast like state. This process 
will exacerbate fibrosis in the liver (Thurman, 2000). Alcohol can also induce 
the release of endothelins from the sinusoidal endothelial cells.  Endothelins are 
potent vasoconstrictors and the hepatic stellate cells in the Space of Disse can 
react to endothelin by contracting, which can reduce hepatic sinusoidal perfusion 
causing hypoxia to the regions of hepatocytes that are cut off from the 
circulation (Rockey, 2001;Rockey and Weisiger, 1996).  Alcoholic liver disease 
is a chronic disorder that is marked by the derangement of vascular perfusion 
when the disease manifests to alcoholic cirrhosis.  Alcohol is a source of calories 
and in many alcoholics can replace the intake of food, which displaces other 
nutrients and vitamins leading to malnutrition and vitamin deficiencies (Lands, 
1995a).  Alcoholic cirrhosis is similar to other forms of cirrhosis with a common 
feature of portal hypertension (Geerts et al., 2008).   Portal hypertension is a 
lethal condition that leads to the development of ascites and varices which can 
lead to fatal infection in the oedema of the abdomen or blood loss respectively 
(Williams and Iredale, 1998). 
 
1.2.3 Hereditary Conditions Leading to Fibrosis 
 
A significant number of cases of liver fibrosis can be attributed to hereditary 
diseases such as Wilson disease, hemochromatosis and α1 antitrypsin deficiency.  
Wilson disease is a autosomal recessive disorder resulting from the bodies 
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in the cytoplasm of the hepatocytes (Schaefer et al., 1999;Llanos and Mercer, 
2002)  The disease usually presents in late childhood with viral-hepatitis like 
symptoms.  Wilson disease also causes an accumulation of copper throughout 
the body but particularly in the liver, connective tissue, eye and the brain.  The 
gene for Wilson disease, designated ATP7B, is on chromosome 12 and encodes 
a 7.5kb transcript for a transmembrane copper transporting ATPase, located on 
the hepatocyte canalicular membrane (Llanos and Mercer, 2002).  Over 30 
mutations of this gene have been identified and the majoritiy of patients are 
heterozygotes with different mutations on each allele.  Defective biliary 
excretion leads to accumulation of copper in excess of the metallothionein-
binding capacity.  The accumulation becomes toxic when there is a formation of 
reactive oxygen species catalyzed by copper.  There is usually a lag period of 
around 5 years before clinical symptoms of the disease appear.  The most 
common presentation is acute or chronic liver disease with increased hepatic 
copper levels and increased urinary excretion but in many cases there may also 
be mild behavioural changes or a Parkinson disease like syndrome due to the 
increased deposition of copper in the brain.  Early diagnosis and the long term 
use of copper chelation therapy has changed the outcome for many patients that 
in the past would have experienced a progressive chronic hepatitis and 
unmanageable cirrhosis with a transplant being the only treatment option 
(Llanos and Mercer, 2002).  
 
Hemochromatosis can be caused by a hereditary condition that affects the 
absorption of dietary iron resulting in elevated levels of serum iron.  This 
condition can lead to a progressive increase in the iron absorbed and depositied 
within parenchymal cells of the liver (hepatocytes) and other organs such as the 
pancreas and heart.  Humans do not have a major iron excretory pathway and are 
therefore particularly susceptible to iron accumulation.  In the normal body there 
is 2-6 grams of iron with 0.5 grams being stored in the liver and 98% of this in 
the hepatocytes.  Fully developed cases of hereditary hemochromatosis can have 
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liver.  Fully developed cases can take as long as 50-60 years to develop 
symptoms and they will all have micronodular cirrhosis, 75-80% will have 
diabetes and 75-80% will have skin pigmentation (Fletcher and Halliday, 2002).   
The hereditary condition is due to the mutation of the HFE gene, located on 
chromosome 6 close to the HLA gene locus (Philpott, 2002). The HFE gene 
encodes a HLA-class 1 like molecule, expressed in the small intestinal crypt 
epithelial cells where it complexes with a transferrin receptor enabling the 
binding of plasma transferrin and its bound iron which is then endocytosed into 
the regulatory pool in the crypt cell. The mutation of the HFE protein abolishes 
the crypt cells ability to remove iron from the circulation.  This system also acts 
as the sensing mechanism for systemic iron balance as well as the regulatory 
iron pool that can set the level of apical iron uptake required (Pietrangelo, 2002).  
Therefore the system that regulates dietary iron absorption is no longer regulated 
by the amount of iron in the systemic circulation leading to iron overload.  The 
most common mutation found in 70-100% of cases is the C282Y mutation 
which substitutes a cysteine to a tyrosine in position 282 of the amino acid 
sequence, which inactivates the protein.  Hereditary hemochromatosis is one of 
the most common genetic disorders but penetrance even with homozygotes for 
the C282Y mutation is still only 20%.  Males are over 5 times more likely to 
develop the disease and it tends to be more severe with earlier presentation of 
symptoms due to women undergoing physiological loss of iron, preventing 
accumulation (Philpott, 2002).  The disease can manifest after 20 grams of iron 
is stored which is thought to be directly toxic to the tissue through lipid 
peroxidation by iron catalysed free radicals, the stimulation of collagen synthesis 
and the interaction of reactive oxygen species (ROS) and iron with DNA leading 
to lethal injury and the increased predisposition to hepatocellular carcinoma 
(HCC) (Houglum et al., 1994).   Secondary hemochromatosis is the name given 
to any condition that results in iron overload that is not through the gene 
mutation.  Conditions such as haemolytic anemias require repeated blood 
transfusions. Left untreated they result in an increased level of iron (iron                                                                                            Chapter 1: Introduction 
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overload) in the body.  These conditions are classified as a secondary 
hemochromatosis (Chandrasoma and Taylor, 2005). 
 
α1 Antitrypsin is a small 394 amino acid glycoprotein, synthesized mainly by 
hepatocytes.  Its main function is as a protease inhibitor of proteins such as 
elastase, cathepsin G and proteinase 3, which are normally secreted by 
neutrophils at the site of inflammation (Fairbanks and Tavill, 2008).  α1 
Antitrypsin deficiency is an autosomal recessive disorder that manifests with 
low serum levels of this important protein, which can cause tissue destructive 
enzymes to become unregulated and this can affect the lung causing pulmonary 
emphysema (Fairbanks and Tavill, 2008).  Patients can also be susceptible to 
developing liver disease, although liver disease will usually only affect neonates 
and young adults and has a distinct mechanism compared to the affect in the 
lung (Perlmutter, 2002;Fairbanks and Tavill, 2008).  The gene for α1 antitrypsin 
is located on chromosome 14 and is very polymorphic.  Up to 75 different 
genotypes have been found for the protein, some that cause the deficiency and 
some that have no obvious phenotype.  Deficiency variants exhibit a defect in 
the migration of the translated protein from the endoplasmic reticulum to the 
Golgi apparatus (Teckman et al., 2002).  Only 10% of the individuals with this 
deficiency variant will exhibit liver disease and this is due to these individuals 
exhibiting a lag in the endoplasmic reticulum protein degradation pathway.  This 
pathway is essential for quality control, detecting and degrading proteins that 
have been misfolded or misassembled.  The accumulated protein in the 
hepatocytes is not toxic per se and the liver does not suffer from the lack of 
protease inhibitor as it is secreted into the circulation for use in other organs 
(Perlmutter, 2002).  The cells response to the lag in the degradation pathway is 
to increase the autophagocytic response in the hepatocytes.  This intense 
autophagocytic response that may affect the mitochodria of the hepatocytes is 
probably the cause of hepatocytoxicity in this syndrome.  Neonatal hepatitis with 
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hepatitis may subside to full recovery but in a small number of patients the 
injury becomes chronic and may lead to cirrhosis (Teckman et al., 2002).   
 
1.2.4 Non-alcoholic fatty liver disease (NAFLD)  
 
Non-alcoholic steatohepatitis (NASH) has been recognised as a major cause of 
liver fibrosis, it is considered part of the spectrum of non-alcoholic fatty liver 
disease (NAFLD) (Clark et al., 2002).  NASH is characterised by the presence of 
histological features of steatohepatitis in the absence of significant alcohol 
consumption.  Non-alcoholic liver diseases range from steatosis to cirrhosis and 
can eventually lead to hepatocarcinoma.  Cirrhosis is present in 10-20% of 
patients at diagnosis (Bataller and Brenner, 2005).  NASH is a component of the 
metabolic syndrome, which is characterised by obesity, type-2 diabetes mellitus 
with insulin resistance as a common feature (Kanda et al., 2005).  Men and 
women are equally affected and patients are largely asymptomatic. NAFLD is 
thought to account for 70% of chronic hepatitis of unknown cause and 10-30% 
of these patients will develop cirrhosis.  There is also evidence that NAFLD can 
contribute to the progression of other liver diseases, such as HCV infection and 
alcoholic liver disease (Clark et al., 2002).   
 
1.3 Normal architecture of the liver and biliary tract 
 
1.3.1 Normal liver and biliary tract physiology 
 
The word hepatic is often used to describe medical terms relating to the liver.  
Hepatic comes from the Greek word hĕpar, meaning repairable, indicating this 
organ can regenerate itself spontaneously in the case of a lesion.  Basic anatomy 
divides the liver into four lobes and two ligaments (figure 1.3). The left and right 
anatomical lobes can be seen from the anterior side and the caudate (superior) 
above the quadrate lobe can be seen from the inferior side (Saxena et al., 1999).  
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vein carrying blood out of the liver.  The two ligaments are the falciform and the 
teres ligament.  The falciform ligament attaches the liver to the anterior 
abdominal wall and the diaphragm and the ligament teres extends from the 
falciform to the umbilicus.  The liver is encapsulated with a network of 
connective tissue named the Glissons capsule (Rapport., 1958;Saxena et al., 
1999). 
 
 
 
Figure 1.3. Basic anatomy of the liver (a) anterior view (b) inferior view, adapted from 
(Saxena et al., 1999). 
 
 The liver has a major role in regulating metabolism with many functions such as 
glycogen storage, decomposition of red blood cells, plasma protein synthesis, 
detoxification and the production of bile, which aids digestion and 
emulsification of lipids (Rapport., 1958;Saxena et al., 1999).  At any one time 
the liver contains an eighth of the body’s blood supply, which means it must 
have a good and uninterrupted circulation.  60-80% of the blood flow is from the 
portal venous system.  The portal venous system is generated from the splenic 
vein joining the inferior mesenteric vein, which then joins the superior 
mesenteric vein forming the hepatic portal vein.  This system brings venous 
blood from the spleen, stomach, pancreas and the small and large intestines and                                                                                            Chapter 1: Introduction 
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the liver processes the blood for nutrients and toxins.  The hepatic vein then 
drains directly into the inferior vena cava.  The hepatic artery usually branches 
from the celiac trunk but can branch from the superior mesenteric artery (Saxena 
et al., 1999).  The remaining 20-40% of the blood is supplied by the hepatic 
artery.  The blood is transported further into the liver through portal venules and 
hepatic arterioles, which enter the lobules or acini, which have vessels called 
capillaries or sinusoids that are perforated by fenestrae.  The capillaries and 
sinusoids separate the circulating blood from the hepatocytes (Saxena et al., 
1999).  The space between the sinusoid and the hepatocytes is called the Space 
of Disse, this is where the hepatic stellate cells reside and this is the region that 
allows the flow of solutes important for hepatic function to and from the 
hepatocytes (figure 1.4a).  This flow is extremely important for the normal 
function of the liver and in some disease states the flow is disrupted through the 
build up extra cellular matrix causing the fenestrae of the epithelial layer to be 
become blocked (figure 1.4b) (RAPPAPORT, 1958;Saxena et al., 1999).  
 
 
 
Figure 1.4. Schematic representation of the blood flow from the hepatic sinusoid to the 
hepatocytes in (a) normal and (b) fibrotic liver. Dotted line represents flow of solutes, 
which is blocked in the fibrotic liver. 
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An important role of the liver is to produce bile and this is collected in the 
canaliculi which merge to form bile ducts (Tsukada et al., 1995).  The bile ducts 
run into the left and right hepatic ducts which in turn merge into the common 
hepatic duct.  The cystic duct then merges with the common hepatic duct to form 
the common bile duct which drains in the duodenum or the gall bladder.  In 
some cases of liver disease the bile ducts proliferate which can be seen very 
easily in biopsy specimens.  The normal bile duct to portal tract ratio is 1:1, but 
in cases of obstruction in the biliary tract and some metabolic disorders the 
number of bile ducts is obviously increased (figure 1.5) (Tsukada et al., 
1995;Crawford, 2002).   
 
 (a)        (b)     
 
Figure 1.5. (a) A portal triad encompassing the portal vein (blue arrow), hepatic artery 
(yellow arrow) and a bile duct (black arrow) (b) A portal triad where the bile ducts 
(black arrows) have proliferated around the hepatic vein (blue arrow)                                                                
 
1.3.2 The cell cycle and proliferation in the liver 
 
The cell cycle consists of G1 (presynaptic), S (DNA synthesis), G2 (premitotic), 
M (mitotic), and G0 (quiescent) and most mature tissue will have a population of 
cells that occupy different phases of the cycle (figure 1.6) (Kumar et al., 2005).  
Adult tissue determines the cell population through the rate of cell proliferation, 
differentiation and death by apoptosis.  Apoptosis can be induced by pathogenic 
stimuli, differentiation depends on the cell type and circumstance, for example 
neurons are terminally differentiated cells that have left the cell cycle but liver                                                                                            Chapter 1: Introduction 
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hepatocytes are normally quiescent cells that still retain the ability to divide and 
cell proliferation can occur from stem cells or normally quiescent cells and can 
be stimulated by physiologic and pathologic conditions.  Cell proliferation can 
become excessive in pathological conditions causing conditions such as prostatic 
hyperplasia (Mullauer et al., 2001).  Cell proliferation is largely controlled 
through signals, either soluble or contact dependent.  These signals can either 
stimulate or inhibit cell proliferation.  Accelerated growth can be through excess 
stimulators or deficiency of inhibitors which shortens the cell cycle.  The most 
important mechanism for repairing tissue is the conversion of resting cells 
(quiescent hepatocytes) in to proliferating cells (Becker and Lane, 1968;Becker, 
1970).  There are three main cell types that populate the body, continuously 
dividing for example the epithelia of the gut, quiescent cells such as hepatocytes 
in the liver and non dividing cells such as neurons and cardiac muscle cells.  
Continuously dividing cells are constantly in the cell cycle and the mature cells 
in most tissues are derived from stem cells which have an unlimited capacity to 
proliferate.  Quiescent or stable cells have a low level of replication in normal 
conditions, they are in G0 in the cell cycle but can be stimulated to enter G1 and 
rapidly proliferate if required to repopulate damaged areas of the tissue.  Non-
dividing or permanent cells have left the cell cycle and cannot undergo mitotic 
division.  Tissue that is largely made up of non-dividing cells will have little or 
no regenerative capacity and any repair will be through scar formation (Kumar 
et al., 2005).   
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Figure 1.6. Schematic of the cell cycle adapted from (Kumar et al., 2005).  Hepatocytes 
reside in G0 until injury and loss of hepatocytes occurs.  They are then stimulated by 
cytokines and growth factors released by Kupffer cells and hepatic stellate cells to re-
enter the cell cycle and duplicate to repopulate the tissue.  There are a number of 
restriction points that hepatocytes have to overcome to be able to replicate and it is only 
when they cannot overcome these restrictions that bone marrow and tissue derived stem 
cells from the canals of herring will be recruited to aid regeneration. 
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1.3.3 Capacity for Regeneration and Wound healing 
 
The body’s ability to replace injured or dead cells and repair tissue after 
inflammation is critical to survival.  The injurious agent will damage the cells 
and affect the structure of the tissue.  If the injurious agent is removed then the 
body must contain and repair the damage that has already occurred and 
therefore the surviving cells must replicate if regeneration or wound healing is 
to take place.  Regeneration and wound healing have very different mechanisms 
and outcomes.  Regeneration is used to describe the growth of cells and tissues 
to replace lost structures (Becker and Lane, 1968;Goss, 1992).  It can be 
confused with compensatory growth that usually occurs after some of the organ 
has been lost for example a partial hepatectomy, when hepatocytes will be 
stimulated to replicate to replace the tissue and therefore stem cells are not 
required.  Stem cells are required to replace lost tissue if hepatocyte replication 
is blocked (Korbling and Estrov, 2003).  Regeneration requires the 
differentiation of stem cells to replace the cells that have undergone apoptosis. 
In many renewing tissue this process is occurring continuously for example the 
epithelia of the skin and the gut, where the cells on the outer surface are 
continuously replaced as long as the stem cells that generate new cells are not 
damaged.  Wound healing is a different process that restores the original 
structures but will involve collagen deposition and scar formation (Clark, 1996).   
The most obvious example of this is a wound on the skin, but it will also occur 
after inflammation in internal organs and where the cells have under gone 
necrosis and are incapable of regenerating.  To remain healthy the body must 
maintain a normal homeostasis and this will include the balance between the 
proliferation and apoptosis of cells in all tissues.  In parenchymal organs such as 
the liver and kidney the replacement of inflammatory cell infiltrate by 
granulation tissue and fibrosis is called reorganisation.  This may occur after 
any injury that causes an inflammatory response (Fausto, 2000).  Regeneration 
requires an intact connective tissue scaffold but wound healing with scar 
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alters the tissue architecture.  The difference in outcome of liver injury 
illustrates this point.  After an acute injury of a single high dose of carbon 
tetrachloride in the rat, more then 50% of hepatocytes can be lost but 
regeneration and complete reversal of injury will occur.  After chronic injury of 
multiple low doses of carbon tetrachloride over a period of time the liver will 
have a degree of hepatocyte necrosis but the main change will be the disruption 
of the extracellular matrix and normal liver architecture and all the repair will 
have been through fibrosis (Fausto, 2001).  Extracellular matrix scaffolds are 
essential for wound healing because they provide the framework for cell 
migration and maintain the correct cell polarity for the reassembly of 
multilayered structures.  Cells that reside in the extracellular matrix such as 
fibroblasts and macrophages are essential to the repair process due to their 
ability to release cytokines and growth factors.  The liver is a highly 
regenerative organ that has the ability to repair itself after acute and chronic 
injury.  The capacity of this repair mechanism means that the liver can function 
and regenerate to a whole liver with as little as twenty five percent of the 
original remaining (Chandrasoma & Taylor., 1998).  The mechanism is 
predominantly through hepatocyte proliferation but there is evidence for 
bipotential stem cells populating the liver and differentiating into hepatocytes or 
cholangiocytes (Forbes et al., 2004).  It is increasingly common for living 
patients to donate or have removed due to primary or secondary tumours, just 
part of their liver (partial hepatectomy) as it will quickly grow through 
compensatory mechanisms to its original size and capacity.   A 70% partial 
hepatectomy of the rat liver elicits a growth response, the ‘mini liver’ can 
rapidly expand to its original mass after 10-14 days.  The expansion occurs 
without regrowth of the lobes, there is only enlargement of the remaining lobes.  
There is a restitution of the functional mass rather then the restitution of the 
form (Fausto, 2001;Fausto, 2000).  Hepatocytes are normally quiescent cells, 
residing in G0 of the cell cycle.  They can be stimulated to reenter the cell cycle 
and when this occurs it can take several hours for the cells to progress through 
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(all of the hepatocytes will enter S phase at the same time) and this is followed 
by the synchronous replication of non-parenchymal cells such as Kupffer cells, 
endothelial cells and stellate cells (Su et al., 2002).  Proliferation of hepatocytes 
is triggered when the liver is injured and hepatocytes are lost.  The combined 
factors of cytokines and polypeptide growth factors such as Transforming 
Growth Factor (TGF) released in an auotcrine manner by the hepatocytes 
themselves or cytokines such as Tumour Necrosis Factor (TNF) released in a 
paracrine manor by the Kupffer and stellate cells, help the hepatocytes 
overcome the major restriction points for replication.  The two major restriction 
points for hepatocyte replication are G0/G1 transition (quiescent cells entering 
the cell cycle) and G1/S phase needed for transition through the late G1 phase 
restriction point.  Proliferating hepatocytes have an early phase gene response 
(Su et al., 2002).  Over 70 genes are activated including C-FOS and C-JUN 
which are protocogenes that dimerise to form AP-1. C-MYC, NF-κB and 
STAT-3 are also activated (Shaulian and Karin, 2002).  C-MYC encodes for a 
transcription factor that regulates the expression of 15% of all genes through 
binding to enhancer box sequences and recruiting histone acetyltransferases.  If 
hepatocytes are able to progress through G1 and enter the S phase, anti-apoptotic 
genes are activated (Su et al., 2002).  S phase starts with the formation of cyclin 
D-CDK4 complex and the phosphorylation of a component of the RB protein 
family followed by the activation of cyclin E-CDK2 complex, replication then 
becomes autonomous.  Hepatocytes require TNF and IL-6 in G0/G1 transition 
and growth factors HGF and TGF-α are involved in cell cycle progression 
through G1.  TNF provides the priming signal for hepatocytes to respond to the 
full mitogenic affects of other growth factors.  Hepatocytes only replicate once 
or twice once they reenter the cell cycle before returning back to G0 in their 
quiescent state.  The process of hepatocytes returning to G0 is less well defined 
but is thought to involve the growth inhibitors Transforming Growth Factor beta 
(TGF-β) and activins (Michalopoulos and DeFrances, 1997).  
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1.3.4 Role of stem cells in liver regeneration 
 
Stem cells are characterised by their prolonged self renewal capacity and by 
their asymmetric replication.  Asymmetric replication describes the ability of the 
cell to divide.  One cell retains its self renewal capacity when the other enters the 
differentiating pathway and is eventually converted to a mature non-dividing 
cell.  In reality this description describes the whole population of cells, some of 
which differentiate and some of which self replicate (Weissman et al., 
2001;Weissman, 2000).  It was previously believed that stem cells existed only 
as embryonic stem cells in blastocytes that were pluripotent (able to differentiate 
into any cell or tissue type) (Martin, 1981).  More recently it has been 
discovered that adults also have stem cell populations.  The largest population is 
contained in the bone marrow and are called hematopoietic stem cells (Lagasse 
et al., 2000).  It is thought that hematopoietic stem cells are usually linage 
specific although there have been stem cells found that have a broad 
differentiation potential in the bone marrow and have been named multipotent 
adult progenitor cells (MAPCs) (Jiang et al., 2002a).  MAPCs are thought to be 
the adult counterparts of embryonic stem cells and their pluripotency has been 
demonstrated when injected into blastocyts (Hadjantonakis and Papaioannou, 
2001).  This technique has been used to create knockout models by manipulating 
the genome before injecting the cells into the blastocytes.  MAPCs have the 
ability to differentiate into many cells types in vitro and they have been found in 
several tissues in the body including the muscle and brain (Jiang et al., 2002b).  
Stem cells are recruited to areas of injury to help regenerate the tissue.  They 
also have a capacity to produce growth factors and cytokines that act on the 
tissues that they have migrated to (Lagasse et al., 2000).  MAPCs that are found 
in various tissues in the body have been identified as having a common origin 
due to their similarity in gene expression profile.   It has also been discovered 
that there are small population of stem cells that permanently reside in tissues, 
these cells are called tissue stem cells and have been found to have a more 
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located in niches for example in the crypts of the colon and the bulge area of the 
hair follicle (Lavker and Sun, 2000;Marshman et al., 2002).  In the liver tissue 
stem cells are contained in the canals of herring which is the junction between 
biliary ductular system and the parenchymal hepatocytes.  These cells give rise 
to oval cells which are bipotential progenitors of hepatocytes or biliary cells and 
are activated when hepatocyte proliferation is blocked (Fausto and Campbell, 
2003).  Stem cell proliferation is prominent in patients recovering from 
fulminant hepatic failure, liver carcinogenesis and some cases of chronic 
hepatitis and cirrhosis (Libbrecht and Roskams, 2002). 
 
Stem cells are therefore important for the regeneration of the liver but there is 
another side to the story.  It has been found that there is a significant 
contribution to liver cirrhosis in humans from extra-hepatically derived 
myofibroblasts in liver disease of different etiology.  These cells are thought to 
have originated from bone marrow derived stem cells (Forbes et al., 2004;Alison 
et al., 2004;Henderson and Iredale, 2007). 
 
1.4 Cell – Extracellular matrix (ECM) interactions 
 
1.4.1 ECM constituents, synthesis and function 
 
It is now well understood that the extracellular matrix (ECM) is a vital and 
dynamic part of every organ in the body.  There is a great deal of evidence that 
suggests maintaining the homeostasis of the ECM in the liver will help maintain 
a healthy organ, as in fibrosis this homeostasis is disrupted.  The cells in any 
tissue must grow, migrate and differentiate and there is overwhelming evidence 
that all these processes are critically influenced by the intimate contact with the 
macromolecules surrounding the cells that constitute the ECM (Sanes, 2003).  
ECM is secreted locally around the cells forming a network that constitutes a 
significant volume in any tissue.  This network of matrix serves many functions 
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minerals to give rigidity in skeletal tissue.  ECM is a reservoir for growth factors 
which can control the proliferation, adherence, migration and apoptosis of cells, 
providing a matrix where the cell form and function can be directly modulated.  
The synthesis and degradation of ECM accompanies morphogenesis, wound 
healing and fibrotic events, as well as tumour invasion and metastasis (Sanes, 
2003).  There are three groups of macromolecules that make up the ECM, 
fibrous structural proteins such as collagen and elastin, adhesive glycoproteins, 
and proteoglycans such as hyaluronic acid (HA).  The most common protein and 
perhaps most relevant when considering fibrosis, in ECM is collagen but all of 
the components have important roles to play that can contribute to scar 
formation and the development of fibrosis.  Proteoglycans consist of a core 
protein linked to one or more polysaccarides in the form of glycosaminoglycans 
(GAGs) (Sugahara and Kitagawa, 2000).  Proteoglycans have remarkable 
diversity including roles in regulating connective tissue structure and 
permeability but also as integral membrane proteins that bind fibroblasts and 
growth factors which regulate cell growth and differentiation.   HA is a large 
polysaccharide of the GAG family that consists of many repeats of a simple 
disaccharide molecule (Toole et al., 2002).  It is found in the ECM of most 
tissues and has the ability to bind a large amount of water.  This gives the 
connective tissue the capacity to resist compression forces but is also found in 
the matrix where migrating and proliferating cells are found where it can inhibit 
cell-cell adhesion which facilitates motility.  HA can bind CD44, a glycoprotein 
expressed by leukocytes, and this function may retain T-cells in the tissue at 
sites of inflammation (Ponta et al., 2003).  Collagen, elastin and adhesive 
glycoproteins will be discussed in further detail below.  ECM is present in all 
intracellular junctions and cell surfaces and will form into two types of matrix, 
basement membrane and interstitial matrix.  Basement membrane is produced by 
epithelial and mesenchymal cells and consists of largely collagen IV, laminin, 
heparin sulphate, proteglycan and other glycoproteins.  Basement membrane is 
associated with the cell surface and provides the cell with a matrix that can be 
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basement membrane is often replaced with more fibril forming collagen 
molecules that form crosslinked matrixes that can inhibit the normal function of 
the cells that it surrounds.  Interstitial matrix is located in the spaces between the 
epithelial and smooth muscle cells and in connective tissue.  Interstitial matrix 
consists largely of collagen, elastin, fibronectin, proteoglycans, hyaluronate and 
other components that form a strong matrix essential for the structure of the 
tissue (Sanes, 2003).   
 
Collagen is the most common protein in the animal world and is essential for the 
framework of all multicellular organisms.  There are 27 different types of 
collagen encoded by 41 genes located on 14 different chromosomes.  Collagen 
types 1, II, III, V, and X1 are fibrillar collagens and are highly abundant (Byers 
et al., 2001).  Type IV collagen is non fibrillar and forms the main component of 
the basement membrane along with laminin.  All types of collagen are produced 
as a triple α-helix from 3 polypeptide chains, normally a combination of α1 and 
α2 chains. Both α1 and α2 chains are around 1400 amino acids in length and can 
form a α-helix due to a small glycine residue occurring every third amino acid in 
the chain.  The difference between fibril and non-fibril collagen comes after 
transcription and formation of the triple helix as the fibril forming collagens at 
this stage are still propeptides that require cleavage of N and C terminal 
peptides, which occurs after secretion from the cell to become mature fibril 
forming collagen whereas non-fibril forming collagen is transcribed and 
modified by hydroxylation of the proline and lysine residues before triple helix 
formation but then this is considered the mature form of the protein and is 
secreted from the cell without further modification (Myllyharju and Kivirikko, 
2001).  The collagenase domain of type IV collagen is longer then fibril collagen 
but is frequently interrupted with non-collagenous sequences.  Most type IV 
collagens consist of a combination of α1 (IV) and α2 (IV) chains but 
combinations of α3 (IV), α4 (IV), α5 (IV) and α6 (IV) chains have been found in 
some basement membranes (Prockop and Kivirikko, 1995).  In skeletal muscle 
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consists of two α1 chains and one α2 chain in the triple helix but collagen III is a 
homotrimer of three α1 chains.  Fibrillar collagen is transcribed from the many 
different collagen genes as preprocollagen, it then undergoes hydroxylation of 
proline and lysine residues before the 3 chains align to form the triple helix of 
procollagen.  Intra and inter-disulphide bonds are formed between the chains to 
form the tight triple α-helix of procollagen.  Procollagen is then secreted from 
the cell where is undergoes further post-transcriptional modification.  The N and 
C terminal domains are cleaved by proteases to produce the basic units of the 
fibrils that are formed by mature fibril collagen. The fibrils are formed 
spontaneously and will be stabilized by covalent cross-links that are generated 
by the conversion of some lysine and hydroxylysine residues to aldehyde 
derivatives by lysyl oxidase (Laurent, 1987).  Vitamin C is required for the 
process of crosslinking which may explain the inadequate wound healing seen in 
cases of scurvy.  Cross-linking increases the tensile strength of collagen 
reducing the body’s ability to break it down.  This is obviously a disadvantage in 
fibrotic diseases, when the build up of fibrillar collagen can overwhelm the 
tissue. 
 
Some tissues in the body require elasticity, for example blood vessels, skin, lung 
and uterus.  The ability to recoil is provided by elastic fibres, consisting largely 
of elastin which provides a central core that is surrounded by a network of 
microfibrils.  The network of microfibrils consists mainly of fibrillin, a 350kd 
glycoprotein that associates with itself or other ECM proteins.  These fibres can 
stretch to several times their length and return to their original size after the 
release of tension with no consequence to the tissue.  The elasticity of the liver is 
lost during fibrosis and in cirrhosis the scar formation can restrict the expansion 
of blood vessels, which can lead to intrahepatic hypertension (Milewicz et al., 
2000).   
 
As described above the maintenance of homeostasis in the tissue relies on cell-
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body are adhesion proteins.  Adhesions proteins have been given the name 
CAMs (cell adhesion molecules) and there are four main families of these 
proteins, immunoglobulin family CAMs, cadherins (calcium dependent adhesion 
proteins), integrins and selectins (Kumar et al., 2005).  These proteins are 
located in the cell membrane where they can function as receptors or they are 
stored in the cytoplasm.  CAMs provide interactions between the same 
(homotypic) or different cell types (heterotypic) and are responsible for many 
events involving adhesion, cell motility, proliferation and differentiation.  
Integrins have a broad specificity and will bind matrix proteins such as 
fibronectin and laminin (Hynes, 2002).  Intergrins will facilitate the adhesion 
between cells and the ECM as well as other cells.  Fibronectin is a large 
molecule that consists of two splice variants.  The tissue splice variant will form 
fibrillar aggregates at wound healing sites and the plasma splice variant will bind 
fibrin forming clots at the site of injury.   Laminin is an abundant glycoprotein in 
the basement membrane and has binding domains for ECM and cell surface 
receptors (Hynes, 2002).  Cadherins are involved in calcium dependent 
homotypic interactions between cells.  Cadherins and integrins together will link 
the cell surface with the cytoskeleton through the binding to actin and 
intermediate filaments.  The mechanism is through not only mechanical force 
but through the activation of intracellular signal transduction pathways.  When a 
ligand binds to an integrin the receptors become clustered on the cell membrane 
and the formation of focal adhesion complexes occurs.  The complexes can act 
as activated receptors and may trigger MAP kinase, PKC and PI-3 kinase 
pathways within the cell (Stupack and Cheresh, 2002).  There is a functional 
overlap between integrins and growth factor receptors that may cross talk via 
these mechanisms that are well known to regulate cell proliferation, apoptosis 
and differentiation.  Cadherins form zonula adherins, which are spot like 
junctions near the apical surface of epithelial cells and desmosomes, which 
connect the plasma membrane of adjacent cells and are the strongest, most 
extensive of cadherin junctions (Hynes, 2002;Stupack and Cheresh, 2002).  
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processes.  There are different classes of secreted adhesion proteins are called 
SPARCs (secreted protein acidic and rich in cysteine), thrombospondins, 
osteopontin and tenacin.  SPARCs are also known as osteonectins and are 
important in tissue remodelling in response to injury due to their function as an 
angiogenesis inhibitor (Bradshaw and Sage, 2001).  Thrombospondins are large 
multifunctional proteins that can also inhibit angiogenesis amongst other 
functions. Ostepontin is the ligand for the CD44 receptor which mediates 
leuckocyte migration and regulates calcification.  Tenacins are a family of large 
multimeric proteins that have important functions in morphogenesis and 
adhesion (Sodek et al., 2002).   
 
The ECM is therefore an important dynamic structure in the body that is vital for 
cellular interactions and the maintenance of homeostasis in tissues.  The 
disruption and subsequent reorganisation of the ECM is dependent upon many 
different cell types, the interaction of which is fundamental for tissue 
remodelling and wound healing events to occur (Sodek et al., 2002). 
 
1.4.2 Tissue remodelling and fibrosis 
 
Resolution of fibrosis involves the restitution of tissue components with either 
identical components of those that were injured (regeneration), or a different 
process that involves a fibroproliferative response that will repair tissue with 
connective tissue scar formation rather then restore the original components 
(wound healing) (Goss, 1992).  Injury can occur by a variety of mechanisms that 
have already been discussed in detail but the initial response of the liver to any 
injury is inflammation.  Inflammation of the liver results in activation of 
macrophages and recruitment of inflammatory cells such as leuckocytes (Henry 
and Garner, 2003).  This mechanism will remove any damaged tissue and help to 
clear the injurious agents such as HBV from the liver (Harty et al., 2008).  Once 
the injurious agent has been removed the growth factors and cytokines that have 
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migration of the hepatocytes and connective tissue cells, allowing spontaneous 
compensatory growth and/or regeneration in non cirrhotic tissue (Iredale et al., 
1998;Issa et al., 2004;Tsukada et al., 1995).  The first repair mechanism is to 
replace the damaged tissue with identical cells by hepatocyte proliferation and 
recruitment of stem cells.  This process is called regeneration and has been 
described in detail above (Fausto, 2000).  Compensatory growth and 
regeneration will only occur if the injury is acute, and once the harmful agent 
has been removed, it has been reported that removal of TGF-β can enhance 
hepatocyte proliferation (Arendt et al., 2005).  The liver will regenerate if the 
injury is not too extensive and not chronic (Iredale, 2007;Fausto, 2000).  Many 
tissues in the body cannot undergo regeneration like the liver and will use a 
wound healing mechanism to repair the tissue (Clark, 1996).   
 
The initial process of wound healing is the same as compensatory growth and 
regeneration involving the recruitment of inflammatory cells and the release of 
growth factors and cytokines.  If the damage is too extensive for regeneration to 
be sufficient the next stage of the wound healing process is initiated with 
vascular endothelial growth factor (VEGF) and other growth factors causing the 
formation of new blood vessels via angiogenesis and the granulation of the 
tissue through the proliferation of fibroblast and vascular endothelial cells which 
can occur as quickly as 24 hours post injury if regeneration has not occurred 
(Dvorak, 2000;Carmeliet, 2003).  The new blood vessels that are formed via 
angiogenesis are permeable to plasma proteins in the presence of Nitric Oxide 
(NO) and VEGF, which are deposited in the ECM (Dvorak, 2000;Carmeliet, 
2003).  Plasma proteins in the ECM cause the in growth of fibroblast and 
endothelial cells.  Growth factors such as TGF-β, PDGF, EGF, FGF and the 
cytokines IL-1 and TNF which are released by platelets, activated HSC, 
activated endothelium and macrophages increase the migration and proliferation 
of fibroblasts and endothelial cells to the site of injury (Werner and Grose, 
2003).  If the appropriate chemo-attractant proteins are in the tissue at the site of 
injury, mast cells, eosinophils and lymphocytes may accumulate in the tissue.  In                                                                                            Chapter 1: Introduction 
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this process it is believed that TGF-β is the most important growth factor due to 
its ability to induce fibroblast migration and proliferation, increase synthesis of 
collagen and fibrosis and to decrease the degradation of ECM proteins by 
inhibiting MMPs (Schnaper et al., 2003).  Activated HSC in the liver become 
self sustaining by the autocrine release of TGF-β.  Synthesis and deposition of 
ECM proteins and collagen will follow causing the remodelling of the tissue due 
to replacing the parenchymal cells (hepatocytes) and basement membrane of the 
tissue with fibril forming collagens and interstitial matrix (Gressner and 
Bachem, 1990;Friedman et al., 1993).   
 
Collagen synthesis is induced by the growth factors PDGF, FGF, TGF-β and the 
cytokines IL-1 and IL-13 released from fibroblasts and leukocytes (Arendt et al., 
2005).  Tissue remodelling is also dependent on the decrease in degradation of 
collagen during this time allowing the granulation scaffolding to be converted 
into a scar composing of spindle shaped fibroblasts (activated HSC in the liver), 
dense collagen, fragments of elastic tissue and other ECM components.  As the 
scar matures it undergoes vascular regression leaving an avascular scar.  Tissue 
remodelling is dependent on the balance between ECM synthesis and 
degradation (Giannelli et al., 2003;Iredale, 1996).  Degradation of collagen is 
achieved by Matrix Metalloproteinases (MMPs), which are zinc binding 
endopeptidases that require cleavage from a propeptide to become activated 
(Hemmann et al., 2007).  There are over 20 MMPs in the family and they all 
retain the 180 residue zinc protease domain.  This distinguishes them from many 
other proteolytic enzymes that can degrade ECM proteins that normally fall into 
the family of serine proteases such as fibroblast activated protein (FAP) (Gorrell 
et al., 2003).  The family of MMPs include intersititial collagenases MMP-1, 2 
and 3, which can cleave fibrillar collagens I, II and III, gelatinases MMP-2 and 9 
that degrade collagen-1, IV, V, VII, X, fibronectin, laminin and elastin and 
stromelysins MMP-3, 10 and 11 that act on a variety of ECM proteins including 
proteoglycans, laminin, fibronectin and amorphous collagens (McCawley and 
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bound, surface associated MMPs and through there proteolytic activity can 
cleave and release extracellular domains of cell surface proteins.  The cleaved 
proteins such as TNF and TGF-α are now active proteins that may remain 
associated with the cell surface or can be released (Matrisian, 1990).  A large 
family of the membrane bound MMPs are called disintegrin and 
metalloproteinase-domain family (ADAM) enzymes and have been associated 
with the pathogenesis of bronchial asthma (Kheradmand and Werb, 2002).  
MMPs are synthesised by fibroblasts, macrophages, neutrophils and some 
epithelial cells as propeptides.  They require proteolytic cleavage for activation 
and their secretion is regulated by PDGF, FGF, IL-1, TNF, phagocytosis and 
physical stress such as oxidative stress from free radical formation.  MMP 
secretion can be inhibited by TGF-β and steroids.  MMPs cleave collagen by 
cutting the triple helix into two unequal fragments, which makes the remaining 
fragments susceptible to digestion by other proteolytic enzymes (Matrisian, 
1990). 
 
MMPs are regulated by tissue inhibitors of metalloproteinases (TIMPs) which 
are produced by mesenchymal cells.  At present there are four TIMPs in the 
family and they are all small 21-28 kD proteins that have a highly conserved set 
of six intramolecular disulphide bonds.  TIMPs all have the ability to form tight, 
non-covalent inhibitory complexes with multiple members of the MMP family.  
TIMPs specifically bind the forth coordination site of the zinc molecule present 
in the active site domain of all MMPs.  TIMP-1, 2 and 4 are inducible proteins 
that are secreted from the cell, whereas TIMP-3 is mainly constitutively 
expressed and is associated with the ECM.  TIMP-1 will form a tight complex 
with MMP-1 and TIMP-2 is known to bind MMP-2 (Hemmann et al., 
2007;Iredale, 1997).  TIMPs are overexpressed by activated HSC thus 
preventing any collagen/matrix degradation of the fibrotic scar (Iredale et al., 
1996;Benyon et al., 1996).  MMPs and TIMPs are spatially and temporally 
regulated within scar formation and the healing wound, the balance of which is 
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once the injurious stimuli has been removed but as described above the balance 
can be shifted in a fibrotic situation to favour the deposition of fibril forming 
collagen with little or no degradation of the scar taking place.  The injury and 
damage can persist for example in alcoholic cirrhosis or HCV infection and this 
can lead to chronic inflammation.  This leads to tissue damage and repair 
occurring concurrently and the connective tissue deposition becomes fibrotic 
(Iredale, 1997).  Fibrosis is the universal response to chronic injury and 
inflammation (Iredale, 2008).  Over time without the removal of the injurious 
stimuli the fibrosis can become extensive, manifesting in excess collagen 
accumulation leading to cirrhosis where the scar formations link together 
(bridging fibrosis).  This can lead to an irreversible loss of tissue function, 
replacing normal tissue with scar tissue which can then contract due to the nature 
of the collagen and cells present causing complications such as portal 
hypertension that will be discussed later.  The underlying pathology of deep 
organ fibrosis remains similar in most cases, suggesting insights into the 
pathogenesis of scarring in one organ can lead to better understanding of fibrosis 
in general (Iredale, 1997). 
 
1.4.3 Molecular mechanisms of hepatic fibrosis  
 
Hepatic fibrosis is characterised by the excessive accumulation of extra-cellular 
matrix (ECM) proteins, particularly collagen type 1.  These matrix proteins form 
a hepatic scar, which can lead to secondary complications often seen in patients 
presenting with advanced fibrosis and cirrhosis (Friedman, 2008).  Injury to the 
liver causes the activation of Kupffer cells, which are the resident macrophages 
of the liver.  As part of the inflammatory response Kupffer cells release an array 
of pro-inflammatory cytokines which can lead to the activation of Hepatic 
Stellate Cells (HSC) (Friedman and Arthur, 1989).  HSC are quiescent, vitamin 
A storing cells but can be stimulated to re-enter the cell cycle differentiating 
from the quiescent into a myofibroblast-like cell (Friedman et al., 1985).  This 
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growth factors released by the Kupffer cells, parenchymal cells and other 
incoming inflammatory cells.  Additionally changes in cell matrix interaction are 
likely to contribute to HSC activation.  The activation process enables HSC to 
become highly proliferative cells that have the ability to contribute to tissue 
remodelling (figure 1.7).    Activated HSC lose their vitamin A (retinoid) storing 
capacity, up regulate α– smooth muscle actin (α-SMA) and fibril collagen 
synthesis.  HSC are believed to be the main progenitors of fibrosis in acute and 
chronic liver injury (Friedman et al., 1985;Rockey et al., 1992;Friedman et al., 
1993).  Cytokines such as Tumour Necrosis Factor-alpha (TNF-a), Transforming 
Growth Factor-beta TGF-b1, angiotensin II and leptin activate HSCs (Bataller 
and Brenner, 2005).   HSC are localised in the Space of Disse and store 80-90% 
of the vitamin A in the body when in their quiescent, non-activated state (figure 
1.7).  When activated, HSC have multifunctional characteristics in releasing 
retinoid, regulating synthesis and secretion of ECM components, production of 
MMPs and TIMPs, and the synthesis and secretion of cytokines (Li and 
Friedman, 1999).  HSC secrete fibril forming collagens type I and III, 
contributing to the fibrotic changes in the ECM.  Upon activation HSC secrete 
an array of MMPs that can breakdown a variety of collagen and ECM 
components.  The activation of HSC in acute injury is required to clear the 
fibrotic scar through the production of MMPs, this enables regeneration to occur.  
Activated HSC will then secrete TIMPs to inhibit the MMPs, preventing 
excessive breakdown of the tissue (Iredale et al., 1998;Hemmann et al., 2007).  
If the injury becomes chronic, the persistent activation of HSC leads to constant 
increase in the activation of TIMPs.  The TIMP-MMP balance is then shifted, 
inhibiting any remodelling occurring.  The HSC can then continue to secrete 
ECM components forming fibril collagen depositions that cannot be broken 
down due to the inhibition of MMPs.  The collagen can then over time become 
crosslinked forming scars that are characteristic of cirrhosis.  A therapy that can 
reduce the expression of TIMPs and increase the expression of MMPs in HSC 
may contribute to tissue remodelling and resolution of fibrosis (Hemmann et al., 
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The progression to fibrosis means that the natural healing response becomes 
pathogenic.  At a molecular level fibrogenic activity may become self-sustaining 
through the HSC expressing and releasing TGF-β, TNF-α and Platelet Derived 
Growth Factor (PDGF) in an autocrine manner (Gressner and Bachem, 
1990;Friedman et al., 1993).  There is not only a change in the composition of 
collagen in the fibrotic liver but also in its distribution.  In normal liver HSC are 
located between the sinusoidal endothelial cells and the hepatic parenchymal 
cells, an area called the Space of Disse.  HSC and their processes encircle and 
contact the endothelial cells and also have contact with the parenchymal cells.  
HSCs coexist with the three dimensional ECM components (e.g. collagen type 
IV and laminin) these along with the long and numerous processes of stellate 
cells make a complicated structure (Imai et al., 2004).   The initial collagen 
deposition is concentrated in the sub-endothelial Space of Disse (figure 1.7).  In 
fibrosis the matrix within the Space of Disse is transformed from a non-fibril 
forming basement membrane like ECM, containing type IV collagen, laminin 
and proteoglycans, to the fibril forming collagens type I and III, with increased 
ECM glyconjugates including fibronectin and hyaluronic acid (Friedman, 1993).  
Although initially confined to the hepatic sinusoid the accumulation of ECM 
proteins eventually invades vascular structures and areas of hepatocellular 
necrosis.  This coupled with the ECM accumulation in the sinusoid causes the 
loss of fenestrae in the endothelial cell lining and increased pressure around the 
vascular structures causing a disruption in blood flow and the movement of 
metabolites from the sinusoid across the Space of Disse, typical in patients with 
advanced fibrosis and cirrhosis (McGuire et al., 1992;Friedman et al., 1992).  
 
1.4.4 Contractility of the hepatic stellate cell  
 
It has been postulated that HSC play a role in the control of blood flow through 
the liver based on anatomic location and contractile characteristics (Mallat, 
1998;Rockey, 1997).  HSC are located in the Space of Disse and can extend up 
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branch off the primary processes and these can encircle the sinusoid in a 
cylindrical manner (Blomhoff and Wake, 1991).  HSCs possess cytosolic 
proteins such as calmodulin, actin and myosin that are characteristic of 
contractile cells (Ramadori, 1991).   HSC have been found to contract in 
response to vasoactive mediators such as endothelin-1 (ET-1) and argenine 
vasopressin (AVP) (Pinzani et al., 1996;Zhang et al., 1994).   ET-1 is 
upregulated in cirrhotic rat livers.  ET-1 upregulation can increase the portal 
pressure by decreasing the radius of the sinusoid in regions that are co-localised 
with HSC (Pinzani et al., 1996;Zhang et al., 1994).  ET-1 antagonists have been 
found to reduce portal pressure and improve hepatic blood flow in cirrhotic rats, 
increasing the evidence that HSC can respond to vasoactive mediators and have 
a vital role to play in the pathogenesis of portal hypertension (Ueno et al., 
1997;Ueno and Tanikawa, 1997;Ueno et al., 2004).  Substances such as ET-1, 
AVP, angiotensin II, substance P and thromboxan A2 can signal through 
membrane receptors that can increase the intracellular calcium concentration 
which in turn can activate cellular contraction.  It is believed this could be the 
mechanism of contraction in HSC (Ueno et al., 1997;Ueno and Tanikawa, 
1997;Ueno et al., 2004).   
 
In the early nineties, Rockey and co workers were interested in the link between 
HSC activation and contractility.  They established that HSC contractility in an 
in vitro setting coincided with activation.  Activation was monitored by the level 
of α-SMA expression and contractility was monitored by contraction of a 
collagen-1 lattice gel that the cells were plated on after isolation (Rockey et al., 
1993). HSC were found to contract the gels when they were activated and the 
level of contraction was dependent on the number of cells.  There was also a 
reduction of cell volume that was monitored by electron microscopy.  No 
contraction was observed when hepatocytes were treated in an identical manner.  
Serum in the media of the HSC was a potent stimulator of contraction as was 
endothelins 1, 2 and 3.  The affect of serum and endothelin-1 was additive.  HSC 
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controls.  The cells from normal controls were found to be less contractile 
immediately after isolation compared to the cells isolated from the injured 
animals.  The collagen-1 matrix predominates in the injured liver and therefore 
could promote contraction and activation of the HSC.  Agents such as IFN-γ that 
can block the activation of HSC were found to inhibit the contraction of these 
cells (Rockey et al., 1993).  These data suggest a link between the level of 
activation and the degree of contractility in these cells.  This has important 
implications when considering portal hypertension.  HSC are ideally situated to 
regulate sinusoidal blood flow and activated cells residing the Space of Disse 
may induce contraction of fibrotic bands leading to the physical distortion of the 
normal liver architecture and blood flow patterns.  Activation and contraction 
inhibiting agents may represent potential points of therapeutic intervention for 
portal hypertension and chronic liver injury (Rockey et al., 1993). 
 
1.4.5 Apoptosis of the hepatic stellate cell 
 
Apoptosis is a form of programmed cell death in multi cellular organisms first 
described by Carl Vogt in 1842.  A more detailed description was offered by an 
anatomist, Walther Flemming in 1885 but it was not until 1965 that the topic 
was resurrected for more detailed investigation.  Dying cells were characterised 
by the gross condensation of cytoplasm and nuclear chromatin, which were 
observed to be fundamentally different from the appearance of those cells 
undergoing coagulative necrosis which is found in tissues damaged by noxious 
stimuli (Trump et al., 1965;Ginn et al., 1969).  Apoptosis involves a series of 
biochemical events that leads to a characteristic cell morphology and death.  
Apoptosis was first described at the cellular level in 1972 by Kerr and 
colleagues. Apoptosis begins with the aggregation of nuclear chromatin, 
followed by the nuclear fragmentation and cytoplasmic condensation associated 
with prolific budding to produce membrane bound apoptotic bodies of varying 
sizes.  A small number of apoptotic bodies are ingested by the remaining viable 
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cells whose cytoplasm becomes progressively laden with telolysosomes (Kerr 
and Searle, 1973).  Processes of disposal of cellular debris whose results do not 
damage the organism differentiates apoptosis from necrosis.  Necrosis is a form 
of traumatic cell death that results from acute cellular injury (Searle et al., 1982).  
Apoptosis is an important process in regulating the cell population of vertebrate 
tissue and organs throughout the organism’s life.  Apoptosis complements 
mitosis in normal and pathological conditions ensuring the homeostatic 
regulation of cell kinetics (Kerr et al., 1972).  A number of pathological 
conditions may arise if the equilibrium between mitosis and apoptosis is 
unbalanced, such as uncontrolled cell proliferation observed in cancer or 
excessive apoptosis causing hypotrophy seen in ischemic damage (Sheahan et 
al., 2008).  Apoptosis is a tightly regulated process that is induced by different 
signals in various cell types.  These signals may arise from the cell itself, from 
the surrounding tissue or from a cell that is part of the immune system.  
Extracellular signals such as TGF-β that either induce or inhibit apoptosis may 
include hormones, growth factors, nitric oxide and cytokines.  Intracellular 
apoptotic signalling is induced as a response to stress and will ultimately result 
in cell suicide (Sheahan et al., 2008).  Many apoptotic proteins affect the 
mitochondria of the cell which is essential to multicellular life.  The 
mitochondria may be affected in different ways, for example swelling through 
the formation of membrane pores or the increase in non-selective permeability of 
the membrane that allows apoptotic proteins to leak out (Kumar et al., 2005).  
There is a growing body of evidence that nitric oxide is able to induce apoptosis 
by helping to dissipate the membrane potential of the mitochondria and therefore 
make it more permeable (Brune, 2003).  P53 is a tumour suppressor gene that 
accumulates when DNA is damaged.  It is a cell cycle checkpoint protein that 
can prevent the cell from replicating by stopping the cell cycle at G1, or 
interphase which gives the cell time to repair any damage.  If the damage is too 
extensive and cannot be repaired the cell will undergo apoptosis, therefore 
regulation of the p53 gene is vitally important for the life cycle of the cell 
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cleavage is used as an early marker of apoptosis in mammalian cells (Kaufmann 
et al., 1993).  Under homeostatic conditions PARP-1 participates in genome 
repair, DNA replication and regulation of transcription (Quenet et al., 2008).  
PARP-1 catalyses the addition of long branch chains of poly adenosine 
diphosphate (poly ADP) to a variety of nuclear proteins using nicotinamide 
adenine dinucleotide (NAD
+) as a substrate.  NAD
+ is broken down to 
nicotinamide and PAR.  Cells undergoing a stress response may upregulate 
PARP-1 to help maintain genomic integrity (Quenet et al., 2008).  Massive 
PARP-1 activation can however deplete the cell of NAD
+ and ATP, ultimately 
leading to energy failure and cell death.  Massive up-regulation of PARP-1 may 
induce cell death through necrosis rather then apoptosis, which is associated 
with PARP-1 cleavage. PARP-1 is cleaved by caspase 3 from a 116 kD protein 
to 89 kD and 24 kD fragments rendering PARP-1 inactive (Kaufmann et al., 
1993).  PARP-1 cleavage not only prevents the survival of damaged DNA but 
will also ensure that the vital energy stores are available for the execution of 
apoptosis (Aikin et al., 2004).  PARP-1 and PARP-1 cleavage products can be 
detected by western blotting and is a common method used to detect early 
apoptosis in cell systems (Kaufmann et al., 1993).  
 
Apoptosis of activated stellate cells may significantly contribute to the resolution 
of fibrosis, acting as a mechanism for the removal of the cell population that is 
responsible for both producing the fibrotic matrix and protecting the matrix from 
degradation via the production of TIMPs (Iredale et al., 1998).  In rat models of 
fibrosis the HSCs were found to have become activated after chronic exposure to 
CCl4.  In a model of progressive fibrosis the HSCs were found to have increased 
expression of α-SMA and TIMPs and the activity of collagenases were 
decreased.  Once the injurious stimulus was removed the model of recovery was 
followed.  In recovery the expression of TIMPs was reduced and the activity of 
the MMPs increased.  The numbers of α-SMA positive cells were reduced and it 
is believed that the mechanism is by apoptosis rather then reversion to a 
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Although recently there has been evidence to suggest senescence or reversion to 
quiescence of HSC also has a role to play in limiting liver fibrosis 
(Krizhanovsky et al., 2008).  It is thought that even relatively advanced fibrosis 
of the rat liver can undergo remodelling with the restoration of normal liver 
architecture over a relatively short period of time (Iredale et al., 1998).    
 
The hepatic stellate cell has become the focus for research into liver fibrosis, 
with the attention being on the development of therapies that target HSC in vitro.  
The next issue to address will then be specifically targeting activated HSC in 
vivo without affecting the surviving areas of normal liver cells (Bataller and 
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Figure 1.7.  Changes in the hepatic architecture during fibrotic injury (a) The normal 
architecture of the liver before repeated injury, and associated inflammatory response 
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(b) activation of hepatic stellate cells through repeated/chronic injury such as Hepatitis 
C infection, chronic alcohol consumption and obesity (c) Following repeated injury, 
inflammatory lymphocytes infiltrate the hepatocytes causing the apoptosis of some 
hepatocytes, activation of Kupffer cells, which release fibrogenic cytokines/mediators.  
HSC proliferate and undergo the phenotypic activation associated with fibrosis, causing 
an increase in secretion of extracelluler matrix proteins, initially in the Space of Disse.  
This in turn causes the loss of fenestrae which are vital for the flow of blood through the 
sinusoid.  This process is thought to be reversible, through the removal of activated 
stellate cells from the site of injury, which is the target cell for new therapies in 
development. 
 
1.5 Cirrhosis and its implications in disease 
 
1.5.1 Hepatic cirrhosis 
 
Cirrhosis is the pathological condition, which results from end stage liver 
fibrosis and is one of the top ten causes of death in the western world.  It is vital 
to appreciate when considering possible therapies that many patients that have 
hepatic fibrosis, which is believed to be reversible, can progress to cirrhosis after 
an interval of 5-20 years (Iredale, 2003).  The average survival rate after five 
years from diagnosis of cirrhosis is only 50% (Kumar and Chandrasekharan, 
1994). Cirrhosis is the result of continuous liver damage representing the late 
stage of progressive scarring through chronic inflammation and development of 
fibrosis throughout the liver.  Fibrosis is the key feature of progressive damage, 
with the continued deposition of fibrous collagen in the Space of Disse by the 
hepatic stellate cells (HSC), leading to the loss of fenestrations of the endothelial 
cells (figure 1.7) (Iredale, 2003).  This process causes the sinusoidal space to 
resemble a capillary rather then channel for the exchange of solutes between the 
hepatocytes and plasma (figure 1.4) (Le et al., 1990;Urashima et al., 1993).  In 
particular the secretion of plasma proteins such as albumin and lipoproteins is 
severely impaired (Friedman, 1993).  The disruption of the interface between the 
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channels as well.  Cirrhotic patients can develop jaundice and hepatic failure 
despite having a normal liver mass (Kumar et al., 2005).  Characteristics of 
cirrhosis are parenchymal nodule formation containing proliferating hepatocytes 
which are encircled by fibrotic scar and bridging fibrous septae, which can take 
the form of delicate bands or broad scars that link the portal tracts with one 
another and with terminal hepatic veins.  Overall this leads to a massive 
disruption in the normal architecture of the entire liver (Iredale, 2003).  
Hyperplasia of existing hepatocytes leading to the regenerative nodules 
described above, distorts the normal liver architecture, which leads to the 
disruption of the vasculature which critically alters the supply of blood to the 
hepatocytes causing abnormal blood flow between portal veins and hepatic 
arterioles (Roncalli et al., 2008).  This can lead to hepatocyte necrosis and portal 
hypertension, which can then lead to the manifestation of varices and ascites 
(Chandrasoma and Taylor, 1998).  Patients with cirrhosis can remain free of 
major complications for several years (compensated cirrhosis) but patients with 
decompensated cirrhosis, where the patient may have symptoms such as 
jaundice and one or more complications such as portal hypertension, varices and 
ascites, is associated with short survival and liver transplantation is often 
indicated as the only effective therapy (Bataller and Brenner, 2005). 
 
The diagnosis of cirrhosis is made clinically on the basis of signs of end stage 
liver disease such as portal hypertension, ascites, muscle wasting, variceal 
bleeding, jaundice and encephalopathy (Bosch and Garcia-Pagan, 2000;Iredale, 
2003).  These features indicate a poor prognosis regardless of etiology due to the 
reversal of cirrhosis being rare.  Often transplantation is seen as the only 
treatment for cirrhosis as the collagen fibers laid down during injury undergo 
extensive cross linking making the collagen much more resistant to collagenases 
and therefore antifibrotic therapies (Iredale, 2003;Bonis et al., 2001).  Therefore 
any future strategy to prevent/treat liver fibrosis will have to consider the 
possibility patients may have advanced fibrosis/cirrhosis at presentation. 
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1.5.2 Secondary complications: portal hypertension, varices and ascites 
 
Increased resistance to portal blood flow (portal hypertension) can arise in a 
number of circumstances that are divided into prehepatic, intrahepatic and 
posthepatic causes.  Pre and post hepatic causes are rare but include obstructive 
thrombosis and narrowing of the portal vein before it connects with the liver 
(prehaepatic) and severe right sided heart failure, hepatic outflow obstruction 
and constrictive pericarditis (posthepatic) (Kumar et al., 2005).  The primary 
intrahepatic cause is cirrhosis and results because of the increased resistance at 
the level of the sinusoids.  There can also be compression of the terminal hepatic 
veins due to scarring and expansion of the parenchymal nodules in these areas.  
Anastomoses between the portal vein and the hepatic artery within the fibrous 
septa can impose extremely high pressure on the venous system.  Intrahepatic 
causes may also include massive fatty change, sarcoidosis and disease that affect 
the portal microcirculation.  The major clinical consequences are ascites, 
formation of portosystemic venous shunts, congestive splenomegaly, the 
development of varices and hepatic encephalopathy (Bosch and Garcia-Pagan, 
2000). 
 
Ascites is the oedema of the peritoneal cavity (Chandrasoma and Taylor, 1998). 
The build up of fluid is due in part to portal hypertension likely to increase 
hydrostatic pressure in the sinusoid, driving fluid into the Space of Disse, which 
is removed by the hepatic lymphatic system.  The loss of liver function and the 
consequent decrease in plasma proteins results in the reduction of osmotic 
potential of the blood also increasing the level of fluid in the Space of Disse and 
therefore increasing the level of fluid in the hepatic lymphatic system further 
(Arroyo, 2002).  The increase in hepatic lymphatic flow eventually exceeds the 
thoracic duct capacity and fluid will accumulate in the peritoneal cavity.  Portal 
hypertension also increases the pressure in the intestinal capillaries, which will 
force fluid out in to the abdominal cavity and water and sodium are retained by 
the kidneys due to hyperaldosteronism.  All these factors combined can increase                                                                                            Chapter 1: Introduction 
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the hepatic lymphatic flow from 1000ml/day to over 20L/day in cirrhotics 
(Arroyo, 2002;Chandrasoma and Taylor, 1998). 
 
Portosystemic shunts are due to the rise in portal pressure causing bypasses to 
develop wherever the systemic and portal circulations share capillary beds.  The 
shunts can manifest in areas such as the rectum and the retroperitoneum but most 
importantly in the falciform ligament and the cardioesophageal junction 
producing gastric and esophageal varices respectively (Toubia and Sanyal, 
2008).  Gastric and esophageal varices are a serious secondary condition 
resulting from portal hypertension.  Esophageal varices are more common, 
usually occurring in the lower part of the esophagus and these veins are prone to 
hemorrhage.  If prolonged or severe, portal hypertension can induce the 
formation of collateral bypass channels.  The portal blood is diverted into the 
coronary veins of the stomach into the esophageal subepithelial and submucosal 
veins, then into the azygos veins and eventually into the systemic circulation 
(Takashi et al., 1985).  The build up of pressure in the esophageal plexus results 
in the tortuous vessels called varices.  90% of all cirrhotic patients will develop 
varices and they are most common in alcoholic cirrhosis.  Damage to varices can 
be caused by chemical and mechanical damage e.g. vomiting, which can lead to 
fatal blood loss (Toubia and Sanyal, 2008).  
 
Hepatic encephalopathy is regarded as a disorder of neurotransmission within 
the central nervous and neuromuscular systems and appears to be associated 
with elevated levels of ammonia in the blood and can occur in cirrhotic patients 
after portosystemic shunts have developed (Rogers, 1985).  Ammonia levels 
may rise in the blood when the livers function has been impaired for any reason 
and its ability to remove toxins for the blood is reduced but if portal 
hypertension develops and there is consequent bypassing of the liver filtration 
system by blood travelling from the intestine due to portosystemic shunts, then 
the blood can travel directly to the brain without being filtered of any toxins.  
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edema (Rogers, 1985).  There is also a risk of increased hepatic encephalopathy 
in patients after transjugular intraheptic portosystemic shunting (TIPS) 
procedure, as a therapy for portal hypertension (Nolte et al., 1998).  
 
The management of portal hypertension is currently a much debated area.  Drugs 
such as beta blockers in conjunction with isosorbide mononitrate are currently 
used as a long term treatment in the reduction of blood pressure and somatostatin 
analogs and antidiruetic hormones such as terlipressin are currently used as an 
acute treatment to inhibit splanchic blood flow thus reducing portal and variceal 
pressure, helping to terminate variceal bleeding (Bosch and Garcia-Pagan, 
2000;Bosch et al., 2003).  Some of these therapies require intravenous infusion 
and are not always effective.  Surgical interventions may be necessary if the 
hypertension is severe and complications such as varices are present (Bosch and 
Garcia-Pagan, 2000;Bosch et al., 2003).  Procedures such as transjugular 
intraheptic portosystemic shunting (TIPS) where a connection between the portal 
and venous system is created and distal splenorenal shunts (DSRS) where the 
distal splenic vein is connected to the left renal vein are carried out in these cases 
(Boyer, 2008;Boyer et al., 2008).  If these procedures are unsuccessful and it has 
been recorded that 30% of patients that undergo a TIPS procedure develop 
hepatic encephalopathy, then a liver transplant may be the only effective 
treatment (Boyer, 2008;Boyer et al., 2008).  It is clear that an effective 
noninvasive therapy that could treat portal hypertension at the intraheptic level 
by reducing blood pressure by not only relaxing the veins and contractile cells 
around the veins but reducing the amount of fibrosis in the liver by clearing the 
activated HSC would be an advantageous treatment above any existing 
therapies. 
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1.6 The history of relaxin, discovery of its receptors and its links 
to fibrosis 
 
1.6.1 The identification of relaxin and relaxin-like peptides structure and 
function 
 
In the early 1920’s a scientist called Hisaw was investigating the physiological 
changes seen in the pubic symphysis in guinea pigs during pregnancy.  He 
reported that when virgin female guinea pigs were injected with serum taken 
from pregnant rabbits there was a relaxation of the pubic ligaments similar to 
that seen to naturally occur in pregnancy.  The substance responsible for the 
relaxation could be extracted from rabbit placenta and was found to work in 
conjunction with estrogen (Hisaw., 1926).  In 1930, a crude extract of this 
substance was extracted from the corpus lutea of sows, identified as a hormone, 
and was given the name ‘relaxin’ (Fevold et al., 1930).  In the 1970’s three 
preparations of relaxin were obtained from frozen sow ovaries (Schwabe et al., 
1976; Schwabe., 1977).  Two peptide chains were identified and sequenced as 
the A and B chain of the mature form of relaxin.  This led to the isolation and 
sequencing of relaxin from several different species including rats (John et al., 
1981), mice (Evans et al., 1993) and humans (Hudson et al., 1983;Hudson et al., 
1984).  Humans and the four great ape species have three forms of relaxin 
encoded by separate genes, which is thought to be a consequence of gene 
duplication during primate evolution.  The three relaxin genes have been 
designated H1 and H2 and H3-relaxin.  Only H2-relaxin is known to be secreted 
into the blood and is therefore the main circulating form of the peptide, therefore 
any reference to relaxin in this thesis refers to H2-relaxin unless otherwise stated 
(Bathgate et al., 2006).   Rodents were found to have two relaxin genes H1-
relaxin and H3-relaxin, which correspond to H2-relaxin and H3-relaxin in 
humans respectively.  H1-relaxin is the circulating form in rodents (Samuel et 
al., 2005).  Modeling of the relaxin structure has revealed it has a primary 
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1.8).  The A chain has 22 amino acids (Schwabe et al., 1976) and the B chain has 
32 amino acids with a combined molecular weight of around 6000 daltons 
(Schwabe and McDonald, 1977).  The two chains are linked via two disulphide 
bridges, with an intra-chain disulphide bridge in the A-chain.  The structure was 
confirmed by the x-ray crystal structure of H2-relaxin, which revealed the 
probable relaxin receptor binding site within the B-chain along the dimer 
interface.  The amino acid motif that has been found to be required for relaxin 
receptor interaction is Arg-X-X-X-Arg-X-X-Ile/Val-X and as suggested from 
the crystal structure is located in the middle of the B-chain (Eigenbrot et al., 
1991).  Relaxin is transcribed as a prohormone that is stored in vesicles in the 
endoplasmic reticulum (ER).  When relaxin is required the prohormone is 
cleaved and transported to the cell membrane where it is released into the blood 
stream (Gast, 1983).  Therefore relaxin has been well characterised in terms of 
structure, and is now a well known hetrodimeric peptide hormone structurally 
related to the insulin family of peptides.  Relaxin is an insulin-like 6 kD peptide 
hormone, detectable in serum during pregnancy and is produced in females by 
the corpus leuteum of the ovary, the breast and during pregnancy by the 
placenta, chorion and decidua.  In males relaxin and its receptors RXFP-1 and 
RXFP-2 are produced by the testis and the prostate (Einspanier et al., 
1997;Gunnersen et al., 1996;Filonzi et al., 2007).    In women serum levels of 
relaxin follow the pattern of chorionic gonadotropin hormone (hCG).  Relaxin 
levels rise after ovulation as a result of production by the corpus leuteum, in the 
absence of pregnancy the levels will decline at menstruation.  During the first 
trimester of pregnancy levels of relaxin are high.  The additional relaxin is 
produced by the decidua.  The levels are maintained during the second trimester 
but decline in the third trimester of pregnancy and it is thought that relaxin is 
important in implantation and maintenance of the embryo in early development 
(Parry and Vodstrcil, 2007;Einspanier et al., 1999).  Although in many species 
relaxin has been shown to be important in pregnancy, the serum level detected 
does not rise above 1 ng/ml in humans.  The levels detected in humans are 
around two orders of magnitude lower than in rats, mice and pigs, where levels                                                                                            Chapter 1: Introduction 
  48
of around 150 ng/ml have been detected.  Relaxin widens the pubic bone 
facilitating labor in guinea pigs.  Relaxin softens the cervix (cervical ripening) 
and relaxes the uterine musculature, which is why relaxin has been thought of as 
a hormone of pregnancy for many years (Parry and Vodstrcil, 2007).  Although 
relaxin does have important roles in pregnancy more recently it has been found 
to have a diverse range of biological actions in several species (Sherwood., 
2004).  Relaxin can affect collagen metabolism, inhibiting its synthesis and 
enhancing its breakdown by increasing matrix matalloproteinases (MMPs) 
expression (Samuel et al., 2005a).  This obviously has implications in fibrotic 
conditions and work has begun to investigate the role of relaxin in several 
fibrotic organs including the heart, lungs, kidneys and the liver (Samuel, 2005b).   
Relaxin enhances angiogenesis having implications in cancer and has been 
found to be a potent renal vasodilator which is important in pregnancy and could 
help protect the kidneys from hypertensive forces (Samuel and Hewitson, 
2006;Jeyabalan et al., 2003;Jeyabalan and Conrad, 2007;Jeyabalan et al., 2007). 
 
 
 
Figure 1.8. Tertiary structure of relaxin showing the A and B chain linked via two 
disulphide bonds and the intra-chain disulphide bond in the A-chain. (Pubmed) 
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In recent years the relaxin family of peptides has expanded with the discovery of 
five more relaxin-related peptide genes, Insulin like-3 (INSL3), Insulin like-4 
(INSL4), Insulin like-5 (INSL5), Insulin like-6 (INSL6) and H3 relaxin.  H3-
relaxin was discovered by Bathgate and colleagues in 2002 (Bathgate et al., 
2002).  Orphan receptor GPCR-135 was used as bait to identify the ligand from 
brain extracts by HPLC.  An amino acid motif in H2-relaxin was found to be 
highly conserved on the peptide eluted with GPCR-135 (RXFP-3), which was 
subsequently found to activate relaxin receptors.  The peptide was identified as 
H3-Relaxin and was found to activate GPCR-135 (RXFP-3) with the greatest 
efficacy, subsequently deorphanising the receptor which has since been 
described as a neurotransmitter-like substance found mainly in the regions of the 
brain where the RXFP-3 receptors have been localized (Bathgate et al., 2002).  
INSL5 was discovered to bind to RXFP-3 and RXFP-4 receptors.  It was 
subsequently found to activate RXFP-4 and by binding to RXFP-3 actually 
inhibits the binding of H3-relaxin to its receptor but does not activate the 
receptor(Liu et al., 2003;Liu et al., 2005b).  
 
1.6.2 Relaxin receptors and signalling mechanisms 
 
The most significant advance in relaxin biology has been the deorphanisation of 
the receptors for relaxin (Hsu et al., 2002).  Relaxin receptors are a relatively 
new family of receptors causing a substantial upsurge in interest in recent years 
in relaxin biology.  The receptors were found to contain a leucine-rich repeat 
domain, and a seven transmembrane region that coupled to G proteins (figure 
1.9).  The receptors were found to be class 1 G-protein coupled receptors 
(GPCRs).  This was the logic behind the original nomenclature used for the 
receptors, leucine rich repeat containing GPCR (LGR7 and LGR8).  An 
international union on nomenclature was agreed in 2006 (table.1) (Bathgate et 
al., 2006).  There are four members of the relaxin receptor family.  RXFP-1 and 
RXFP-2 are seven transmembrane receptors that have a large leucine rich 
extracellular domain that is essential for ligand binding (Halls et al., 2005c;Halls                                                                                            Chapter 1: Introduction 
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et al., 2005b), and a low density lipoprotein domain that is thought to influence 
receptor maturation and trafficking to the membrane (Kern et al., 2007).  RXFP-
3 and RXFP-4 are also seven transmembrane receptors but lack the leucine rich 
repeat domain found in RXFP-1 and RXFP-2.  RXFP-3 and RXFP-4 were 
originally called GPCR 135 and GPCR 142 before deorphanisation respectively.  
Binding to RXFP-3 and RXFP-4 is less well defined but the lack of the leucine 
rich repeat domain may explain the differences in ligand binding and potency of 
activation (Liu et al., 2005a). 
 
 
 
 
Figure 1.9.  Schematic representation of the relaxin receptor structure and orientation in 
the cell membrane. 
 
RXFP-1 (LGR7) is able to bind to H2-relaxin, H3-relaxin and INSL3, but its 
main activating ligand is H2-relaxin.  H2-relaxin binds to and activates RXFP-1 
with greater efficacy then any of the relaxin family peptides.  RXFP-2 (LGR8 or 
GREAT) is able to bind to INSL3, H2 relaxin and H3 relaxin, but its main 
activating ligand is RXFP-2.  RXFP-2 and INSL3 knockout models have the 
same phenotype.  This was the first piece of evidence that linked these receptors, 
and led to the deorpahnisation of further relaxin family receptors.  RXFP-3 
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acts as an antagonist at the RXFP-3 receptor.  RXFP-4 (GPCR142 or GPR100) 
is able to bind to INSL5 and H3 relaxin, although the main activating receptor is 
believed to be INSL5.  There have been no RXFP-4/INSL5 or RXFP-3/H3-
relaxin knockout models developed to be able to study the importance of these 
receptors and to be able to link the receptor/ligand complex in an in vivo setting.  
The accepted nomenclature, relative ligand potencies, potential signalling 
mechanisms and knockout model phenotypes are described in table 1 (Bathgate 
et al., 2006).  
 
Receptor  Ligand potencies  Potential Signalling
Mechanism 
Knockout model 
phenotype 
RXFP-1 
(LGR7) 
H2-Rlx>H3 Rlx>> 
INSL3 
    cAMP,  PI3-K,      
    NOSII, Erk1/2 
Age related heart, lung 
and kidney fibrosis.  
RXFP-2 
(LGR8) 
INSL3>H2 
Rlx>>H3 Rlx 
    cAMP  Cryptochirdism  
RXFP-3 
(GPCR135) 
H3 Rlx>H3 Rlx B-
Chain >>INSL5 
    cAMP  No Knockout model 
RXFP-4  
(GPCR142) 
INSL5=H3 
Rlx>>H3 Rlx B-
Chain 
    cAMP  No knockout model 
 
Table.1. The accepted receptor and ligand nomenclature (Bathgate et al., 2006). 
 
Binding studies have been carried out to identify the region of the RXFP-1 and 
RXFP-2 receptors that are important for binding and activation by their 
respective ligands H2-relaxin and INSL3.  Maximal activation of the RXFP-1 
receptor requires interaction with both the ectodomain and exoloop 2 of the 
transmembrane domain (Halls et al., 2005b). Further studies identified the 
ectodomain to be the high affinity binding site and exoloop 2, the lower affinity 
binding site.  A third region has also been discovered to be involved in the 
activation of these receptors; the N-terminal low density lipoprotein class-A 
(LDLa) module that is unique to the class C LGR’s (Halls et al., 2005c;Kern et 
al., 2007;Bathgate et al., 2005).   Stimulation of RXFP-1 and RXFP-2 receptors 
causes an increase in cAMP, although the coupling of these receptors still under                                                                                            Chapter 1: Introduction 
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investigation and other potential downstream pathways have been suggested 
(figure 1.10) (Bathgate et al., 2005). 
 
Much emphasis has been put on relaxin utilising the activation of cAMP 
accumulation pathway.  The cAMP signalling pathway can be observed using 
simple assays, allowing the manipulation of receptor-ligand interactions in 
different cell types to be studied.  The possible signalling pathways have been 
investigated through the use of reporter gene and cAMP assay in the RXFP-1 
expressing THP-1 cell line and through transfecting a RXFP-1 construct into 
HEK293T cells (Halls et al., 2005a;Nguyen et al., 2003).  The increase in cAMP 
has been found to be biphasic.  The biphasic nature of cAMP accumulation 
observed in THP-1 and myometrial cells suggests the activation of adenylate 
cyclase may be by more then one mechanism (Dessauer and Nguyen, 2005).  It 
is thought that the initial accumulation of cAMP is due to the classic Gs-
adenylate cyclase pathway, and the delayed response may be due to the Gi-
linked PI3-Kinase pathway.  Further studies have also shown that the delayed 
response is reliant on the PI3-kinase-dependent protein kinase C (PKC) 
translocation to the cell membrane (Halls et al., 2006).  
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Figure 1.10. Potential signalling pathways of RXFP-1. Signalling pathways highlighted 
in red are used in assays to assess RXFP-1 activation, adapted from (Bathgate et al., 
2005). 
 
RXFP-3 and RXFP-4 have been less extensively studied compared to RXFP-1 
and RXFP-2 but several downstream signalling mechanisms have been 
suggested (figure 1.11) (Bathgate et al., 2005).   RXFP-3 and RXFP-4 are 
negatively coupled to cAMP, activation of the receptors decreases the 
accumulation of adenylate cyclase through the activation of G-protein Gi.  The 
decrease in adenylate cyclase reduces the production of cAMP in the cell.  In 
addition activation of Gi can activate PI3K and phospholipase C (PLC) and 
subsequently PKC, which may all have downstream affects on gene transcription 
and cellular responses (Zhong et al., 2005).  PLC is an enzyme that hydrolyses 
glycerophosphatidates with the formation of diacylglycerol and a 
phosphorylated nitrogenous base such as choline (Long and Maguire., 1954).  At 
the present time the down regulation of cAMP is possibly the most robust 
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method of detecting activation of RXFP-3 and RXFP-4 in the cell systems used 
in this study. 
 
 
 
 
Figure 1.11. Potential signalling pathways of RXFP-3 and 4, adapted from (Bathgate et 
al., 2005).  
 
PKCs are a family of protein kinases that consists of 10 isoforms in 3 
subfamilies.  The 3 subfamiles are divided into conventional, novel and atypical 
which is based on their second messenger requirements (Dempsey et al., 2000).  
The structure consists of a regulatory domain and a catalytic domain tethered by 
a hinge region.  The catalytic domain is highly conserved among the different 
isoforms and to a lesser degree among other serine/threonine kinases (Dempsey 
et al., 2000).  Relaxin is thought to activate the PKC zeta isoform which is an 
atypical PKC phosphorylated only on the activation loop and turn motif 
(Dessauer and Nguyen, 2005).  Phosphorylation of the hydrophobic motif is 
unnecessary due to the presence of glutamic acid in the place of a serine which 
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as a negative charge acts similarly to a phosphorylated residue.  Phosphorylation 
events are essential for the activity of the enzyme.  Conventional and novel 
forms of PKC require Ca
2+ and/or diacylglycerol (DAG) for activation but 
atypical forms such is activated by relaxin require neither Ca
2+ or DAG but in 
this instance are thought to be dependent on phosphoinositde 3-kinase (PI3 
Kinase) (Dempsey et al., 2000).  Upon activation PKC enzymes are translocated 
to the plasma membrane by receptor activated C-kinase (RACK) proteins that 
are responsible for binding the active forms of PKC.  The different isoforms of 
PKC use different RACK proteins as they mediate differential subcellular 
targeting (Csukai and Mochly-Rosen, 1999).  Relaxin elicits a biphasic increase 
in cAMP when the RXFP-1 receptor is present.  PKC proteins are known for 
there long term activation, and could be responsible for the second phase of the 
relaxin signalling response (Dessauer and Nguyen, 2005).     
 
Relaxin has been found to stimulate protein kinase A (PKA) activity in bronchial 
epithelial cells and was found to activate PKA in reporter gene studies (Wyatt et 
al., 2002;Halls et al., 2005a).  The increase in activity was 3-4 fold after 4 hours 
with a return to baseline after 8-10 hours.  This differs from the very rapid 
activation of PKA through the activation of beta-adrenergic receptors (Wyatt et 
al., 2002).  PKA also known as cAMP dependent protein kinase, which refers to 
a family of enzymes whose activity is dependent on the level of cAMP in the 
cell (Van den Berg et al., 1980).  PKA is a holoenzyme consisting of two 
regulatory and two catalytic subunits.  Under low levels of cAMP the enzyme 
remains intact and catalytically inactive.  If the cAMP concentration increases in 
the cell the cAMP molecule will bind to the regulatory subunits of the PKA 
molecule which then undergoes a conformational change that releases the 
catalytic subunits, which are then free to phosphorylate other proteins in the cell.  
Direct protein phosphorylation by PKA can increase or decrease the activity of 
proteins and can be fast acting (Servillo et al., 2002).  PKA can affect protein 
synthesis through the activation of cAMP response element binding proteins 
(CREB) which are transcription factors that bind cAMP response elements in                                                                                            Chapter 1: Introduction 
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DNA, altering transcription and synthesis of proteins (Tacke et al., 2005).  
Proliferation of activated HSC has been reduced by the phosphoylation of CREB 
through a PKA mediated pathway (Houglum et al., 1997). 
 
More recently there is evidence that relaxin can act on cells both acutely and 
chronically by increasing the expression and activity of nitric oxide synthase 
(NOS) and therefore increased processing of nitric oxide (NO) (Nistri and Bani, 
2003).  Nitric oxide is a secretory product present in most mammalian cells.  The 
biological properties of nitric oxide were first widely appreciated when it was 
discovered that nitric oxide was endothelial derived relaxing factor (EDRF) 
(Furchgott and Vanhoutte, 1989;Ignarro et al., 1988).  EDRF had already been 
described as having potent vasodilatory properties in stimulated endothelia 
(Furchgott and Zawadzki, 1980;Furchgott et al., 1984).   NO is now recognized 
as being a pleiotropic biological mediator that regulates a diverse range of 
activites from neuronal function to immune system regulation.  Upon secretion it 
can locally activate the host defense immune response, and has homeostatic and 
developmental functions by either direct stimulation or through intracellular cell 
signalling (Billack, 2006;Bilzer et al., 2006).  NO is a gaseous free radical and is 
the product of five electron oxidation of the amino acid L-Argenine mediated 
through nitric oxide synthase (NOS).  Members of the NOS family include 
neuronal (nNOS), endothelial (eNOS) and inducible (iNOS).  nNOS is highly 
expressed in neurons of the central and peripheral nervous system and has been 
described in other cells types such as skeletal muscle myocytes, lung epithelial 
cells and skin mast cells.  eNOS is highly expressed by endothelial cells and may 
also be found in neurons, dermal fibroblasts, epidermal karatinocytes, thyroid 
follicular cells, hepatocytes and smooth mucle cells.  iNOS is expressed in a 
wide range of cell types including chondrocytes, epithelial cells, hepatocytes, 
glial cells and several cell types of the immune system.  eNOS and nNOS are 
constitutively expressed and regulated by Ca
2+/calmodulin, whilst iNOS is 
induced by endotoxin and inflammatory cytokines and exhibits a relative 
insensitivity to Ca
2+ (Alderton et al., 2001;Kone et al., 2003).  NO has the                                                                                            Chapter 1: Introduction 
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potential to mediate its effects on its target tissue via several different 
mechanisms, as a direct effector molecule NO can activate kinases, proteases 
and regulatory proteins directed by reactive oxygen intermediates.  As a 
messenger molecule NO interacts with target molecules based on their redox 
potential rather then their non covalent complimentarity.  Activation of the 
immune system is associated with an increase in macrophage nitric oxide 
production.  NO exerts a variety of homeostatic influences as an activator of 
soluble guanylyl cyclase (GC), which catalyses the formation of the second 
messenger Guanosine 3’, 5’-cyclic Monophosphate (cGMP).  cGMP has a range 
of biological functions such as axon guidance and synaptic plasticity, cell 
survival and proliferation, angiogenesis, inflammation and a contraction 
regulator of both smooth muscle and vascular tissue.  Defects in cGMP 
signalling have been reported in HSC from cirrhotic patients, which has been 
suggested contributes to the impaired NO responses in the relaxation of HSC 
(Perri et al., 2006).  NO also has functions as an anti-tumor and anti-mircobial 
agent via mechanisms that include its conversion to peroxynitrite (ONOO
-), the 
formation of S-nitrosothiols, and the depletion of argenine (Bogdan, 2001). 
Another role for NO includes the suppression of mitochondrial respiration 
through the inhibition of cytochrome oxidase (Antunes et al., 2004).  NO may 
also modify protein activity through the post-translational nitrosylation via the 
attachment of an NO moiety to the thiol side chain of cysteine residues (Hess et 
al., 2005).  NO is lipid soluble and is therefore not stored but synthesized when 
needed and then freely diffuses across lipid membranes.  NO has a very short 
half life in vivo as it is metabolized to two stable products nitrate (NO3) and 
nitrite (NO2) within a few seconds or less. The levels of these more stable 
metabolites can be used for indirect measurements of NO in biological fluids.  
Altered levels of NO have been associated with vascular disease, pregnancy 
related disorders, inflammatory diseases, hypoxia and cancer (Wimalawansa, 
2008). 
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Relaxin has also been reported to act on Glucocorticoid receptors (GRs).  GRs 
belong to a receptor superfamily that includes steroid, thyroid and retinoic acid 
receptor proteins.  GRs function as ligand dependent transcription factors i.e. 
nuclear receptors.  When relaxin binds the cytoplasmic GR it activates and 
translocates to the nucleus where it binds specific glucocorticoid response 
elements (GRE) of the DNA, thereby stimulating transcription of the responsive 
gene (Dschietzig et al., 2004;Dschietzig et al., 2005).  Activated GRs can also 
interact with transcription factors such as NF-κB and AP-1, which then may 
indirectly influence gene expression.  Cytoplasmic GR is complexed with 
different proteins such as molecular chaperones Hsp70 and Hsp90 that appear to 
be essential for ligand binding and receptor activation.  There are two human 
isoforms of GRs, GR-α and GR-β (Dschietzig et al., 2004;Dschietzig et al., 
2005).  The two different isoforms originate from the same gene but are 
alternatively spliced.  The GR-α form is the most abundant with GR-β hardly 
detectable.  The function of GR-β is still under debate but it has been suggested 
that it is a dominant negative inhibitor of GR-α (Dschietzig et al., 
2004;Dschietzig et al., 2005).  Treatment with relaxin reduces the production of 
pro-inflammatory cytokines by human macrophages; this action is blocked by 
the glucocorticoid receptor antagonist RU486.  Relaxin not only enters intact 
cells but it appears to become concentrated in the nucleus where it competes 
with GR agonists to activate GR receptors, and induces nuclear translocation and 
DNA binding.  This action has been reported to be independent from the 
activation at RXFP1 receptors as modified relaxin unable to bind the RXFP1 
receptor retains activity at the GR receptor (Bathgate et al., 2005).  Relaxins role 
as a GR agonist and its pivotal effects in cytokine secretion by human 
macrophages will help our understanding of the abundant physiological actions 
that relaxin exerts far beyond its role in pregnancy (Dschietzig et al., 2004) 
 
Relaxin may stimulate many different pathways in different cell types.  The 
mechanism of this activation is important to further understanding the role of 
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vital importance when considering relaxin receptors as a target for therapeutic 
intervention in humans.  Studies characterising the phenotype of cells and 
animal models after exposure to recombinant human relaxin are required before 
relaxin therapies can be justified in human trials.  The safety of relaxin is not in 
question but understanding the potency of action and effect on different cell 
types will ultimately influence the outcome of any trials. 
 
1.6.3 Relaxin and fibrosis 
 
Relaxin has been found to play an important role in the ripening of the cervix 
ready for parturition, inhibiting uterine contraction and softening the birth canal, 
which requires tissue remodelling of the cervix and the interpubic ligament. The 
tissue remodelling of the cervix has been studied and the effect of relaxin seems 
to be due to the decrease in production of collagens type 1 and III and the 
increase in production of collagenases (Sherwood, 2004a).  One of the most 
consistent biological effects of relaxin is its ability to stimulate the breakdown of 
collagen, not only stimulating collagen remodelling in the birth canal but in cells 
and tissues affected by fibrosis.  The use of relaxin to treat scleroderma was 
suggested in the 1950s (Casten and Boucek., 1958).  In the late 1990s relaxin 
was used in clinical trials to treat scleroderma, which is a complex disorder of 
the connective tissue, characterised by thickening and fibrosis of the skin.  
Scleroderma if severe, can affect several internal organs such as the heart, lung, 
liver and kidneys.  Relaxin treatment reduced skin thickening and increased 
mobility, although the efficacy end points were not reached highlighting the 
need to determine the potency and mechanism of action of relaxin in fibrotic 
disorders (Seibold et al., 2000).  Relaxin was shown to inhibit collagen 
accumulation in a bleomycin induced model of lung fibrosis by inhibiting TGF-
β-induced production of matrix proteins and stimulating MMP-induced collagen 
breakdown (Mookerjee et al., 2005a).   Relaxin affects cardiac function and 
participates in the regulation of blood pressure, blood flow and fluid balance 
(Sherwood., 2004).  Studies have been carried out showing relaxin exerting a                                                                                            Chapter 1: Introduction 
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significant cardioprotective effect in the ischemic and reperfused rat heart.  
Systemic administration of relaxin results in a marked reduction of the 
myocardial areas damaged by post-ischemic reperfusion as well as a reduction in 
the occurrence of ventricular arrhythmias.  Ischemic-reperfused hearts from the 
relaxin treated group showed a marked decrease in the recruitment of neutrophils 
from the circulation into the myocardium compared to the non-treated group 
(Bani et al., 1998).  Relaxin has been studied in an animal model of liver 
fibrosis.  Human recombinant relaxin was used to continuously treat a group of 
six male Sprague-Dawley rats via an osmotic pump, that were also injected 
(interperitoneally) with Carbon Tetrachloride (CCl4) for a period of twenty eight 
days to induce hepatic fibrosis.  This group was compared to a control group of 
six rats also being injected with CCl4, but instead of relaxin were given PBS 
continuously via an osmotic pump.  There was a decrease in collagen-1 synthesis 
and deposition as well as a decrease in liver weight in the relaxin treated group, 
which was repeated in vitro with cultured rat HSC when treated with relaxin 
(Williams et al., 2001a).  The effect of relaxin in inhibiting collagen synthesis in 
the above rat model of liver fibrosis and in cultured rat HSC suggests relaxin 
could have similar effects in human HSC.  Currently there are no data in the 
effect of relaxin on human HSC biology.   
 
Relaxin knockout mice were developed, lacking H1-relaxin which is the main 
circulating form in rodents (Samuel et al., 2005).  Endogenous relaxin is a 
naturally occurring inhibitor of collagen turnover, playing a role in maintaining 
the balance between collagen production and degradation in most major organs 
of the body (Samuel et al., 2005).  The effect of relaxin is believed to be 
significant from normal growth and development, pregnancy through to aging.  
Male relaxin knockout mice show marked deficiencies in the reproductive tract 
and by 3 months of age several reproductive organs, including the prostate, testis 
and seminal vesicle, were significantly smaller then in age matched wild types 
(Samuel et al., 2005). Further studies confirmed the increase in collagen content 
in the prostate and testis which was associated with impaired function (Samuel                                                                                            Chapter 1: Introduction 
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et al., 2003).  Male relaxin knockout mice consistently develop organ fibrosis in 
the lung, heart, kidneys and prostate which led to altered tissue structure and 
organ dysfunction.  Female relaxin knockout mice demonstrate increased 
fibrosis in the reproductive tract and nipples during late pregnancy which 
resulted in the inability of relaxin knockouts to suckle their young.  Subsequent 
studies have connected these deficiencies to excess collagen deposition (Zhao et 
al., 1999;Zhao et al., 2000).  Female relaxin knockout mice demonstrate delayed 
onset of fibrosis in the lung but did not display fibrosis in the heart and kidneys 
(Samuel et al., 2005).  There are obvious phenotypic differences between male 
and female relaxin knockout mice. The presence of androgens in males has been 
suggested to contribute to increased fibrosis (Du, 2004) and female specific 
factors such as hormones, particularly estrogen may compensate for the loss of 
relaxin.  Estrogen has been found to decrease collagen synthesis and to inhibit 
the profibrogenic effects of TGF-β (Neugarten et al., 1999;Negulescu et al., 
2002).  Treatment of relaxin knockout mice with recombinant H2-relaxin 
restored the normal tissue architecture in the lung, heart and kidneys particularly 
if applied at the early onset of the fibrotic changes (Samuel et al., 2005). RXFP-
1 knockout mice were found to have a similar phenotype to the H1-relaxin 
knockouts (Krajnc-Franken et al., 2004).  Taken together these data add further 
supporting evidence to the idea that relaxin is antifibrotic in many organs.   
 
Relaxin was shown to inhibit fibroblast proliferation as early as 1989.  It was 
demonstrated that relaxin could affect the normal course of cell division in the 
3T3-L1 fibroblast cell line (Pawlina et al., 1989).  Since this observation it has 
been shown that relaxin can directly inhibit fibroblast differentiation by 
inhibiting α-SMA expression and reduce cell number and proliferation in rat 
cortical fibroblast, rat cardiac fibroblasts, rat hepatic stellate cells and TGF-β 
stimulated renal fibroblasts (Masterson et al., 2004;Samuel et al., 2004;Bennett 
et al., 2003).  Relaxin has been shown to reduce newly formed collagen 
secretion in vitro when applied to human dermal fibroblasts, human lung 
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fibroblasts (Unemori and Amento, 1990;Unemori et al., 1996;Williams et al., 
2001b;Samuel et al., 2004).  Relaxin had a marked effect even in the presence of 
profibrotic factors such as TGF-β1, Interleukin-1 and Angiotensin II in some cell 
culture models.  Relaxin did not effect the basal collagen expression in any of 
the cells it was applied to highlighting its specificity to affect scarred tissue and 
not normal collagen architecture (Samuel, 2005a).  The ability of relaxin to 
inhibit collagen deposition has been studied in numerous human and rat in vitro 
and in vivo models of fibrosis.  It appears that relaxin can stimulate the 
expression and activation of several MMPs, including MMP-1, MMP-2, MMP-
3, MMP-9, MMP-12 and MMP-13 in various organs and animal models (Garber 
et al., 2001;Lekgabe et al., 2005;Williams et al., 2001b;Mookerjee et al., 2005a).  
Relaxin was also documented as inhibiting the expression of TIMPs, particularly 
TIMP-1 and TIMP-2 (Unemori and Amento, 1990;Williams et al., 2001b).  The 
mechanism by which relaxin down regulates collagen deposition may then in 
part be due to regulating the expression of MMPs and TIMPs, shifting the 
MMP-TIMP balance to a pro-resolution phenotype (Hemmann et al., 2007).   
 
The most potent profibrogenic cytokines are TGF-β1 and AngII and their 
downstream mediators CTGF, PDGF and ET-1.  TGF-β1 is a potent stimulator 
of ECM and collagen synthesis in fibroblasts and HSC.  Relaxin has been 
documented as inhibiting the TGF-β1 induced secretion of ECM and collagen in 
human dermal, pulmonary and renal fibroblasts (Unemori and Amento, 
1990;Unemori et al., 1996;Heeg et al., 2005).  Relaxin was found to inhibit 
smad2 phosphorylation and its translocation to the nucleus which prevented 
smad2 forming a complex with smad3 and therefore inhibiting the action of 
TGF-β1.  Relaxin was also found to be a potent inhibitor of TGF-β1 induced 
renal fibroblast activation and in a rat in vivo model of chronic renal disease 
relaxin reduced the expression of TGF-β1 (Unemori and Amento, 1990;Unemori 
et al., 1996;Heeg et al., 2005).  There is evidence that relaxin is a functional ET-
1 antagonist.  Relaxin not only inhibited the stimulation of ET-1 but increased 
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ERK-1/2 dependent pathway that subsequently activated NF-κB (Dschietzig et 
al., 2003).   
 
It is acknowledged that relaxin is an important mediator of human gestational 
renal adaptation.  Data from rat models (Conrad et al., 2005) and human studies 
(Smith et al., 2005) have suggested that relaxin functions to regulate renal 
hemodynamic and osmoregulatory changes by decreasing the vascular resistance 
in the kidneys, thereby increasing the glomerular filtration rate (GFR) and 
cardiac output facilitating the expansion of plasma volume which stimulates 
renal sodium and water retention.  There have been several mechanisms 
suggested by which relaxin has these effects.  Nitric Oxide (NO) is a well known 
vasodilator and increased excretions of NO metabolites have been found in 
pregnant rats.  Infusion of inhibitors to NO such as L-NAME and L-NMA were 
found to decrease GFR and increase vascular resistance therefore indicating a 
direct role for NO in renal adaptation during pregnancy (Conrad et al., 2005).  
The increase in NO in the cell was suggested to be through several mechanisms 
including increased activation of NOS II and NOS III enzymes through the 
activation of second messenger systems linked to RXFP-1 activation and the 
increased expression and activation of the endothelin B receptor (ETB).  It was 
hypothesised that relaxin could upregulate gelatinase activity (MMP-2) during 
pregnancy which increases the cleavage of big ET at the gly-leu bond to ET1-32.    
ET1-32 was discovered at the end of the nineties by Fernadez-Patron and 
colleagues (Fernandez-Patron et al., 1999) and was found to be a novel ET-1 
agonist that was dependent upon MMP-2 for cleavage and activation.  ET1-32 
was found to have activity at both ETA and ETB receptors.  Activation of ETB 
can increase the activity of nitric oxide synthase enzymes (NOS) in the target 
tissue.  NOS catalyses the reaction which produces NO from L-Arginine, 
NADPH and O2.   NO induces vasodilatation through a range of second 
messenger systems depending on the target tissue.  The traditional endothelin 
converting enzyme (ECE) that processes big ET to ET1-21 was not involved in 
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expression of ETB receptors was increased in the target tissue and there was 
increased processing of the precursor for ET1-32  thus increasing the activation of 
the receptor, this could increase the level of nitric oxide synthase III (NOS III) in 
the tissue which in turn increases the level of NO in the tissue inducing renal 
vasodilatation (Fernandez-Patron et al., 1999).  It has been documented that 
endothelin-1 is released in the fibrotic liver inducing contraction of the HSC and 
other structures which can exacerbate the injury and cause complications such as 
portal hypertension observed in the cirrhotic liver (Zhang et al., 1994;Pinzani et 
al., 1996).  
 
1.7 Hypothesis, Rationale and Objectives 
 
1.7.1 Hypothesis 
 
Relaxin receptors are expressed in human liver and H2-relaxin can antagonise 
the profibrogenic phenotype in cultured HSC.  H2-relaxin inhibits the 
contraction of HSC in collagen gels.  The knockdown of RXFP-1 inhibits the 
antifibrotic and anticontractile effect of H2-relaxin. 
 
1.7.2 Rationale 
 
Since the discovery of the family of GPCRs that respond to relaxin and relaxin-
like peptides in 2002 there has been resurgence in interest in research into 
relaxin in multiple disease states.  There are publications describing the possible 
antifibrotic role of relaxin for review see (Samuel, 2005a).  Many of the papers 
are based on data collected from in vitro and in vivo animal work.  Recombinant 
relaxin was used in the liver group in Southampton to treat CCl4 injured rats.  
The results revealed relaxin had antifibrotic properties in the rat liver (Williams 
et al., 2001).  Human clinical trials have been carried out using H2-relaxin as a 
continuous subcutaneous treatment for scleroderma (a form of skin fibrosis).  
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improved mobility and function.  This affect was seen in patients with moderate 
to severe diffuse scleroderma (Seibold et al., 2000).  The earlier studys of relaxin 
carried out by Williams and colleagues were before the deorphanisation of the 
receptors.  The previous observations justified a preliminary experiment too 
quantify the relaxin receptor expression in CCl4 injured rat liver. The results 
confirmed that relaxin receptors were expressed in the liver and were up 
regulated during injury (appendix 1).  There has only been limited work carried 
out in rat liver and very little work has been published investigating relaxin in 
human models of liver fibrosis.  The relaxin field would benefit from studies 
carried out to investigate the antifibrotic properties in human liver fibrosis 
therefore these preliminary results supported the study of relaxin in human 
models of liver injury.  
 
1.7.3 Objectives 
 
•  To assess the relaxin receptor expression profile in human liver and 
hepatic stellate cells. 
•  To investigate the effect of H2-relaxin on the expression of markers of 
fibrosis such as α–SMA, TIMP-1, procollagen-1, MMP-1, MMP-2. 
•  To test the effect of H2-relaxin on cell viability through MTS assays and 
the expression of PARP-1. 
•  To determine the effect of H2-relaxin on the contractile properties of 
HSC in gel contraction assays. 
•  To determine if the phenotypic effects observed for H2-relaxin in HSC 
are through the activation of RXFP-1. 
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2.1 Extraction and culture models of human hepatic stellate cells 
and hepatic stellate cell lines 
 
All methods were carried out by the author unless otherwise stated.  All human 
tissue was obtained and stored in accordance with the Human Tissue Act 2004. 
Liver tissue was sourced from Southampton General Hospital through surgeons 
carrying out tumour resections (Mr Pierce and Professor Primrose).  Normal 
margins around the tumour tissue (around 30-50 grams) were dissected by a 
pathologist (in the pathology unit at Southampton General Hospital).  The tissue 
was then used to extract cells and some was kept for fixation for later staining 
procedures. 
 
The isolation and culture of Kupffer cells, sinusoidal endothelial cells and HSC 
was first described by (Friedman and Roll, 1987).  This enabled researchers to 
study the cells which were believed to be major contributors to hepatic fibrosis 
in more detail.  Human HSC have since been extensively characterised and are 
accepted as good model to study fibrotic changes in vitro.  If cultured on plastic 
or a collagen-1 type matrix, HSC undergo a phenotypic change from a quiescent 
vitamin A storing cell, to a proliferative myofibroblast like cell.  This mimics 
what is believed to occur in vivo during liver injury.  The isolation of HSC 
depends on a density gradient that isolates the vitamin A storing cells from red 
blood cells and hepatocytes. 
 
2.1.1 Human hepatic stellate cell isolation, preparation of enzyme solutions 
Enzymes were weighed out, 100 mg Pronase (Sigma), 20 mg Collagenase 
(Roche), 10 mg DNase-1 (Roche).  Each enzyme was dissolved in 20ml Hanks 
Buffered Salt Solution (HBSS-) (Invitrogen) and filtered through a 0.2 micron 
sterile filter (Fisher).  HBSS is supplied with or without calcium chloride, 
magnesium chloride and sodium bicarbonate.  When HBSS is used it will be 
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2.1.2 Preparation of the liver 
 
The liver was washed in HBSS- the peripheral fibroblast rich area was removed 
and the remaining liver was then cut into the smallest pieces possible. 2 ml of 
diluted DNase-1 was added. The liver was then transferred to a 500 ml 
autoclaved bottle and the diluted pronase and collagenase B were added.  HBSS- 
was added up to 150 ml and this was incubated at 37ºC for 30-45 minutes in an 
orbital shaker (until liver is pale in colour). The liver homogenate is then filtered 
through a small weave Nybolt mesh (John Stainer + Co) (this is to achieve 
complete homogenous suspension), 1 ml DNase is added to non-specifically 
cleave any DNA released from damaged cells without harming the intact cells.  
HBSS+ was used to wash the liver through the nybolt mesh to make up a final 
volume of 200 ml of homogenate, which was then split into four 50 ml 
polypropylene Falcon tubes (Becton Dickenson). 
 
2.1.3 Density Gradient Centrifugation 
 
The four 50 ml Falcon tubes were then centrifuged at 1800 rpm for 7 minutes 
with the brake on. The supernatant was discarded and the pellet was resuspended 
in 1 ml of diluted DNase-1, add then HBSS+ to 50 ml.  The tubes were then 
centrifuged for a further 7 minutes at 1800 rpm with the brake on (optional wash 
spin). The supernatant was discarded and the pellets were resuspended in 1 ml 
diluted DNase-1.  The pellets are all pooled into one Falcon tube and were then 
made up to a final volume of 44.4 ml with HBSS+.  14 ml of Optiprep (Axis 
Shield) and 15.6 ml of HBSS+ were added to an autoclaved 100ml bottle and 
mixed.  The pooled pellets were added to the optiprep/HBSS mix (gradient mix) 
and mixed well and were then divided into two Falcon tubes, 35 ml in each. A 
layer of 3 ml HBSS+ was then added slowly against the wall of the tube, this 
remained a layer on top of the gradient mix. The tubes were then centrifuged at 
3500 rpm for 17 minutes with the brake off. This spin produced layers.  The top 
layer was HBSS+, the next layer was the stellate cells, and there was a clear                                                                           Chapter 2: Methods and Materials 
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band of cells between the HBSS+ and the optiprep layers.  The layer of stellate 
cells was removed carefully (around 10 ml per 50 ml Falcon tube) and pooled 
together in a new 50 ml Falcon tube.  1 ml of diluted DNase-1 was added and 
then made up to 50 ml with HBSS+. The Falcon tube was gently inverted to 
wash the cells and then centrifuged at 1800 rpm for 7 minutes with the brake on.  
The supernatant was discarded from the cell pellet.  The optional wash step was 
carried out, so the cells were resuspended in 1 ml diluted DNase-1 to 50 ml with 
HBSS+.  The stellate cells were re-pelleted by spinning for 7 minutes at 1800 
rpm, and discarding the supernatant as before leaving a cell pellet.  
 
2.1.4 Cell culture 
 
The pellet is resuspended in 16% Dulbecco’s Modified Eagles Medium 
(DMEM) (with phenol red) (Invitrogen).  To make up the 16% DMEM, 100 ml 
of DMEM was removed from the 500 ml bottle, 80 ml of fetal bovine serum 
(FBS) (Invitrogen) , 5 ml of pen/strep (Invitrogen), 5 ml of L-glutamine 
(Invitrogen) and 5 ml of sodium pyruvate (Invitrogen) was then added to the 
DMEM. 10% FBS DMEM was used for all of the assays carried out and the 
cells were cultured in 10% DMEM for 24 hours prior to the assay taking place. 
The addition of antibiotic and pyruvate is assumed unless otherwise stated.  
Cells were counted on a heamocytometer and plated out at 1 million cells per 
T75 flasks (Greiner), the number of flasks depended on the size of the cell pellet.  
The next day the cells were checked for fluorescence (retinoid droplets inside 
the stellate cells shine under the light microscope).  The cells were fed by 
changing the media on day one, then every 3-4 days until confluent. Cells are 
passaged using an enzymatic reaction using trypsin.  10 x Trypsin-EDTA 
(Autogen Bioclear) was diluted with HBSS- or 1 X phosphate buffered saline 
(PBS) (Invitrogen) to a 1 X solution by adding 1 ml of trypsin to 9 ml of HBSS 
or PBS.  HBSS- is used as trypsin efficiency is reduced in the presence of 
calcium and FBS.  5 ml of 1x trypsin was added to a T75 flask.  The flask was 
returned to the humid 37°C, 5% C02 incubator for 5 minutes or until the cells                                                                           Chapter 2: Methods and Materials 
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had lifted from the plastic.  Ensuring all the cells had been removed from the 
plastic 5 ml of 16% DMEM was added to the T75 flask.  This was to inhibit the 
enzyme reaction before the cells were damaged.  The 10 ml cell solution was 
then added to a 15 ml Falcon and the cells were centrifuged at 800 rpm for 5 
minutes.  The supernatant was removed and discarded.  The remaining cell pellet 
was resuspended in 9 ml of 16% DMEM.    3 ml of cell solution was then added 
to three T75 flasks.  7 ml of 16% DMEM was then added to each flask and the 
cells were returned to the 37°C incubator for 24 hours.  The media was then 
removed and discarded form each flask and 10 ml of 16% DMEM was added to 
each flask.  The cells were then retuned to the incubator until confluent or 
required feeding.  Any liquid waste including cell culture media that came into 
contact with human cells was treated with a bleach solution (diluted virkon) to 
ensure no microorganisms could survive before disposal of the liquid waste. 
 
2.1.5 Culture of human HSC cell lines 
 
LX-2 cells were sourced from Professor Friedman’s lab (Xu et al., 2005).  LX-2 
cells were made from primary stellate cells extracted from a normal liver, 
allowed to activate after being cultured on plastic and then transformed with the 
SV40 promoter, large T-antigen.  These cells were named LX-1 cells.  LX-1 
cells were then grown under low growth serum selection pressure (2% serum), 
the majority of the cells died but the cells that grew through were found to have 
lost the SV40, large T antigen.  These cells were named LX-2 cells and were 
found to tolerate low growth serum conditions with no loss of replication 
capacity (Xu et al., 2005).  LX-2 cells can be cultured up to 50 passages but for 
use in these experiments the cells were not used over passage 25.  LX-2 cells 
were cultured in 10% DMEM with phenol red. 
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2.1.6 Cell culture on matrigel 
 
Growth factor reduced (GFR) matrigel basement membrane (Becton Dickenson) 
was coated on 100 mm culture dishes (Greiner) using the thick coating method.   
GFR matrigel was thawed by keeping on ice for 24 hours.  All serological 
pipettes (Greiner) and 100 mm culture dishes that were to be coated were 
cooled.  The coating procedure was carried out using aseptic techniques in a 
tissue culture hood.  The culture plates were kept on ice whilst 5 ml of GFR 
matrigel was pipetted using cooled pipettes.  The solution was spread evenly 
across the surface of the dish and then placed at 37ºC to solidify for one hour.  
The coated dishes were then washed with culture media before cells were plated 
on the matrix.  Primary HSC that had been part activated by two days culture on 
plastic were plated on the matrigel matrix alongside being plated on plastic 
tissue culture dishes.  Cells from the same prep were used for comparison.  The 
cells were extracted after 2 weeks of culture.  A cell dissociation solution, 
matrisperse (Becton Dickenson) was added to the cells plated on matrigel.  This 
was to release the cells from the matrigel as after a few days the cells do not 
remain on top of the matrix but become associated with it.  RNA and protein 
extracted is extracted from the isolated cells.  Cells plated on tissue culture 
plastic are harvested for either RNA or protein directly from the plate after 
washing any media from the cells.  The RNA and protein was then screened for 
HSC activation markers and relaxin receptor expression.  
 
2.1.7 H2-Relaxin treatment of hHSC 
 
Activated primary HSC and LX-2 cells were harvested using trypsinisation. The 
cells were counted on a heamocytometer using trypan blue exclusion and plated 
in 6 well culture plates (Greiner) at a density of 100,000 cells per well.  The cells 
were cultured in 10% DMEM for 24 hours.  The H2-relaxin ligand (Phoenix 
Pharmaceuticals) was reconstituted with PBS (Invitrogen) containing 1% BSA 
(Promega).  The ligand was supplied in 20 µg vials and a 1 mM stock solution                                                                           Chapter 2: Methods and Materials 
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was made by adding 3.35 µl PBS-BSA. The volume required to make the stock 
solution was calculated using the molecular weight of H2-relaxin.   
 
Number of moles = mass 
                                Molecular weight (MW) 
 
Number of moles = 20 x 10
-6    = 3.354 x 10
-9 
                                                  5963 
 
Number of moles = volume  x  concentration 
                                 1000 
 
3.354 x 10
-9  = volume x 1 x 10
-3 
                         1000 
 
3.354 x 10
-9  x 1000 = volume x 1 x 10
-3 
 
3.354 x 10
-6 = volume 
1 x 10
-3 
 
 
 
 
 
A 1 in 100 dilution was made from the stock to give a concentration of 10 µM in 
PBS-BSA.  The media was replaced in the 6 well culture plates with 1.5 ml of 
10% DMEM directly before treatment.  The primary HSC and LX-2 cells were 
then treated with 1.5 µl of stock, 1.5 µl of the 10 µM dilution or 1.5 µl of PBS-
BSA (the control well).  This made the final concentration in the well 1 µM and 
10 nM.  The cells were then incubated at 37ºC for a further 24 hours before the 
same treatments are added.  The cells were incubated for a further 24 hours 
before a third treatment is added.  The cells were then incubated until the next 
morning before a final treatment is added.  The cells were then incubated for a 
further 6 hours before the conditioned media was removed and placed in 2 ml 
Eppendorfs (Greiner).  The media was stored at -20°C for future use.  The cells 
were washed with two changes of PBS and then protein and RNA was extracted 
from the cells directly off the plate.  If the assay was to asses the degree of 
apoptosis the culture media (10% DMEM) was replaced 24 hours before the 
Volume = 3.354 x 10
-3 ml or 3.354 µl                                                                           Chapter 2: Methods and Materials 
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cells were lysed for protein extraction with SFM.  The cells were incubated in 
SFM to induce apoptosis.  The effect of relaxin could then be assessed in the 
presence or absence of serum.    The assay was carried out after transfection with 
RXFP-1 siRNA.  The affect of relaxin could then be assessed without the 
presence of its main functional receptor.  The cells were also plated in 96 well 
plates (5000 cells per well) and treated with the same concentrations of relaxin 
and control vehicle as before for the use in the MTS assays.  The assay was 
carried out with or without RXFP-1 siRNA in 6 well plates for use in the LDH 
cytotoxicity assay.  The media used in this assay had no added pyruvate or 
antibiotics.  The media was retained in 2 ml Eppendorfs before the cells were 
lysed in 1.5 ml of DMEM with 1% Triton X.  The cells were incubated in the 
triton x solution for 5 minutes at room temperature.  If the cells were fully lysed 
the cell culture supernatant was removed and stored at -20ºC in 2 ml Eppendorf 
tubes. 
 
 
Figure 2.1. General protocol used to treat human stellate cells with a RXFP-1 agonist, 
H2-relaxin. 
Day 1 
Day 2 
Day 3+4 
Day 5 
Plate cells in a 6 well plate 
 (100,000 cells per well) and 
culture for 24h 
Using reduced serum media
treat cells with different  
concentrations of H2-Rlx  
agonist  
Replace media and agonist 
 every 24h using non-frozen 
stock of agonist 
1000nM, 10nM, Control (PBS-BSA)
Treat cells with H2-Rlx 6 
hours before cells and 
media were collected for 
Protein and RNA extraction 
Human HSC, LX-2  
Western Blot and RT-PCR  
for fibrotic and apoptotic 
markers  
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2.2 Phenotypic analysis of cells through RNA isolation and PCR 
amplification  
 
The relaxin receptor expression was established and cell culture models were 
analysed for any phenotypic changes by looking at any up or down-regulation in 
gene transcription of mRNA.  To enable us to detect any changes, the total RNA 
was isolated from the cells and then transcribed to cDNA.  The cDNA was then 
used as the template in PCR amplification reactions using primers designed to 
amplify regions of the DNA specific to genes such as TIMP-1, MMP-2, GAPDH 
and the relaxin receptors.  Extraction of RNA was carried out using Qiagen spin 
columns.  The columns have been designed to purify RNA from small amounts 
of starting material through the selective binding of RNA to a silica based 
membrane.  High salt buffer systems allow up to 100 μg of RNA longer then 200 
bases to bind to the silica membrane using the high speed microspin technology.  
Samples are lysed and homogenised using a highly denaturing guanidine 
thiocyanate containing buffer which inactivates RNases (buffer RLT).  This 
ensures purification of intact RNA.  Ethanol is added to the buffering systems 
ensuring appropriate binding conditions.  Total RNA binds to the membrane and 
the contaminates are washed away, this systems enriches mRNA binding as 
rRNAs, tRNAs and are excluded based on size (rRNA and tRNA are usually 
smaller then 200 bases).  The RNA was then used for creating cDNA templates 
for use in PCR amplification reactions.   
 
The amplification reaction can be carried out using a standard reverse 
transcription PCR (RT-PCR) reaction where the end point product is analysed.  
All PCR reactions are based on a three stage cycle that critically depends on 
temperature and time for efficient amplification of the PCR product (figure 2.2).  
This method allows semi quantitative analysis if housekeeping genes are also 
amplified from the same samples.  The amount of PCR product is measured 
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GAPDH or β-actin amplified from the same sample.  The amount of product is 
detected on the gel through software analysis that enables the intensity and size 
of the band on a gel to be quantified.  The quantified end product is normalised 
relative to the housekeeping gene and this value for each sample relates to the 
amount of mRNA for that particular gene in the original sample.  The 
disadvantage of standard PCR is the end product may be anywhere in the 
amplification stage (figure 2.3).  If the reaction has reached a plateau for all of 
the samples it may be very difficult to detect any difference in the amount of 
product.  To reduce any error in standard PCR the cycle numbers for 
amplification where kept below 28 cycles for both housekeeping genes and 
genes of interest, which will increase the chance of the reaction being stopped in 
the linear phase of the amplification cycle.  The Reverse Transcription (RT) 
system provides lot-tested reagents to efficiently reverse transcribe poly (A) + 
mRNA or total RNA to cDNA within 15 minutes.  cDNA synthesised with the 
Reverse Transcription System can be used directly in PCR. KOD hot start DNA 
polymerase (Promega) is a premixed complex of KOD HiFi DNA polymerase 
and two monoclonal antibodies that inhibit the DNA polymerase and 3’-5’ 
exonuclease activities during PCR reaction assembly at ambient temperatures 
(Mizuguchi et al., 1999).  KOD polymerase is named after the bacteria that it is 
isolated from Thermococcus Kodakaraensis.  KOD hot start couples the high 
fidelity, fast extension speed and processivity of KOD HiFi with the high 
specificity of an antibody mediated hot start.  Non-specific amplification is 
reduced since the mispriming events during set up and initial temperature 
increases are avoided.  This enzyme efficiently amplifies genomic and 
phage/plasmid DNA targets up to 12 to 20 kbp, respectively.  Guanine-Cytosine 
(GC)-rich targets are also efficiently amplified although the maximum GC 
content for primers was kept below 50% where possible. 
 
Quantitative reverse transcription PCR (qRT-PCR) uses fluorescent dyes to 
detect the amount of product at each cycle in the amplification reaction.  There 
are two common methods for qRT-PCR, one uses a fluorescent dye such as                                                                           Chapter 2: Methods and Materials 
  76
SYBR green that intercalates with double stranded DNA and one that uses a an 
oligo sequence labelled with a fluorescent dye such as FAM (called a fluorescent 
probe) that will only bind to a specific sequence of DNA, the PCR target 
sequence.  Continuous data retrieval, i.e. the amount of fluorescence detected 
after each cycle, throughout the amplification reaction (up to 45 cycles), enables 
sensitive and accurate detection of the amount of dsDNA for a specific gene.  
The fluorescence can be compared to a standard curve created for each gene that 
you which to amplify by amplifying from a known starting mRNA 
concentration, using 6-8 points on a logarithmic scale which allows you to give 
an absolute value, copies/µl for each gene of interest.  The fluorescence can also 
more simply be compared to a set of housekeeping genes for each sample giving 
a relative amount but will also control for presence of primer dimmers.  
Threshold values are used to detect in which cycle of the reaction the 
fluorescence crossed the baseline and amplification becomes exponential.  The 
reaction is continued until the fluorescence reaches a plateau. The cycle number 
at which the fluorescence detected crosses the baseline is called the CT value 
(figure 2.3).  The CT value is used in a calculation to give you a final value, 
allowing comparison of fold changes in amount of product. The relative gene 
expression is calculated assuming 100% efficiency of the PCR (Stahlberg et al., 
2005). 
Sample 1        2
(CT
B1
- CT
B2 
) 
           
Sample 2        2
(CT
A1
 - CT
A2
) 
 
Taq polymerase (Primer Design) was used in all of the qRT-PCR reactions. Taq 
was also named after the bacteria that it was isolated from, thermus aquaticus 
(Chien et al., 1976).  Taq polymerase is a hot start enzyme with an optimum 
operating temperature of 75-80˚C.  It has a half life of 9 minutes at 97˚C and 
similar to KOD polymerase can amplify 1000 base pairs in 30-60 seconds at 
72˚C.  Taq has a low replication fidelity due to the lack of 3’-5’ exonuclease 
proof reading activity, it has an error rate of 1 in 9000 nucleotides (Lawyer et al., 
1993).  RNA and DNA methods were carried out using aseptic techniques.  The 
= = 2
(CT
B1
-CT
B2
) – 2
(CT
A1
-CT
A2
) = 2
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plastic ware and water used were DNase and RNase free and also UV 
illuminated before use. UV illumination ensures crosslinking of any 
contaminating DNA which ensures the DNA cannot be amplified.  
 
 
 
Figure 2.2.  PCR amplification cycle.  1. cDNA is denatured at 95°C.  2. The 
temperature is then rapidly cooled to the melting temperature of the primers (usually 
between 50-60°C) to allow primers to anneal to the specific sites in the genome to 
which they were designed.   3. The temperature is then rapidly ramped to the extension 
temperature (68°C for KOD polymerase) where your chosen polymerase will continue 
adding dNTPs along the region of the gene which is to be amplified.   Each polymerase 
can add base pairs at different rates (KOD polymerase requires 1 minute to add 1000 
base pairs). The polymerase will discontinue adding dNTPS when the reverse primer 
stop codon is reached, KOD polymerase is a hot start, proof reading enzyme that 
enables accurate amplification of long sequences.   4.  The newly amplified DNA goes 
back into the cycle which is repeated up to 25-35 times, increasing the number of copies 
of DNA exponentially. qRT-PCR undergoes the same reaction but a dye such as SYBR 
green will bind to any dsDNA products formed and the reaction is continued to 45-50 
cycles. 
5’ 
3’ 5’ 
5’ 3’ 
5’ 
5’ 3’ 
5’  3’ 
5’
3’ 5’ 
5’ 3’ 
3’ 5’ 
5’ 3’ 
3’ 5’ 
5’ 
5’ 
5’ 3’  3’ 
3’  5’ 3’ 
P
P
1
2
3
4
3’                                                                           Chapter 2: Methods and Materials 
  78
 
 
Figure 2.3.  PCR cycle.  The graph is a read out from a qRT-PCR but both qRT-PCR 
and standard PCR follow the same cycle.  To be able to accurately semi quantitate a 
standard PCR, the reaction should be stopped within the linear phase.  
 
2.2.1 RNA isolation 
 
All centrifugation steps were performed at 20–25°C in a standard 
microcentrifuge at room temperature.    Cells were either disrupted by adding 
buffer RLT directly to the cell culture vessel after several washes with PBS, 
method continues below, or cells were harvested from the cell culture vessel by 
trypsinisation. The cells were pelleted and the supernatant was removed by 
gentle aspiration.  Complete removal of the cell-culture medium was essential as 
any carry through would inhibit lysis of the cells and dilute the lysate.  This 
would affect the conditions for binding of RNA to the RNeasy silica-gel 
membrane, which would reduce RNA yield. Cells were grown in a monolayer 
and no more then 1 x 10
7 cells were used per column. 
 
 
Threshold CT 
Exponential phase
Linear phase
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Cell lysis 
The cells were disrupted by addition of Buffer RLT (Qiagen). The pelleted cells 
were loosened by thoroughly by flicking the tube. The appropriate volume of 
Buffer RLT (<5x10
6 cells= 350 μl, 5x10
6 – 1x10
7 cells = 600 μl) was added 
depending on the number of cells pelleted. Complete resuspension of the pellet 
was achieved by vortexing or pipetting up and down.  Incomplete loosening of 
the cell pellet would lead to inefficient lysis and reduced yields. β -
Mecaptoethanol (Sigma-Aldrich) was added to Buffer RLT before use (10 
μl/ml). 
 
Homogenisation 
Incomplete homogenization would lead to significantly reduced yields and can 
cause clogging of the RNeasy mini spin columns (Qiagen). Homogenization 
with rotor–stator or QIAshredder homogenisers generally resulted in higher 
RNA yields than with a syringe and needle.  The lysate was pipetted directly 
onto a QIAshredder spin column (Qiagen) placed in a 2 ml collection tube, and 
was centrifuged for 2 min at maximum speed. 
 
RNA extraction 
1 volume (usually 350 µl or 600 µl) of 70% ethanol (Fisher) was added to the 
homogenized lysate, and mixed well by pipetting. The lysate at this point was 
not centrifuged. Some volume of lysate is lost during homogenization, so the 
volume of ethanol was adjusted accordingly.  Visible precipitates formed after 
the addition of ethanol when preparing RNA from certain cell lines, but this did 
not affect the RNeasy procedure.  700 µl of the lysate, including any precipitate 
that may have formed, was added to an RNeasy mini column placed in a 2 ml 
collection tube (Qiagen). The tube was closed gently and centrifuged for 15 s at 
8000 x g (10,000 rpm). The flow-through was discarded and the collection tube 
reused.  When the volume of the lysate exceeded 700 µl, aliquots were loaded 
successively onto the RNeasy column, and centrifuged as above. Again the flow-
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(Qiagen) was loaded on to the RNeasy column and the tube gently closed before 
being centrifuged for 15 s at 8000 x g (10,000 rpm).  This step was to wash the 
column.  The flow-through was discarded and a new 2 ml collection tube was 
used for the next step (provided in the Qiagen kit).  500 µl of Buffer RPE 
(Qiagen) was added onto the RNeasy column. The tube was gently closed and 
centrifuged for 15 s at 8000 x g (10,000 rpm). The flow through was discarded.  
Buffer RPE is supplied as a concentrate. 220 ml of 100% absolute ethanol was 
added to Buffer RPE before use.  500 µl of Buffer RPE was again added to the 
RNeasy column and centrifuged for 2 min at 8000 x g (10,000 rpm) to dry the 
RNeasy silica-gel membrane.  It was important to dry the RNeasy silica-gel 
membrane since residual ethanol may interfere with downstream reactions. The 
extra centrifugation step ensured that no ethanol was carried over during elution. 
Following the centrifugation the RNeasy mini column was removed from the 
collection tube carefully so the column did not contact the flow-through as this 
will result in carryover of ethanol.   The RNeasy column was placed in a new 1.5 
ml elution tube and 30–50 µl RNase-free water (Qiagen) was pipetted directly 
onto the RNeasy silica-gel membrane, the tube was closed gently and 
centrifuged for 1 min at 8000 x g (10,000 rpm).  If the expected RNA yield was 
<30 µg, the elution step was repeated as described above with a second volume 
of RNase-free water and eluted into the same collection tube.  To obtain a higher 
total RNA concentration, this second elution step was performed by using the 
first eluate. The yield was 15–30% less than the yield obtained using a second 
volume of RNase-free water, but the final concentration was higher. 
 
2.2.2 Concentration and cleanup of RNA 
 
The volume of the sample was adjusted to 100 µl or 200 µl with RNase-free 
water. 350 µl or 700 µl of Buffer RLT was added and mixed thoroughly. If 
started with an RNA pellet, the pellet had to be dissolved in RNase-free water 
before Buffer RLT was added. 250 µl or 500 µl of 96–100% ethanol was added 
to the diluted RNA, and mixed thoroughly by pipetting.  700 µl of the sample                                                                           Chapter 2: Methods and Materials 
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was added to an RNeasy MinElute Spin Column in a 2 ml collection tube. The 
tube closed gently, and centrifuged for 15 s at 8000 x g (10,000 rpm) the flow-
through was discarded.  For samples >700 µl the remaining sample was applied 
(up to 700 µl) and the centrifugation was repeated.  The flow-through and 
collection tube were discarded at this point.  The spin column was transferred 
into a new 2 ml collection tube (Qiagen). 500 µl of Buffer RPE was added to the 
spin column. The tube was gently closed, and centrifuged for 15 s at 8000 x g 
(10,000 rpm) to wash the column. The flow-through was discarded. 500 µl of 
80% ethanol was added to the RNeasy MinElute Spin Column. The tube was 
gently closed, and centrifuged for 2 min at 8000 x g (10,000 rpm) to dry the 
silica-gel membrane. The flow-through was discarded. Following the 
centrifugation, the RNeasy MinElute Spin Column was removed from the 
collection tube carefully so the column does not come into contact with the flow-
through as this will result in carryover of ethanol. The spin column was then 
placed into a 1.5 ml elute tube and 30-50 μl of nuclease free water was added to 
the column before being centrifuged for 1 minute at full speed.  The RNA was 
stored at -80°C. 
 
2.2.3 RNA quantification  
 
Preparing the gel-dye mix (RNA 6000) 
550 µl of RNA 6000 gel matrix (Ambion) was pipetted into a spin filter 
(Ambion).  The gel matrix was then centrifuged at 1000 rpm for ten minutes. 
65 µl of filtered gel was aliquoted into 0.2 ml RNase-free microfuge tubes. The 
filter was discarded and the filtered gel was kept in 4°C and used within 4 
weeks.  The dye concentrate was equilibrated to room temperature for 30 min. 
The dye concentrate was vortexed for ten seconds, and spun down.  1 µl of dye 
was added to a 65 µl aliquot of filtered gel.  The solution was mixed well by 
vortex and then spun at 10,000 rpm for ten minutes at room temperature.     
During the preparation of the gel-dye mix all of the reagents were protected from 
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use and aseptic techniques, minimalising contamination from RNA, DNA and 
RNase, were strictly adhered to throughout the procedure.     
 
Running the RNA 6000 assay 
The bioanalyser was cleaned before the start of every assay using a cleaning chip 
(Ambion) containing deionised water followed by a chip containing RNA zap 
(Ambion) to clean the electrodes. 9 µl of the gel preparation was pipetted into 
the first well marked G on the quantification chip (Ambion). The chip was 
placed in the pressurizer (Ambion) and the plunger pushed down for 30 seconds.  
The pressure was released and the plunger was allowed to rise for 5 seconds 
before the plunger was retuned to the 1 ml mark.  9 µl of gel preparation was 
pipetted into the two other wells marked G.  5 µl of marker (Ambion) was 
pipetted into all the sample wells including the well marked for the ladder 
(Ambion).  2µl of each RNA sample and ladder were denatured at 70°C for 2 
minutes in a heated lid thermocycler before loading on the chip.  1 µl of ladder 
was pipetted into the ladder well and 1 µl of each RNA sample into each of the 
sample wells.  If there were any sample wells unused 1 µl of marker was added 
to ensure the chip was loaded correctly.  The chip was vortexed for 60 seconds 
and immediately place in the bioanalyser.  The software enabled each well to be 
labeled and the quantification of each well could be followed on screen.  The 
bioanalyser could detect the quantity and quality of RNA in the sample, 
preventing use of denatured or contaminated RNA. 
 
2.2.4 cDNA synthesis for RT-PCR 
 
A master mix containing Nuclease-Free Water (Promega), Reverse Transcription 
(RT) 10x Buffer (Promega), deoxyribonucleotide triphosphate (dNTP) mixture 
(Promega), Magnesium Chloride (MgCl2) (Promega), Recombinant RNasin® 
Ribonuclease Inhibitor (Promega), avian myeloblastosis virus (AMV) Reverse 
Transcriptase (Promega), and  Random Primers (Promega) was made up using 
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on the number of RNA samples.  10% extra master mix was made to cover 
pipetting error.  The use of a master mix not only reduced the time taken to set 
up the reaction but also the number of pipetting steps reducing error and the 
chance of contamination. 
 
Component  Amount 
MgCl2 
Reverse Transcription 10x Buffer 
DNTP Mixture 
Recombinant RNasin Ribonuclease Inhibitor 
AMV Reverse Transcriptase 
Oligo (dT) 15 Primer OR Random Primers 
 
4 μl 
2 μl 
2 μl 
0.5 μl 
0.75 μl  
2 μl 
 
Total volume  11.25 μl 
 
 Table 2. Contents of master mix used for reverse transcription reaction  
 
1µg of total RNA was placed in 0.2 ml microcentrifuge tubes and incubated at 
70ºC for 10 minutes.  No more then 8.75 μl of RNA could be added to the final 
volume.  If 1 µg of RNA exceeded 8.75 μl, the concentration was reduced to 0.5 
or 0.25 µg.  If 1 µg of RNA was under 8.75 μl then the volume would be made 
up with nuclease free water.  The tubes were spun briefly in a microcentrifuge, 
and then placed on ice.  A 20 μl reaction mix was prepared by adding 11.25 μl of 
master mix to each 8.75 μl sample of denatured RNA.  Random primers were 
used (random hexamers), so the samples were incubated at room temperature for 
ten minutes before placing the tubes in a thermocycler for 15 minutes at 42ºC.  
Random hexamers are a mix of short oligomers, usually six base pairs long that 
should be able to anneal to all of the sequences found.  Random hexamers will 
transcribe rRNA, tRNA and mRNA (Kubista et al., 2006).  The additional 
incubation at room temperature allowed extension of the primers so they remain 
hybridised when the temperature was raised to 42ºC.  The samples were then 
ramped to 95ºC for 5 minutes, and then ramped back down to 4ºC for 5 minutes.  
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the cDNA.  The first strand cDNA template was stored at -20ºC.  The reaction 
was performed in a thermocycler due to the quick ramping times and heated lid 
which prevents recoiling of the RNA and evaporation of the reaction mix. 
 
2.2.5 RT-PCR 
 
In many cases the standard reactions will provide satisfactory amplification.  A 
negative control reaction should be included lacking only the template.  The 
inclusion of a positive control reaction using a template known to amplify with 
the primers may also be helpful.  The concentration of enzyme, MgCl2, template 
and primers can be varied to optimise the reaction.  For each 25 μl reaction, the 
following assembly was prepared in a 0.2 ml PCR tube on ice (Table. 3). 
 
Component  Amount 
PCR grade Water (Novagen) 
10X PCR Buffer for KOD Hot Start DNA polymerase (Novagen) 
dNTPs (final concentration 0.2 mM) (Novagen) 
DMSO (1% in final reaction) 
MgSO4 (final concentration 1 mM) (Novagen) 
5’ primer (final concentration 0.3 μM) (Sigma Genosys) 
3’ primer (final concentration 0.3 μM) (Sigma Genosys) 
KOD Hot Start DNA polymerase (Novagen) 
14.5 μl 
2.5 μl 
2.5μl 
1 μl 
1 μl 
1 μl 
1 μl 
0.5 μl 
Total Volume  24 μl 
 
Table 3. Contents of master mix for RT-PCR.  
 
The master mix was then mixed gently and centrifuged briefly to bring reaction 
components to the bottom of the tube. 1 µl of cDNA template from RT reaction 
was added to each tube. The thermocyclers used all had heated lids and therefore 
no oil droplets to prevent evaporation were required.  The samples were placed 
in a thermocycler where the PCR reaction can take place.  The KOD polymerase 
was activated by heating for 2 minutes at 95˚C followed by 15 seconds at 94˚C, 
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primer sequences to the exposed nucleotides (step 1).  The reaction was then 
ramped to 60˚C for 30 seconds.  This allowed the primers to anneal to the 
correct sequence in DNA ready for the extension step (step 2).  The extension 
step was carried out at 68˚C for 30 seconds.  The KOD polymerase requires a 
temperature of 68˚C to be able to carry out the extension step with the greatest 
efficiency.  The polymerase will move along the single stranded cDNA from the 
position at which the primers have annealed at the 5’ end.  The polymerase adds 
dNTPs, which are free in the buffered reaction mixture, to the single stranded 
cDNA.  The primer annealed at the 3’ end contains a stop codon so the 
polymerase will drop off the DNA after the sequence between the forward and 
reverse primers has been completed (step 3).  The double stranded DNA is now 
ready to under go another round of amplification.  Steps 1-3 are repeated for 28 
cycles. The amplification reaction is depicted in figure 2.1.  The annealing 
temperature in step 2 can vary depending on the melting temperature of the 
primers.  The extension time in step 3 can vary depending on the size of the 
product.  KOD polymerase can add 1000 nucleotides every minute and therefore 
a DNA product expected at 500 base pairs will require a 30 second extension.  
The annealing temperature and extension times stated above were used for all of 
the primers designed for standard PCR reactions in this thesis.  The primers all 
had similar melting temperature and the product sizes were also similar. The 
cycle number was reduced for GAPDH and β-actin as these are more abundant 
proteins. Conditions were optimised for all primer pairs. 
 
Primer design is important for successful PCR amplification.  The primers 
should be complementary to the template, especially the 3’ end.  It is important 
to determine the proper annealing temperature for any pair of primers.  Long 
extension times may cause smearing.  For all RT-PCR and qRT-PCR primer 
sequences see Appendix 2. 
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2.2.6 RT-PCR product analysis by agarose gel 
 
To analyse the reaction products, 10 μl of sample was removed and added to a 
loading dye (Promega).  A 1.5 % agarose gel containing 0.5 μg/ml ethidium 
bromide was used to load and run the reaction products. To prepare the agarose 
gel 0.75 grams of agarose is weighed out and added to 50 ml of 1x Tris Borate 
ethylene diamine tetra-acetic acid (EDTA) or TBE buffer (Sigma) containing 5 
µl of 0.5 μg/ml ethidium bromide (Sigma).  The gel is pored into a gel tank and 
the appropriate lane comb placed in the gel.  The gel is left to solidify before the 
DNA plus loading dye is carefully loaded onto the gel.  A DNA molecular 
weight ladder (Promega) is also loaded onto the gel.  There were two ladders 
available, a lower molecular weight marker that went up to 2000 base pairs and a 
high molecular weight marker that could accurately separate bands up to 10,000 
base pairs.  The bands were visualized under UV illumination using the 
SynGene System (Syngene Ltd UK, 2002) and camera or the transilluminator.  
Pictures could then be analysed using phoretix software to quantify the density 
and area of the bands.  The products on the gel were often sequenced to ensure 
the correct DNA product was amplified.  The bands on the gel were cut out and 
the DNA extracted. 
 
2.2.7 DNA isolation from an agarose gel 
 
300 μl of SpinPrep GelMelt Solution (A) (Novagen) was added per 100mg of 
gel slice for DNA run on a gel of up to 2% agarose. For DNA run on gels greater 
than 2% agarose, 600μl of GelMelt solution was added.  The tube was vortexed 
briefly and transfered to a 50°C water bath or heat block. The gel slice was then 
incubated for ten minutes or until the gel slice had fully melted.  A SpinPrep 
Filter (Novagen) was placed into a SpinPrep eluate 2 ml receiver tube 
(Novagen).  700μl (maximum capacity) of the dissolved gel solution was 
transferred to the SpinPrep filter and centrifuged at top speed for 30 seconds.  
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Gel Melt Solution (A) was added to the spin filter and was centrifuged again at 
top speed for 30 seconds. The flow-through in the receiver tube was discarded 
before 650 μl of reconstituted SpinPrep Wash Buffer (B) (Novagen) was added 
and centrifuged at top speed for 30 seconds.  The flow-through in the receiver 
tube was discarded and the empty spin filter was centrifuged for an additional 2 
min to remove residual SpinPrep Wash Buffer (B) (this was important as any 
transfer of residual buffer can result in reduced yield of DNA).  The SpinPrep 
Filter was then transferred to the provided 1.5 ml Eluate Receiver Tubes 
(Novagen).  Between 30 and 50 μl of pre-warmed (50°C) SpinPrep Elute Buffer 
(C) (Novagen),  (or DNase free/distilled water) was added to the SpinPrep Filter 
membrane. The cap of the receiver tube was closed before being incubated for 3 
min at 50°C in a heat block.  The Spinprep unit was then centrifuged for 1 min 
to elute the DNA into the 1.5ml receiver tube and the DNA was stored at -20°C 
or sent off for sequencing. DNA for sequencing was sent to GATC.   
 
2.2.8 DNA-free treatment of RNA  
 
All tubes and water is UV irradiated to ensure any contaminating DNA was 
crosslinked.  The RNA was then cleaned of any genomic DNA contamination 
by undergoing a DNAase-free reaction.  0.1 volume of 10X DNase 1 buffer 
(Ambion) was added to the RNA and mixed gently.  For routine DNase 
treatment 1 µl of recombinant DNase 1 (Ambion) was added to up to 10 µg of 
RNA in a 50 µl reaction and was incubated at 37°C for 20-30 minutes.  The 
reaction conditions removed up to 2 µg of genomic DNA from the total RNA in 
a 50 µl reaction.  If the reaction requires more rigorous DNase treatment, then 
various methods such as diluting the RNA or increasing the concentration of 
enzyme can be adopted.   0.1 volume of DNase Inactivation reagent (Ambion) 
was added to each reaction and mixed well.  Each reaction was incubated for 2 
minutes at room temperature, mixing occasionally.  Each reaction was then 
centrifuged at 10 x g for 1.5 mins and RNA transferred to a fresh tube.  RNA is 
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2.2.9 cDNA synthesis for quantitative RT-PCR (qRT-PCR) 
 
The DNase treated RNA was then used to carry out a reverse transcription 
reaction to create cDNA for use as the template in the PCR reaction.  Master 
mix was prepared in a microcentrifuge tube containing 4 µl of moloney murine 
leukemia virus (MMLV) 5 X buffer (Primer Design), 5.2 µl of RNase/DNase 
free water (Primer Design), 0.8 µl of MMLV enzyme (Primer Design).  The 
volumes were scaled up for the number of reaction to be carried out plus an 
extra 10% for pipetting error.  8 µl of RNA was added to 2 µl of 
OligodTprimer/dNTP mix (primer design) in a sterile 1.5ml Eppendorf.  The 
advantage of using oligodT primers is they will only create cDNA from mRNA 
due to hybridizing to the poly A tail of the mRNA molecule.  The primers 
hybridise to the RNA at the 3’ end and transcription of the RNA molecule 
proceeds, as long as there are no breaks before the PCR target sequence reverse 
transcription using OligodT primers is more efficient and less dependent on 
temperature.  The possibility of amplifying non-specific products in the PCR 
reaction is reduced (Kubista et al., 2006).  Tubes were incubated at 65°C to 
denature for 5 minutes in a heating block.  Tubes were placed directly on ice 
and 10 µl of ice cold master mix was added to each denatured sample before 
incubating for 1 hour at 42°C. cDNA was then stored at -20°C or used in a PCR 
reaction.   
 
2.2.10 SYBR Green qRT-PCR in 96 well format 
 
Master mix was prepared for each final 20 µl reaction.  10 µl of SYBR green 
master mix (primer design), 1 µl of primer mix (pre-validated for each primer 
set, including house keeping genes UBC and pLA2 from primer design) and 4 µl 
of DNase free water were added to a microcentrifuge tube.  The volumes are 
scaled up for the number of reactions to be carried out, including an extra 10% 
for pipetting error.  
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15 µl of master mix was aliquoted into each well and each cDNA sample was 
diluted 1/10 into DNase free water, before adding 5 µl per reaction.  Each 
sample is run in duplicate for each primer set and negative control. Negative 
controls were a PCR control without cDNA and an RT control without RNA.   
The 96 well plate was sealed with 96 well plate adhesive covers (biorad), the 
plate was then spun down at 4°C for 30 secoonds at 1000 x g.  The reaction was 
carried out on a Icycler using a SYBRGreen filter, 45 cycles with melt curve 
analysis  Data was analysed using biorad IQ5 software and the CT values were 
normalised to the house keeping genes and fold changes were calculated using 
2
ΔΔct.  All primers used in SYBR green qRT-PCR were from primer design and 
all sequences are listed in Appendix 2. 
 
2.3 Protein analysis of cell culture models 
 
Western blotting was used to analyse the phenotype of the cells used in the in 
vitro cell culture models described above. Any changes in protein expression of 
fibrotic and apoptotic markers such as α-SMA and PARP-1 cleavage products 
were detected using this method.  The protein of interest must be obtained in 
soluble form before separation by SDS-PAGE. This is carried out by using 
buffer containing a detergent and also peptidase inhibitors to inhibit intracellular 
proteases released during the solubilisation process from denaturing the proteins 
of interest. Dissociation of proteins into polypeptide subunits is achieved using 
strongly anionic detergent, SDS, a reducing agent e.g. mercaptoethanol), and 
heat.  This denatures the proteins before being loaded on the polyacrylamide gel 
for analytical electrophoresis. The gel itself is composed of cross-linked chains 
of polymerized acrylamide, N, N, N’, N’-tretramethylethylenediamine 
(TEMED) and ammonium persulfate are added to accelerate the polymerization. 
The denatured proteins bind to SDS and become negatively charged. The 
proteins of larger molecular weight migrate through the polyacrylamide gel 
more slowly because they bind more SDS. When an electric current is passed 
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electric current is used for transfer of the proteins from the polyacrylamide gel to 
a nitrocellulose sheet. The western blot is first exposed to specific primary 
antibody and thereafter, extensive washing before the secondary alkaline 
phosphatase conjugated antibody is applied.  Again the blot undergoes extensive 
washing before the substrate for alkaline phosphatase is applied (Laemmli, 
1970).  
 
Cytokines play an important role in innate immunity, apoptosis, angiogenesis, 
cell growth and differentiation.  They are involved in most disease processes 
such as cancer and fibrosis.  Cytokines interact with the cellular immune system, 
this is a dynamic process that involves positive and negative stimuli as well as 
positive and negative feed back loops.  These processes often involve multiple 
cytokines therefore the ability to detect multiple cytokines in the same sample 
could lead to an increase in understanding of how cytokines interact in cellular 
and disease processes (Rameshwar et al., 2003).  Currently two dimensional 
polyacrylamide SDS page coupled with mass spectrometry is the main stream 
approach to analyzing multiple protein expression levels.  The applications 
require sophisticated devices and lack quantitative measurements that limit there 
broad application.  Cytokine arrays offer a simple format that is a highly 
sensitive approach that can simultaneously detect multiple cytokine expression 
levels from conditioned media, cell lysates, patient’s sera and other sources 
(Zhou et al., 2005;Turtinen et al., 2004).  Cytokine arrays were used to detect 
any changes in the conditioned media after H2-relaxin treatment of HSC.  
Cytokines are traditionally detected by elisa but the array format allows the 
simultaneous detection of many cytokines.  Cytokine arrays can detect as little as 
4 pg/ml of protein.  Therefore the sensitivity as well as the detection range is 
greater then an elisa and there is also less variation between samples.  The array 
format utilizes antibodies to detect active cytokines that would be secreted from 
the cell, reflecting a snap shot of the activity of the cell when the sample was 
taken.                                                                             Chapter 2: Methods and Materials 
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Figure 2.4. Principle of human cytokine antibody membrane array 
 
The cytokine array procedure is similar to the technology developed for 
immunhistochemical staining and elisa assays (figure 2.4).  The antibody 
detection system uses an indirect two stage system to amplify the signal.  The 
array membranes are spotted with antibodies for many different cytokines.  The 
samples are incubated with the membranes to allow the antigens in the 
conditioned media to bind to the antibodies on the membrane.  Once the 
cytokines have bound to the membrane a cocktail of biotinylated primary 
antibody, designed to bind to different epitopes then the antibody spotted on the 
membrane, is then applied.  The biotinylated primary antibodies bind to the 
various antigens of the cytokines bound to the membrane.  The alkaline 
Array support  Sample (conditioned media) 
Cocktail of biotin labelled 
anti-cytokine antibody 
AP-labelled Steptavidin 
Detection with AP substrate 
1-2 hour incubation at RT 
1-2 hour incubation at RT 
1 hour incubation at RT 
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phosphatase -labelled streptavidin is then applied and binds with high affinity to 
the biotin labelled primary antibody.  The activity of the alkaline phospahtase 
now bound to the specific antigens can be detected using an alkaline 
phosphatase substrate, the colour develops as a purple precipitate.   
 
2.3.1 Total protein extraction 
 
Total protein extraction from mammalian cells was achieved by incubating the 
adherent cells with an appropriate amount of mammalian protein extraction 
reagent (M-PER) (Pierce) including halt protease inhibitor cocktail (Pierce) at 10 
μl/ml concentration.  Adherent cells in a 100mm dish or 6-well plate were 
washed with PBS, M-PER was then added directly to the cells (300 μl per well 
for a 6 well plate or 1 ml in a 100mm dish).  The cells were gently agitated for 5 
minutes at room temperature (until the cells were fully lysed). The cells may 
require scraping if they do not appear fully lysed.  Cell lysate is then added to 
microcentrifuge tubes to be spun at 10,000 rpm for 5 minutes.  All the cell debris 
should remain at the bottom of the tube and the supernate can be added to a new 
microcentrifuge tube.  The protein is then quantified using the BCA 
 
2.3.2 Protein quantification 
A fresh set of protein standards were prepared by diluting the 2.0 mg/ml BSA 
stock standard, in the same diluent as the samples (the dilutions are given in 
table.4).  A 1 ml ampoule of the 2.0 mg/ml BSA standard was sufficient to 
prepare a set of diluted standards.  
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Volume of BSA stock  Volume of diluent to add  Final BSA 
concentration 
0.5 ml of Stock 
2.0 ml of A 
4.0 ml of B 
4.0 ml of C 
4.0 ml of D 
4.0 ml of E 
3.2 ml of F 
4.0 ml of G 
4.5 ml 
8.0 ml 
4.0 ml 
4.0 ml 
4.0 ml 
4.0 ml 
4.8 ml 
4.0 ml 
200 µg/ml (A) 
40 µg/ml (B) 
20 µg/ml (C) 
10 µg/ml (D) 
5 µg/ml (E) 
2.5 µg/ml (F) 
1.0 µg/ml (G) 
0.5 µg/ml 
 
Table 4.  Serial Dilution of BSA stock solution 
 
The Working Reagent (WR) was prepared by mixing 25 parts of Micro BCA 
Reagent MA (Pierce) and 24 parts of Micro BCA Reagent MB (Perbio/pierce) 
with 1 part of Micro BCA Reagent MC (Pierce). When Micro BCA Reagent MC 
was initially added to the solution, turbidity was observed that quickly 
disappeared upon mixing to yield a clear green WR. A sufficient amount of WR 
was prepared to enable each test to be done. Each test tube assay to be done 
required 150 µl of WR. The WR was stable for at least 1 day when stored in a 
closed container at room temperature (it is sensitive to light). 
 
150 µl of each standard or unknown sample were pipetted into the appropriate 
plate wells.  150 µl of the diluent was used for the blank wells.  150 µl of the 
working reagent was added to each well, the plate was then mixed on a plate 
shaker for 30 seconds.  The plate was covered and then incubated at 37ºC for 2 
hours.  After incubation, the plate was cooled to room temperature. The 
absorbance was measured at or near 562 nm on a plate reader.  The average 562 
nm reading for the blanks was subtracted from the 562 nm reading for each 
standard or unknown sample.  A standard curve was prepared using Graph Prism 
(Graph Pad Software, Inc San Diego USA); by plotting the average blank 
corrected 562 nm reading for each BSA standard verses its concentration in 
µg/ml. The protein concentration for each unknown sample was determined 
using the standard curve. 
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2.3.3 Gel Electrophoresis 
 
The correct volume of protein was calculated from the concentration (in the 
protein bank) to load 5 µg of protein for α-SMA detection and 25 µg for PARP-1 
detection.  The protein samples were then added to a micro-centrifuge tube and 
the volume made up to 20 μl with ultra pure water.  10 μl Sample Buffer LDS 
(Invitrogen) and 5 μl NuPage 10x reducing agent (Invitrogen) was then added 
making the total volume 35 μl.  Reducing agent was added to the sample 
immediately before heat denaturing.  The final sample solution was heated at 
90ºC for ten minutes. Samples were mixed and 20 μl was loaded on to the gel.  
A short centrifugation was used to remove bubbles before loading if necessary.  
20 μl of each sample was loaded on to a NuPAGE-pre cast bis-tris 10% 12 well 
gel cassette (Invitrogen), and using the X-cell Surelock Mini-cell (Invitrogen) 
and NuPAGE running buffer (Appendix 2), the samples were run at 200 volts 
(constant) for fifty minutes or until the front had reached 5 mm from the bottom 
of the gel. 
 
2.3.4 Western transfer to nitrocellulose membrane 
 
During the following procedures, gloves were worn at all times to prevent 
contamination of gels and membranes and exposure to irritants commonly used 
in electrophoresis and electro-transfer.  The gels were removed from the 
Cassettes and placed in the correct orientation for transfer using Novex pre-cut 
membrane/filter paper sandwiches and blotting pads (Invitrogen) ensuring no 
bubbles remained within the blotting pads or between the gel and the 
nitrocellulose membrane (this was important as any air bubbles may 
compromise the quality of the transfer).  The blot module was then placed into 
an X-cell Surelock Mini-cell and the transfer buffer (Appendix 2), was placed 
into the blotting chamber, only to just above the level of the sandwich, to ensure 
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at this level.   Deionised water was placed in the outer chamber to keep the set 
up cool.  30 volts constant current was then run through the blotting module for 
90 minutes. Preparing Tris-Buffered Saline (TBS) (Sigma), Tris-Buffered 
Saline-Tween (TBS-T) and blocking reagent solutions TBS was diluted 1 in 10 
in deionized water 100ml TBS in 900 ml deionised water.  This was then used in 
preparation of TBS-T where 500 µl of 0.05% Tween 20 (Sigma) were added to 
the 1000 ml of TBS.  200ml of TBS-T were then removed to be used for the 
blocking reagent.  2.5 grams of 1% blot qualified Bovine serum Albumin (BSA) 
(promega) were weighed out and dissolved into the 200 ml of TBS-T (blocking 
reagent).  
 
2.3.5 Antibody probe of nitrocellulose membranes 
 
Stored nitrocellulose membranes were rewetted with TBS-T, before being 
incubated for 30 minutes at room temperature in blocking reagent as described 
above.  Primary antibodies were diluted 1:500-1:5000 with TBS-T (table.5).  
The membranes were then incubated in this solution for two hours using a 
rotating table.  The membranes were washed three times for five minutes each in 
TBS-T.  The secondary antibody (anti-mouse IgG-AP conjugate from Promega) 
was also diluted using TBS-T to a 1:5000 concentration.  The membranes were 
then incubated in the secondary antibody for 45 minutes.  After washing the 
membranes three times using TBS-T and once in TBS to remove any unbound 
antibody, Western Blue Stabilised Alkaline Phosphatase (Promega) was used to 
start the colour reaction.  Colour development usually took between 1 and 15 
minutes. Once sufficient colour had developed the membranes were washed in 
distilled water. 
 
A picture was taken of each blot using a CCD camera.  The image was analysed 
using the Phoretix software.  The Phoretix software package allowed the 
molecular weight of the bands to be calculated compared to a molecular weight 
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volume and intensity of the band allowing a quantity to be assigned to the target 
band which could then be normalised to a GAPDH or β-actin band in the same 
sample. 
 
Antibody  Concentration  Molecular weight 
Monoclonal TIMP-1 (Sigma) 
Monoclonal α-SMA (Sigma) 
Monoclonal MMP-1 (Sigma) 
Monoclonal MMP-2 (Sigma) 
Monoclonal PARP-1 (Serotec) 
Monoclonal GAPDH (Abcam) 
Monoclonal β-actin (Abcam) 
1/500 
1/1000 
1/500 
1/500 
1/500 
1/3750 
1/3750 
28 kD 
42 kD 
53 kD and 51 kD 
72 kD and 68 kD 
116 kD, 89 kD, 24 kD 
36 kD 
42 kD 
 
Table 5.  Antibodies used in western blotting, concentrations and molecular weights of 
target bands. 
 
2.3.6 Safestain of electrophoresis gels 
 
After electrophoresis the gel can be stained directly before transferring the 
proteins to a nitrocellulose membrane.  The stain used will bind to all the 
proteins on the gel.  This enables detection of over expressed proteins and can 
also be used to ensure even loading of protein across the gel.  The stain can also 
be used on the electrophoresis gel after transfer to a nitrocellulose membrane to 
detect if the transfer was complete.  The mini-gel was rinsed 3 times for 5 
minutes with 100 ml deionized water to remove SDS and buffer salts, which 
interfere with binding of the dye to the protein.  The mini-gel was stained with 
enough Simplyblue Safestain (~20 ml) to cover the gel. Staining took around 1 
hour at RT with gentle shaking. Bands began to develop within minutes. After 
incubation the stain was discarded and was not reused (gel can be stained for up 
to three hours, but after that, sensitivity will decrease). After staining the mini-
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water for several days without loss of sensitivity. (There is a small amount of 
dye in the water that is in equilibrium with the dye bound to the protein, so 
proteins will remain blue.)  To obtain the clearest background for photography, a 
second 1-hour wash with 100 ml water was performed.  An alternative method is 
to heat the gel with Simplyblue Safestain (Invitrogen).  This enhances the 
staining process, allowing faster detection.  After electrophoresis the gel was 
placed in 100 ml of ultrapure water in a loosely covered container and 
microwaved on High (950 to 1100 watts) for 1 minute until the solution almost 
boiled.  The gel was shaken on an orbital shaker or rocker for 1 minute the water 
was then discarded.  Steps 1 and 2 were repeated two more times.  After the last 
wash 20 ml of SimplyBlue Safestain was added and the gel and microwaved on 
high for 45 seconds to 1 minute until the solution almost boiled.  The gel was 
shaken on an orbital shaker or rocker for 5 minutes.  The gel was washed in 100 
ml of ultrapure water for 10 minutes on a shaker.  A picture was taken of the gel 
directly and if the gel is to be kept it was dryed using gel drying solution 
(Invitrogen). 
 
2.3.7 Cytokine membrane array  
 
Blocking solution is diluted one in two with deionised water. Enough blocking 
solution was made up to use four ml per membrane. Blocking solution was 
applied to the membranes and they were incubated at room temperature on a 
rocker for thirty minutes. Media samples were thawed on ice and centrifuged at 
10,000 rpm for two minutes. 600 µl of sample was then added to each membrane 
including a media control sample that has not been incubated with cells but 
contains the same percentage FBS, P/S and glutamine/pyruvate that was applied 
to the cells to obtain the conditioned media.  Samples were incubated for 2 hours 
at room temperature.   
 
Wash buffer one and two were made up whilst the samples were incubating.  
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wash buffer was made to use 2 ml per wash for each membrane. Samples were 
removed from the membranes and 2 ml of wash buffer one was applied to each 
membrane for 5 minutes at room temperature. This was repeated twice more 
before wash buffer two was applied to the membranes, again for 5 minutes.  
Wash buffer two was repeated and then the biotin conjugated anti-cytokine 
antibody was applied to the membranes for 1 hour 30 minutes.  The biotin 
conjugated anti-cytokine antibody was supplied with the kit and each vial 
supplied was diluted into two ml of blocking solution. 1 ml of antibody was 
applied to each membrane. 
 
The membranes were washed as previously described with wash buffer one and 
two.  The protocol was then altered from the manufactures protocol.  The 
detection system was changed to enable and AP-substrate to detect the spots.  
Therefore an AP-conjugated Strepavidin (DAKO) was diluted 1:1000 in 1x 
blocking solution and incubated at room temperature for 1 hour.  Membranes 
were then washed as described previously and then two additional washes with 
TBS for five minutes at room temperature were carried out before 1 ml of AP-
substrate (promega) was applied to each membrane.  The substrate was left on 
the membranes for as long as was required for the spots to become visible.  Each 
membrane was left for the same period of time before they were washed in 
distilled water and then tap water before a picture was taken in the syngene.  All 
of the membranes were pictured together to ensure the exposure time of the 
CCD camera was the same for each membrane. Spots were quantified using 
phoretix array software. 
 
2.4 Histological staining of human tissue sections and fixed cells  
 
Sirius red was discovered as a connective tissue stain in the 1960s (Sweat et al., 
1964).  Sirius red is a strong anionic dye that stains collagen via its sulphonic 
acids groups that interact with the basic groups present in collagen.  The 
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their long axes are in parallel.  The parallel relationship between dye and 
collagen results in enhanced birefringency.  When examined through polarised 
light the larger collagen-1 fibres are yellow, orange or red depending on the 
tissue and the thinner collagen III fibres appear green.  Collagen II fibres are of 
variable colours according to tissue and species (Junqueira et al., 1978;Junqueira 
et al., 1979).  Birefringence was found to be highly specific for collagen and the 
use of circularly polarised light enabled simple detection (Whittaker et al., 
1994).  Sirius red is a well characterised histological method of staining collagen 
in tissue sections and can be used to help grade the level of scarring and damage 
in fibrotic tissue.  
 
Immunohistochemistry/immunocytochemistry is the in situ detection of antigens 
in tissue sections and cells by labeled reagents such as lectins, monoclonal and 
polyclonal antibodies. The antibody:antigen reaction is exploited, the antigen 
can display one or more specific binding sites or epitopes which are identified by 
using labeled antibodies.  Antigen-antibody interactions are visualised through 
markers such as fluorescent dyes, enzymes or radioactive elements.  Albert H 
Coons and colleagues were the first to label antibodies with fluorescent dyes and 
use them to identify antigens in tissue sections (COONS and KAPLAN, 1950).  
With the advancement of the immunhistochemistry technique enzyme labels 
such as peroxidase and alkaline phosphatase were developed (Nakane and 
Pierce, Jr., 1966;Avrameas and Uriel, 1966;Mason and Sammons, 1978).   The 
detection system used was the avidin-biotin complex (ABC) method. Avidin is a 
large glycoprotein that is labeled with peroxidase.  It has a very high affinity for 
biotin which is a low molecular weight vitamin which can be conjugated to a 
variety of biological markers such as secondary antibodies.  The ABC system is 
a 3 layer indirect method of visulising the antigens that allows signal 
amplification.  An unlabeled primary antibody will bind to the antigen allowing 
several different reactions with the biotinylated secondary antibody with 
different antigenic sites on the primary antibody.  A complex of avidin bound to 
biotin peroxidase is then applied which can bind to the multiple biotin labeled                                                                           Chapter 2: Methods and Materials 
  100
secondary antibodies.  The colour development is then dependent on peroxidase 
activity.  The 3, 3’-diaminobenzidine (DAB) chromgen is the final stage which 
reacts with the peroxidase enzyme to form a coloured end product at the specific 
antigen sites (figure 2.5).   
 
The tissue sections used were paraffin embedded and required processing before 
antibody staining could commence.  Kidney and liver tissue has a high level of 
endogenous biotin.  To prevent unwanted avidin binding the sections had to be 
pretreated with unconjugated avidin which is then saturated with biotin.  Many 
tissues have a level endogenous peroxidase activity and this was blocked before 
introduction of the primary antibody by saturating the tissue with hydrogen 
peroxide.  An additional blocking step was carried out using media containing 
fetal bovine serum (FBS) and bovine serum albumin (BSA).  This was to reduce 
the primary antibody from binding to nonspecific antigen sites.   
 
Figure 2.5. ABC method of immunhistochemistry.  Paraffin-embedded sections were 
hydrated with water and treated with protein blocking agents to reduce non-specific 
binding of antibodies. The tissues were then sequentially incubated with 1) primary 
antibody, which binds to specific tissue antigens, 2) secondary biotinylated antibody, 
1. Unlabeled 
primary antibody 
2. Biotinylated 
secondary antibody 
3.Streptavidin-biotin 
peroxidise complex 
4. DAB chromgen                                                                           Chapter 2: Methods and Materials 
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which binds to the primary antibody and 3) Streptavidin-biotin peroxidase complexes 
bind to the biotinylated secondary antibody. 4. Addition of the DAB chromagen mixture 
results in a coloured precipitate at the sites of the where the primary antibody has bound 
to the specific tissue antigen. Visualization is aided by counterstaining with 
haematoxylin.   
 
2.4.1 Sirius red stain 
 
Before Sirius red staining could be carried out the following solutions were 
prepared.  0.5 grams of Sirius red F3B (BDH VWR international Ltd) was added 
to 500ml of saturated Picric Acid solution 1.3% (Sigma Aldrich), (ensuring the 
picric acid solution is saturated, this was achieved by adding a little solid picric 
acid).  This is solution A.  5 ml glacial acetic acid (Sigma Aldrich) was added to 
1 litre of distilled water, this is solution B. 
 
To de-wax and rehydrate the paraffin sections they were placed in xylene 
substitute (sigma-aldrich) and different concentrations of ethanol (Sigma-
Aldrich).  Sections were dewaxed in three changes of xylene substitute.  The 
sections wee left in the xylene substitute for ten minutes at a time.  The sections 
were then rehydrated with graded alcohol solutions.  Sections were placed in 
100% ethanol, 95% ethanol, 70% ethanol and filtered distilled water, each for 5 
minutes. 
 
Optional staining of the nuclei was carried out using Weigert’s haematoxylin.  
The slides were then washed for ten minutes in running tap water (this develops 
the blue colour of the haematoxylin stain).  The slides were stained in the Picro-
Sirius red solution (Solution A) for one hour, this gave optimal levels of staining 
as the equilibrium was reached, and staining for longer times did not increase the 
intensity.  Sections were then washed twice in acidified water (Solution B).  The 
majority of the water was physically removed by either vigorously shaking or 
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100% ethanol.  The sections were then cleared in xylene substitute before being 
mounted in a resinous medium (DPX).  In bright-field microscopy collagen is 
red on a pale yellow background (Nuclei are ideally stained black but may be 
grey or brown).  The crosslinked collagen fibers can be seen using polarized 
light. 
 
2.4.2 Immunohistochemistry 
 
All liver tissue was fixed in 4% paraformaldehyde for at least 48 hours before 
embedding in paraffin wax and cutting tissue sections can commence.  Pre-fixed 
tissue was given to a histology unit technician to embed in paraffin wax and cut 
sections, who also carried out H+E staining on every ten serial sections  Kidney 
sections were cut from normal or fibrotic kidney held in the tissue store that had 
already been embedded in paraffin wax.  Each staining run began by using a 
positive control tissue section that is known to display a specific positive 
reaction with the primary antibody and that has been prepared in identical 
manner to the test tissue. Failure of the positive control tissue to stain 
appropriately invalidates the results with the test specimens for the antibody.  
Each staining run included a negative control antibody or non-immune serum in 
place of the primary antibody, to permit identification of non-specific staining. 
Evaluation of specific staining on the test slide was made in comparison to any 
nonspecific staining seen on the negative control slides.   
 
Dewaxing, rehydrating and blocking of endogenous peroxidase 
All stages were carried out at room temperature unless otherwise stated.  
Sections were allowed to warm to room temperature before the protocol was 
started.  Sections were deparaffinised in xylene substitute and rehydrated 
through graded alcohols to 100%-70%.  The sections were not allowed to dry 
out after this point.  The endogenous peroxidase activity was blocked for ten 
minutes with 0.5% hydrogen peroxide (Calbiochem) in methanol (Romil) (0.1ml 
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for at least 5 minutes.  The antigen retrieval technique was then carried out that 
was appropriate for the antibody used.  The technique used for the relaxin 
receptor family of antibodies was microwave pre-treatment in citrate buffer pH 
6.0 (appendix 2).   
 
Antigen retrieval 
Three plastic staining racks were filled with slides (some that are to be stained 
and some that are blanks to fill the racks) and then placed in polythene boxes of 
the same size.  The load was maintained by always using 3 polythene boxes, 
together with 72 slides.  The temperature will hopefully be constant throughout 
all of the sections.  Each box was then filled with 330 ml of citrate buffer and the 
perforated lids placed firmly on the boxes.  The three boxes were then placed in 
the microwave on medium power for 25 minutes.  The slides were then placed 
under cold running water for 2-3 minutes. 
 
IHC antibody staining 
Slides were placed in staining racks and washed three times for five minutes in 
TBS (Sigma).  The slides were drained and the avidin solution (vector 
laboratories) was applied for twenty minutes.  Slides were rinsed three times for 
two minutes with TBS.  Slides were then drained and the biotin solution (vector 
laboratories) was applied for twenty minutes.  The slides were drained and 
washed three times for two minutes in TBS, drained and the blocking culture 
media (appendix 2) was applied for twenty minutes.  The slides were then 
drained (not rinsed) and the primary antibody is applied at this point in the 
appropriate dilution (table.6) and the slides were incubated overnight at 4˚C in 
the humid staining rack to prevent evaporation. 
 
The slides were removed from the fridge 30 minutes before the resumption of 
the protocol.  The slides were drained and washed three times for five minutes 
before the addition of the biotinylated secondary antibody at appropriate dilution 
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minutes and then the strepavidin biotin-peroxidase complexes (Dako 
cytomation) were applied for thirty minutes.  The slides were drained and 
washed three times for five minutes and then the DAB substrate (Biogenex) 
(appendix 2) was added for between three and five minutes. The working 
chromogen solution was prepared immediately prior to use, and was used within 
24 hours.  Slides were rinsed in distilled water and washed in running tap water 
for five minutes before being counterstained with Mayer’s Haematoxylin 
(sigma).  The sections were then blued in running tap water.  The sections were 
then dehydrated through graded alcohol, cleared in xylene substitute and 
mounted in DPX.  Sections were allowed to dry for 24 hours before taking 
pictures with the axioskop camera, microscope and software.  
 
Antibody  Concentration  Tissue 
Polyclonal RXFP-1 (12715) (Abcam) 
Polyclonal RXFP-1 (12714) (Abcam) 
Polyclonal RXFP-3 (Abcam) 
Polyclonal RXFP-4 (Abcam) 
Monoclonal α-SMA (Sigma) 
Monoclonal VEGF C1 (Santa Cruz) 
Monoclonal Synaptopodin (Progen) 
Monoclonal EMA (Vector) 
Lectin LTA (Vector) 
Secondary Swine anti-rabbit (Dako) 
Secondary Rabbit anti-mouse (Dako) 
1/400 
1/600 
1/200-1/400 
1/50 
1/40,000 
1/200 
1/20 
1/300 
1/3000 
1/200 
1/200 
Liver 
Kidney 
Liver and Kidney 
Liver and Kidney 
Liver and Kidney 
Kidney 
Kidney 
Kidney 
Kidney 
Liver and Kidney 
Liver and Kidney 
 
Table.6. Antibody concentrations used for IHC (EMA-epithelial membrane antigen, 
LTA- lotus teragonolobus antigen). 
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2.4.3 Immunocytochemistry 
 
Primary HSC were cultured on cover slips in 6 well plates.  50,000 cells were 
plated per well and grown to confluence.  Tissue culture media was then 
removed and cells were washed with several changes of PBS.  The cells were 
then fixed by applying ice cold methanol and incubating at 4ºC for 10 minutes.  
The cell were then washed with ice cold PBS.  Cells could be stored at this stage 
at -20°C for later use or used directly in the staining protocol.  The 
immunodetection of α-SMA and RXFP-1 could now take place.  The assay was 
carried out following the immunhistochemistry protocol.  The only change was 
the concentration of primary antibodies, α-SMA was applied at 1/5000 and 
RXFP-1 was applied at 1/400. 
 
2.5 Functional/mechanistic cell based assays 
 
cAMP assays were used to detect functional relaxin receptors in LX-2 and 
primary HSC and to establish if the siRNA knockdown of RXFP-1 could abolish 
the cAMP response to H2-Relaxin.  A new generation of cAMP assay has been 
developed for high throughput screening that allows fast and accurate results.  
Enzyme fragment complementation (EFC) technology is a homogeneous, non-
radioactive technology based on splitting the E. coli β-galactosidase into two 
genetically engineered fragments, a large protein fragment (enzyme acceptor, 
EA) and a small peptide fragment (enzyme donor, ED).  These fragments are 
inactive separately but in solution they rapidly recombine to form an active 
enzyme that hydrolyse substrate to produce an easily detectable luminescent 
signal.  cAMP from cell lysates compete for antibody binding against labeled 
cAMP (ED-cAMP).  Unbound ED-cAMP is free to complement EA to form 
active enzyme by EFC, which subsequently produces the luminescent signal.                                                                             Chapter 2: Methods and Materials 
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Figure 2.6. cAMP assay principle 
 
A mechanistic assay was carried out to test the vasoregulatory properties of 
relaxin in activated HSC, to determine if relaxin receptors may be a potential 
target in the treatment portal hypertension.  The contraction of collagen lattices 
by human fibroblasts was first described in 1979 by Bell and collegues (Bell et 
al., 1979).   The contractility of HSCs was found to be activation dependent and 
could be manipulated by vasoactive mediators.  Hepatocytes did not possess the 
same contractile properties as activated HSC (Rockey et al., 1993). The 
principle of the assay is to determine the contractility of cells cultured on a 
collagen-1 lattice.  Collagen lattice contraction assays provide a model for tissue 
contraction that takes advantage of the finding that cell populated hydrogels 
contract over time in a predictable consistant manner (Ngo et al., 2006).  The 
collagen lattice will shrink as the cells contract, the traditional method to 
quantify the shrinkage is to measure the diameter of the gel.  HSC have been 
found to contract in the presence of serum in the tissue culture media as well as 
ET-1 and other vasoactive substances.  The assay conditions for all of the cells 
was kept consistent, the only change for each well was the treatment of either 
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The principle of the nitric oxide (NO) assay was to determine the nitric oxide 
concentration in culture media supernatant, based on the enzymatic conversion 
of nitrate to nitrite by nitrate reductase. The reaction was followed by the 
colorimetric detection of nitrite as an azo dye product of the Greiss reaction.  
The Greiss reaction was based on the two step diazotization reaction in which 
acidified NO2 produced a nitrosating agent reacts with sulfanillic acid to 
produce the diazonium ion. This ion was then coupled to N-(1-naphthyl) 
ethylenediamine to form the chromophoric azo-derivative which absorbs light at 
540-570 nM. 
 
2.5.1 cAMP assay (Amersham) 
 
All reagents were supplied by amersham as part of the discoverX kit unless 
otherwise stated.  Cells were harvested and counted either on a haemocytometer 
using trypan blue exclusion.  Cells are resuspended in antibody solution 
supplied in the kit at the appropriate dilution for the required seeding density.  
500 mM 3-Isobutyl-1-methylxanthine (IBMX) (sigma) suspended in 100% 
DMSO is diluted into the cell solution 1/1000.  IBMX is a potent non-specific 
inhibitor of cAMP and cGMP phosphodiesterases.  As a result of this inhibition 
the levels of cAMP in the cell will increase leading to activation of Protein 
Kinase A (PKA), which can lead to decreased proliferation, increased 
differentiation and induction of apoptosis.  IBMX can also act as an adenosine 
receptor antagonist. IBMX is added to prevent the breakdown of any cAMP that 
accumulates in the cell in response to the ligand. LX-2 cells were then plated 
into a 384 well plate at a density of 10,000 cells per well. Primary HSC were 
plated at a density of 12,000 cells per well.  Each well contained 10 μl of cell 
solution or wells that were required for the cAMP standard curve in duplicate 
contained 10 μl of antibody solution alone.  The plate was returned to the 37˚C 
incubator whilst the serial dilutions of cAMP standard (supplied in the kit 
already reconstituted), relaxin receptor agonist (H2-relaxin, INSL3, H3-relaxin 
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with 1% PBS-BSA or 100% DMSO respectively.  Forskolin was reconstituted 
with 100% DMSO to make a stock solution of 10 mM.  Relaxin agonists were 
reconstituted with PBS-BSA to a stock concentration that depended on the top 
concentration used in the assay.  An example of the reconstitution volume 
required is given below. 
 
100 µM stock solution = 33.54 µl PBS-BSA to reconstitute 20 µg of H2-relaxin 
(MW: 5963.06) 
 
20 µl of stock is added to 190µl of PBS-BSA, this gives a top concentration of 
3.5 µM in the assay plate.  Half log serial dilutions are then carried out by 
adding 63 µl of the top concentration to 137 µl of PBS-BSA, this is then 
repeated to give a 12 point curve. 
 
cAMP standard was diluted from stock, 1/3 in PBS.  50 µl of stock solution was 
added to 100 µl of PBS, this was used as the top concentration in the assay and 
then a further 11 descending serial dilutions in PBS were made.   The serial 
dilutions ranges used in the assay for all of the ligands are stated as final 
concentrations in the plate in table 7, the dilution factor is 1 in 3 in the plate. 
The assays were optimized using a half log 12 point curves for each of the 
ligands, ranging from the highest to the lowest concentration stated. 
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Molar  E  LOG 
 
3.16 µM 
 
316 nM 
 
31.6 nM 
 
3.16 nM 
 
316 pM 
 
31.6 pM 
 
3.16 pM 
 
316 fM 
9.48e-6 
3.16e-6 
9.97e-7 
3.14e-7 
9.92e-8 
3.13e-8 
9.87e-9 
3.11e-9 
9.82e-10 
3.10e-10 
9.78e-11 
3.08e-11 
9.73e-12 
3.07e-12 
9.68e-13 
3.05e-13 
-5 
-5.5 
-6 
-6.5 
-7 
-7.5 
-8 
-8.5 
-9 
-9.5 
-10 
-10.5 
-11 
-11.5 
-12 
-12.5 
 
Table 7.  Serial dilutions of relaxin ligands or forskolin using half log increments were 
made by adding 63 µl of the top concentration to 137 µl of PBS-BSA or DMSO.  
Molar concentrations are the final concentrations in the plate. 
 
5 μl of relaxin agonist, cAMP standard or forskolin were then added.  Each dose 
response to the relaxin agonist was repeated in triplicate for each cell extraction, 
the cAMP standard and forskolin dose responses were repeated in duplicate for 
each plate.  Plate was returned to the 37˚C incubator for 90 mins.   20 μl of 
ED/subtrate lysis mix was then added to all of the wells.  ED/substrate lysis mix 
contained 7.6 ml of lysis buffer, 400 μl of galacton star, 2 ml of emerald II and 
10 ml of ED reagent (all reagents supplied in the kit).  Plate was covered with 
foil to protect the reagents from light and incubated at room temperature for 60 
mins.  20 μl of EA-reagent was added to all of the wells and the plate is then 
sealed with Packard Topseal film, covered in foil and left to develop in the dark 
at room temperature for 6-16 hours.  The plate seal was removed and the 
luminescence was then measured on the analyst AD, all wells read as counts per 
second.  Raw data is captured to windows XP excel file for further data 
processing and evaluation on graphpad prism.  If the assay required the cells to 
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of 5 μl forskolin (chosen to be 80% of the maximal response concentration in 
each cell type) for 5 mins.  5 μl of relaxin ligands were then added to the cells 
and the assay was continued as described previously. 
 
2.5.2 Gel contraction assay  
 
500 µl of Bovine Collagen-1 (Cultrex) was added to each well of a 24 well 
culture plate under culture sterile conditions. The acidified collagen is 
neutralized with ammonia.  An ammonia (sigma) soaked tissue is taped to the 
inside of the lid of the 24 well plate.  The plate was incubated at 37°C for two 
hours and was then removed from the 37°C incubator and the ammonia soaked 
tissue removed. The plate was then left with the lid off in a tissue culture hood 
for 2-4 hours. The collagen gel would remain solidified, therefore 500 µl of PBS 
(Invitrogen) is then added to each well for 10 minutes at room temperature.  PBS 
is removed and another 500 µl is added to the wells and the plate is incubated at 
37°C overnight. 
 
Activated human stellate cells that had been cultured on plastic non-transfected 
or LGR7 and –ve control siRNA (ambion) transfected were enzymatically 
removed from the culture plastic and plated onto the prepared collagen-1 gels in 
a 24 well plate. The cells were plated at a density of 100,000 cells per well and 
were cultured overnight at 37°C, 5% CO2 in DMEM (Invitrogen) containing 
10% FBS (Invitrogen).  DMEM was replaced before treatments were added.  
Single concentrations of H2-Relaxin (Phoenix Pharmaceuticals Inc), Endothelin-
1 (Phoenix Pharmaceuticals Inc), (table 2.7). The plate is incubated for a further 
2 hours at 37°C, 5% CO2 and then another dose of the treatments are applied 
before the gels are released (ringed) from the well using a small pipette tip. 
Images are taken of the gels at 24, 48 and 72 hours post ringing. These images 
are imported into Imagej where gel contraction can be measured as the area of 
the gel. 
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Pre-treatment  Treatment at T=0 
Serum free DMEM 
 
10% DMEM + Vehicle (PBS-BSA) 
 
10% DMEM + 1 µM H2-Rlx 
 
10% DMEM + 200 nM ET-1 
 
10% DMEM + 1 µM H2-Rlx 
 
10% DMEM + 200 nM ET-1 
 
10% DMEM 
 
10% DMEM + Vehicle (PBS-BSA) 
 
10% DMEM + 1 µM H2-Rlx 
 
10% DMEM + 200 nM ET-1 
 
10% DMEM+ 200 nM ET-1 
 
10% DMEM+ 1 µM H2-Rlx 
 
 
Table 8. Treatment of HSC in gel contraction assays. 
 
2.5.3 Total NO/Nitrite/Nitrate detection (R+D systems) 
 
Test samples were collected from gel contraction assay wells.  The cell culture 
supernatant was collected after 72-96 hours of cell culture.  Cell culture 
supernates were centrifuged at 13000xg for 2 mins to remove particulates. 500 
µl of each sample was then filtered using 10,000 molecular weight (MW) cut-
off filters (Millipore). 500 µl of each test sample was centrifuged through the 
10,000 MW filters at 10,000 rpm for two minutes.  Supernatant that was able to 
pass through the filter was collected and stored in 2 ml Eppendorf tubes.  
Samples were stored at -20°C until ready to assay. 
 
Reagent Preparation 
All reagents were brought to room temperature before use.  10x reaction diluent 
(30ml of a 10 fold concentrated buffer containing detergent) was diluted using 
distilled water, 30 ml into 300 ml. Nitrate reductase enzyme was reconstituted 
with 1.0 ml nitrate reductase storage diluent (1.2ml of buffer containing 
glycerol) and vortexed vigorously, allowed to sit for 15 mins at room 
temperature and vortexed again, allowed to sit for an additional 15 mins at room 
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before use, determining the number of samples and standards in duplicate, the 
following equation was used: 
 
A.  Nitrate Reductase (µl) =  no. of wells x 5 µl 
B.  Reaction Diluent (1 x) (µl) = volume from step A x4 
C.  Volumes from steps A and B were added to a clean test tube and vortexed 
D.  Reaction was placed on ice and used within 15 mins of dilution 
 
NADH Reagent (lyophilized reduced ß-Nicotiamide adenine dinucleotide-
must be stored in the dark)  
NADH was reconstituted with 5 ml deionized water and allowed to sit for 3 
minutes with gentle agitation. NADH was used within 15 minutes or placed on 
ice. 
 
Nitrite/Nitrate standard (0.5ml of sodium nitrate/nitrite solution 2000 
µmol/L in buffer)  
500 µl of 1x reaction diluent was then added to eight sterile 2 ml Eppendorfs. 
500 µl of the 2000 µmol/L standard (nitrate or nitrite) stock was added to the 
first 2ml Eppendorf in the dilution series, the tube was mixed thoroughly and 
the serial dilution was continued, changing pipette tips between each transfer. 
This resulted in an eight point standard curve, top of curve high standard was 
500 µmol/L and 1x reaction diluent was the blank.    
 
Nitrite assay procedure - The assay procedure was used to measure the 
concentration of endogenous nitrite present in the sample 
All reagents were brought to room temperature before use and all samples and 
standards are assayed in duplicate. All reagents, standards and samples were 
prepared as above. The microplate was removed from the sterile bag and any 
unwanted wells were returned to the storage bag. 50 µl of 1x reaction diluent 
was added to the blank wells. 50 µl of nitrite standard or sample was added to 
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µl of Griess Reagent 1 (12 ml Sulfanilamide in 2N Hydrochloric acid, was 
added to all the wells before 50 µl of Griess Reagent II (12ml of N-(1-Naphthyl) 
Ethylenediamine in 2 N Hydrochloric acid) was added to all the wells. The plate 
was then mixed well by tapping the plate gently and incubated at room 
temperature for 10 minutes.  The optical density was determined for each well 
of the microplate using a plate reader set to read at 540 nm with a wavelength 
correction of 620 nm. 
 
Nitrate reduction assay procedure – The assay procedure was used to 
measure total nitrite by converting nitrate to nitrite.  
To determine the nitrate concentration in the sample, the endogenous nitrite 
concentration measured from the Nitrite Assay procedure must be subtracted 
from the converted nitrite concentration measured in this procedure.  All 
reagents were brought to room temperature before use and all samples and 
standards are assayed in duplicate. All reagents, standards and samples were 
prepared as above. The microplate was removed from the sterile bag and any 
unwanted wells were returned to the storage bag. 50 µl of 1x reaction diluent 
was added to the blank wells. 50 µl of nitrate standard or sample was added to 
the remaining wells.  25 µl of NADH, diluted as above was added to all the 
wells. 25 µl of diluted nitrate reductase was added to all the wells. Plate was 
mixed and covered with the adhesive strip provided. Plate was then incubated at 
37˚C for thirty minutes. 50 µl of Griess reagent I and 50 µl of Griess reagent II 
were added to all the wells, plate was mixed and incubated for 10 minutes at 
room temperature. Optical density was determined in a microplate reader set at 
540 nm with wavelength correction at 620 nm. 
 
Calculation of results 
All duplicate readings were averaged and a standard curve plotted on a log scale 
to linearise the data. Concentration of samples read form the standard curve are 
multiplied by the dilution factor (samples were read undiluted in this case).  
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total nitrate concentration the endogenous nitrite concentration is subtracted 
from the total nitrite concentration. 
 
Nitrate concentration = (Y-X) µmol/L. 
The results from the test samples were averaged from the three wells before 
entering them into the calculation.  The results from the three experiments were 
averaged and plotted on a histogram, including the standard deviation.  A t-test 
was used to determine if the differences observed were significant. 
 
2.6 siRNA studies 
 
RNA interference (RNAi) is an evolutionary conserved phenomenon observed 
in nearly every eukaryote ever studied.  In nature RNAi is a recognised pathway 
in the cellular defence against viral invasion and represents a unique form of 
post transcriptional gene silencing (PTGS).  RNAi can be initiated when the 
host cell encounters long dsRNA transcribed from an invading virus, an 
endogenous inappropriately transcribed sequence or by the newly identified 
class of regulatory non-coding micro RNAs (miRNAs).  The RNAi pathway 
was recognised as a biological pathway that could be utilised to develop 
valuable tools for systematic gene function analysis.  Functional intermediates, 
short interfering RNAs (siRNA) can be synthesised by a variety of methods and 
can be introduced to the cell or organism to effect changes in gene function.  
SiRNA has become a potent and specific method of gene silencing which 
exploits a naturally occurring pathway.   
 
The original observations were explained over a decade ago.  Fire and Mello 
described injection of a double stranded RNA that lead to the efficient loss of 
target mRNA.  There was little or no silencing by injecting single stranded 
sense or antisense RNA.  The silencing observed was specific for the homologs 
of the dsRNA sequence.  The dsRNA had to correspond to the mature mRNA, 
neither intron nor promoter sequences triggered a silencing response.  It was                                                                           Chapter 2: Methods and Materials 
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hypothesised that the dsRNA was acting post transcriptionally utilising a 
cytoplasmic mechanism.  The targeted mRNA disappeared suggesting it was 
degraded.  It was observed that only a few molecules of dsRNA were required 
per cell for effective silencing, it was suggested that the dsRNA is amplified or 
is acting catalytically (Fire et al., 1998).  Since the discovery of effective 
silencing through the injection of dsRNA, great advances have been made.  The 
RNAi interference pathway has been elucidated (figure 2.7) 
 
 
Figure 2.7.  The RNA interference pathway 
 
The appearance of dsRNA induces a cascade of events that involves a 
cytoplasmic RNase III like protein known as a dicer and the multi-protein RNA 
induced silencing complex (RISC).  In the cytoplasm Dicer is responsible for 
cleaving double stranded molecules, endogenously expressed miRNAs, 
replicating viruses or siRNAs, which are 19-25 base pairs long and have 
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characteristic 3’ overhangs.  siRNA is incorporated into RISC and the RISC 
associated ATP dependent helicase activity unwinds the duplex.  This enables 
either two strands to independently guide target mRNA recognition.  
Complimentarity between the guide strand and the target mRNA determines 
whether silencing is achieved via site specific cleavage of the message in the 
region of the siRNA-mRNA duplex or through a miRNA like mechanism of 
translational repression.  SiRNA silencing releases the cleavage products which 
are degraded leaving the siRNA programmed RISC to survey and further 
deplete the available pool of target mRNA (Fire et al., 1998).  Synthetic siRNAs 
function catalytically at nanomolar concentrations.  They are capable of 
cleaving up to 95% of the target mRNA in the cell.  Highly potent siRNAs have 
been found to effectively silence the gene through several cell divisions, 
persisting up to 10 days in mammalian culture.  Researchers are using siRNA to 
assess the contribution of genes to cellular processes such as apoptosis, 
differentiation and signalling.  The ability to produce knockout animals that 
stably suppress gene expression through a version of siRNA called short hairpin 
RNA (shRNA) has advanced the field not only through increased accessibility 
but through the capacity to produce multigene knockouts (Leung and Whittaker, 
2005).  ShRNA are siRNA sequences that have been ligated into a vector to 
create a plasmid that is incorporated into the cell or organisms genetic 
machinery.  SiRNA has also become a screening tool to elucidate the function 
of genes or to identify which genes are important in a particular biological 
process.  The siRNA field has advanced in recent years, developing rational 
design and pooled siRNA which not only increases successful knockdown of 
the gene but reduces the off target affects.  There are many different delivery 
methods such as lipid based transfection reagents or electroporation, none of 
which have been found to universally suit all cell types.  Cell lines are more 
robust and can be transfected using higher concentrations of siRNA and 
transfection reagent compared to primary cells.  This usually increases the 
efficiency of delivery and the level of knockdown achieved.  Lipid based 
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primary cells.  This has to be controlled for by using cell viability and 
cytotoxicity assays to assess the cell viability after each different experimental 
condition to ensure the decrease in gene expression is not due to cellular 
necrosis (Fire et al., 1998;Leung and Whittaker, 2005).   
 
3(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium, inner salt (MTS) is used as an indicator of cell viability.  The 
MTS assay used has combined MTS with an electron coupling agent, phenazine 
ethosulfate (PES) that has enhanced stability allowing it to combine with MTS 
to form a stable solution.  MTS is bioreduced by cells to form a coloured 
formazan product that is soluble in tissue culture medium (figure 2.8) (Cory et 
al., 1991).  The coloured formazan product is produced through the break down 
of NADPH or NADH to NADP or NAD
+ respectively.  The process requires 
dehydrogenase enzymes from metabolically active cells (Berridge and Tan, 
1993). 
              
 
 
Figure 2.8. Conversion of MTS to Formazan (Promega) 
 
The colour change produced by the formation of formazan can be measured by 
reading the absorbance wavelength at 490 nM on a spectrophotometer.  The 
colour change is directly proportional to the number of viable cells in the well 
(figure 2.9.).  The assay can be used to detect the number of viable cells after 
manipulation by siRNA or cytotoxic substances.  It can be used in conjunction                                                                           Chapter 2: Methods and Materials 
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with other assays such as apoptosis and LDH cytotoxicity assays to ascertain the 
method by which cells may be reducing or increasing their viability and 
number. 
 
 
 
Figure 2.9. Absorbance plotted against cell number to show linearity (Promega) 
 
The advantage of using MTS over traditional MTT or INT assays is that the 
coloured product is soluble in tissue culture media and the PES electron 
coupling reagent is stable when combined with MTS.  Also there are no 
radioactive or volatile organic solvent compounds to handle unlike similar 
assays.  This not only allows for fewer steps in the assay, reducing the time and 
any possible error but also increases the flexibility of the assay.  The plate can 
be returned to the incubator for further colour development if required. 
 
The lactate dehydrogenase (LDH) assay is a colorimetric assay used to quantify 
cell death and cell lysis. Cell death has been classically evaluated by 
quantification of plasma membrane damage.  Many different standard methods 
including the uptake or exclusion of vital dyes or the release of radioactive 
isotopes are used to quantify cell death (Yuhas et al., 1974;Oldham et al., 1977).  
The disadvantage of these techniques is the quantification can be easily under or 
over estimated.  The measurement of cytoplasmic enzyme activity released from 
damaged cells is a robust method that directly relates to the proportion of lysed 
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LDH is a stable cytoplasmic enzyme present in all cells that is rapidly released 
upon damage to the plasma membrane.  The colour reaction required for 
quantification undergoes two steps.  Firstly NAD
+ is reduced to NADH/H
+ by 
the LDH catalysed conversion of lactate to pyruvate.  The second step is 
catalysed by diaphorase which transfers the hydrogen ions from NADH/H
+ to 
the tetrazolium salt INT, which reduces it to form the coloured product 
formazan (figure 2.10) (Korzeniewski and Callewaert, 1983). 
 
 
Figure 2.10.  Colorimetric LDH cytotoxicity assay reaction (Roche) 
 
If there is an increase in dead/lysed cells then there will be an increase in LDH 
enzyme activity in the cell culture supernatant.  The enzyme activity directly 
correlates to the amount of formazan formed which is soluble in water or cell 
culture media.  The absorbance wavelength of formazan can be detected at 490 
nM on a standard spectrophotometer or elisa plate reader.  A reference 
absorbance can be measured above 600 nM.  The reference absorbance is 
subtracted from the actual reading and is used to eliminate any interference from 
colours absorbed at different wavelengths.  Pyruvate can inhibit step 1 of the 
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formulations of cell culture media and serum and therefore care must be taken 
to ensure the concentration is as low as possible in this assay.  
 
2.6.1 SiRNA transient transfection  
 
Human HSC or LX-2 cells were plated at a density of 100,000 cells per well in 
a 10 cm dish or 50,000 cells per well in a 6 well plate.  Cells were cultured for 
24 hours in antibiotic free 10% DMEM.  Media was then replaced with 4.8 ml 
or 800 µl of serum free media and cells returned to the 37°C incubator whilst 
the siRNA/lipid complexes were formed. All serum free media (SFM) used was 
DMEM with phenol red, without serum, antibiotics or sodium pyruvate.  
Concentration of siRNA was determined by transfecting several different 
concentration of siRNA into HSC or LX-2 cells.  The lowest possible 
concentration which gave the maximum knockdown and the least cytotoxicity 
for each cell type was used.  LX-2 cells could be transfected with a higher 
concentration of siRNA due to the minimal toxicity observed in these cells. 
 
Preparation and transfection of complexes in LX-2 cells 
LX-2 cells were transfected with 100nM of siRNA whilst primary HSC were 
transfected with 25 nM siRNA.  LX-2 cell transfection in a 6 well plate was 
carried out entirely in a tissue culture hood using aseptic techniques.  2 µl of 
RXFP-1 or –ve control siRNA (ambion) were added to 183 µl of serum free 
media (SFM) in a DNAase/RNAase free 1.5ml Eppendorf tube.  4 µl of 
oligofectamine transfection reagent (Invitrogen) was added to 11 µl of SFM in a 
separate sterile Eppendorf.  Each tube was incubated at room temperature for 5 
minutes.  The siRNA and oligofectamine was then combined and incubated at 
room temperature for 20 minutes.  The 200 µl siRNA/lipid complexes were then 
added directly to the cells that contain SFM.  The cells are then returned to the 
37°C incubator for 4 hours before 0.5 ml of 30% DMEM w/o antibitotics or 
pyruvate was added to the cells.  The cells remained in antibiotic and pyruvate 
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assays that the cells were used in.  All amounts were multiplied by 6 for 
transfections in a 100 mm dish. 
 
Preparation and transfection of complexes in primary HSC 
Primary HSC transfection in a 6 well plate was carried out entirely in a tissue 
culture hood using aseptic techniques.  0.5 µl of RXFP-1 or –ve control siRNA 
(ambion) were added to 184.5 µl of serum free media (SFM) in a 
DNAase/RNAase free 1.5ml Eppendorf tube.  4 µl of oligofectamine 
transfection reagent (invitrogen) was added to 11 µl of SFM in a separate sterile 
Eppendorf.  Each tube was incubated at room temperature for 5 minutes.  The 
siRNA and oligofectamine was then combined and incubated at room 
temperature for 20 minutes.  The 200 µl siRNA/lipid complexes were then 
added directly to the cells that contain SFM.  The cells are then returned to the 
37°C incubator for 4 hours before 0.5 ml of 30% DMEM w/o antibiotics or 
pyruvate was added to the cells.  The cells remained in antibiotic free media 
throughout the transfection process and during any subsequent assays that the 
cells are used in.  All amounts were multiplied by 6 for transfections in a 100 
mm dish. 
 
2.6.2 MTS cell viability assay (Promega) 
 
MTS assays were used to determine the cell viability after transfection with 
siRNA and after relaxin treatment in HSC.  Suitable controls were carried out 
for each assay and the optimal cell density was determined before experimental 
conditions were tested.  The optimal cell density for HSC was found to be 5000 
cells per well of a 96 well plate.  Each condition was plated in triplicate and the 
background was read and subtracted each time using wells containing cell 
culture media DMEM containing 10% serum and phenol red but no cells.  MTS 
reagent (Promega) was thawed before each use and returned to -20ºC thereafter.  
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The cells were then transfected with RXFP-1 and –ve control siRNA in a 6 well 
plate as described previously.  The cells were also exposed to transfection 
reagent and the siRNA alone.  This was to ensure neither the transfection 
reagent nor the siRNA could individually effect the viability of the cells.  The 
cells were trypsinised and counted using a haemocytometer after 5 hours 
exposure to the siRNA.  A flat bottom 96 well clear cell culture plate was used 
to seed each condition in triplicate at a density of 5000 cells per well in 100 µl 
of 10% FBS DMEM with phenol red.  The cells were placed back in the 37ºC 
incubator overnight.  After 24 hours 20 µl of MTS reagent was added to the 
wells which were to be read 24 hours after transfection.  The plate was protected 
from the light and replaced in the 37ºC incubator for 1 hour.  The absorbance 
was then read at 490 nM on a spectrophotometer.  The plate was returned to the 
37ºC incubator for a further 24 hours.  The wells which were to be read 48 
hours after transfection now had 20 µl of MTS reagent added.  The absorbance 
was again read after 1 hour in the dark at 37 ºC at 490 nM on a 
spectrophotometer and returned to the incubator.  The procedure was carried out 
again 72 hours after transfection.   
 
The MTS assay was also used to detect the cell viability after 72 hours of 
relaxin treatment.  Cells were plated at a density of 5000 cells per well in a flat 
bottomed 96 well cell culture plate.  Cells were retuned to the incubator 
overnight before culture media was replaced, ensuring each well had 100 µl of 
10% FBS DMEM.  Cells were then treated with 1 μM of relaxin or vehicle 
(PBS/BSA) and returned to the incubator for 72 hours (cells were treated with 
relaxin every 24 hours).  20 µl of MTS reagent was added to each well 
including control well and the plate was returned to the incubator protected 
from the light for 1 hour.  The absorbance was then read at 490 nM on a 
spectrophotometer.   
 
Both assays were carried out with three different preps of HSC.  The average 
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to compare between treatment groups and therefore absolute values of cell 
viability were not required.   
 
2.6.3 LDH cytotoxicity assay 
 
Colorimetric LDH cytotoxicity assays were used in conjunction with MTS 
assays to determine if siRNA transfection and treatment with relaxin is 
cytotoxic to HSC.  The assay required 3 different controls to be carried out to 
enable a percentage cytotoxicity to be calculated.  The background LDH activity 
was controlled for by adding 10% FBS DMEM that had not been exposed to 
cells.  The high control was the maximal LDH released from the cells.  This was 
achieved by adding 1% triton X diluted in 10% FBS DMEM to the cells after 
the culture supernatant had been removed.  Triton X is a detergent that lyses the 
cells but does not interfere with the colour reaction.  The final control was an 
internal experimental control such as –ve control siRNA and non-transfected 
cells being used to compare RXFP-1 siRNA transfected cells.  Also within the 
relaxin treatment experiment the internal control was cells treated with PBS 
containing 1% BSA.  This was the vehicle used to deliver relaxin to the cells in 
culture.  Assay samples were collected directly from the 6 well plates in which 
the cells were either transfected or exposed to relaxin in.  The high control was 
collected for each individual sample by adding 1% triton X to the adherent cells 
in the 6 well plate.  Each sample % cytotoxicity was calculated using its own 
high control.  This controlled for any changes in cell number.   
 
Directly before the experiment could be carried out the reaction mixture was 
prepared.  The catalyst diaphorase/NAD+ mixture (Roche) had to be 
reconstituted with 1 ml of deionised water.  This was left to stand at room 
temperature for ten minutes before 250 µl was added to 11.25 µl of dye solution 
(iodotetrazolium chloride (INT) and sodium lactate) (Roche).  The reaction 
mixture was sufficient to carry out 100 reactions in a 96 well plate.  The 
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in 2 ml Eppendorf tubes.  The samples were spun at 10,000 rpm for 2 minutes 
and the supernatant was removed and stored in a new 2 ml Eppendorf.  The 
samples were stored at -20ºC or used directly in the assay.  100 µl of 
supernatant was added in triplicate for each sample to a flat bottomed 96 well 
culture plate.  100 µl of reaction mix was added to each sample which was 
incubated at room temperature in the dark for 30 minutes.  The absorbance was 
then measured at wavelength 490 nM on a spectrophotometer.  The reference 
wavelength was above 600 nM.  The cells used in the assay were cultured in 
10% FBS DMEM with phenol red.  Although the assay conditions suggest using 
serum concentrations of below 5%, the experimental conditions had to 
correspond with the experimental conditions for all of the siRNA studies.  There 
were no antibiotics in the media used for the siRNA transfected cells and the 
percentage pyruvate was kept as low as possible, i.e. there was no extra 
pyruvate added to the media and the DMEM used did not have a high 
percentage pyruvate content. Percentage cytotoxicity was calculated using 
averaged experimental and control values from each experiment that used 
triplicate wells and from the three different cell preps, see below.  
 
                                  (Experimental value-background control)    
% Cytotoxicity =                                                                                       x 100 
                               (Experimental value+ high control)-background 
 
All of the samples were calculated using this formula.  The experimental values 
such as relaxin treated cells were then compared to the control wells such as 
PBS-BSA treated cells and were plotted on a graph plus or minus standard of the 
mean and a t-test was used to calculate any significant differences.  Absolute 
LDH activity could be calculated using a spiked standard curve but this was not 
deemed necessary as only the percentage cytotoxicity was required to be able to 
compare samples.   
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2.7 Statistical analysis 
 
Results are all normalized to appropriate controls and standard deviations are 
applied as error bars on all control and experimental values.  A two tailed, paired 
T-Test was then carried out to compare each result to the control.  Results are 
shown as significant ** (p<0.01) = 99% confidence, * (p<0.05) = 95% 
confidence.  One results has been shown as * (p<0.1) = 90% confidence.  
Cytokine array data in chapter 4 was analysed using Graphpad Prism4.  A 
repeated measures one way ANOVA was carried out using a suitable post hoc 
test, in this case a Bonferroni correction analysis.  This enabled each column of 
values for each respective cytokine to be compared to each other, allowing for 
comparisons between each cytokine and its respective control value, between 
each cytokine within the control and treatment groups and each cytokine 
between these two groups.    
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3.1 Introduction 
 
3.1.1 Introduction 
 
Relaxin knockout mice develop age related fibrosis (Samuel et al., 2005b) and 
consequently there has been a resurgence of interest in relaxin by academic labs 
and pharmaceutical companies alike in the idea of using relaxin as an antifibrotic 
therapeutic agent.  Two receptors that respond to H2-relaxin and INSL3 were 
identified in 2002 (Hsu et al., 2002) and more recently the receptors that respond 
to H3-relaxin (RXFP-3) (Liu et al., 2003) and INSL5 (RXFP-4) (Liu et al., 
2005b).  Therefore the relaxin receptor family are a relatively new area of 
research and the discovery of the relaxin receptors has enabled more detailed 
pharmacological approaches to help reveal the true therapeutic potential of this 
hormone.  Previous studies have revealed relaxin receptors to be expressed in rat 
HSC and localised in rat and human cirrhotic liver sections (Bennett et al., 
2005;Bennett et al., 2007).  The characterisation of these receptors in hepatic 
stellate cells (HSC), which are the main effector cells in fibrotic liver disease 
(Friedman et al., 1985;Friedman et al., 1985), will allow the evaluation of the 
key issues to be addressed in the thesis.  Relaxin receptor expression and 
localisation in liver tissue will be studied using several different techniques 
including RT-PCR and immunohistochemistry in in vitro models of fibrotic liver 
disease including growth of HSC on Matrigel.  In the normal liver HSC reside 
on basement membrane and grow long projections that link the endothelial and 
hepatocyte layer in the Space of Disse (Imai et al., 2000).  Culture of HSC on 
Matrigel can deactivate HSC, allowing the study of HSC in a less fibrotic 
phenotype (Gaca et al., 2003).  The activity of the relaxin receptors in response 
to their respective ligands will be determined by cAMP assay.   
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3.1.2 Hypothesis, Aims and Objectives 
 
Hypothesis 
Relaxin receptors are expressed in LX-2 and primary HSC and the expression 
may be dependent upon activation. 
 
Aims 
Determine the expression and localisation patterns of the relaxin receptors in 
HSC and human liver sections, whilst confirming the presence of active 
receptors that respond to their respective ligands. 
 
Objectives 
•  Determine the expression pattern of relaxin receptors in LX-2 and 
primary HSC using RT-PCR and immunocytochemistry. 
•  Assess RXFP-1 and RXFP-2 expression in activated HSC, hepatocytes 
and hepatocellular carcinoma (HCC) by RT-PCR. 
•  Establish the receptor localisation in human liver sections by 
immunhistochemistry. 
•  Verify the loss of RXFP-1 expression in deactivated HSC using cells 
cultured on Matrigel. 
•  Confirm the presence of active receptors in LX-2 and primary HSC in 
cAMP assays and assess the in vitro pharmacological ligand 
concentrations required for a maximal response required for later studies.   
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3.2 Results-Relaxin receptor expression profile in different liver 
cell types 
 
3.2.1 Expression patterns of the relaxin receptors and their ligands in 
activated HSC 
 
RNA extracted from LX-2 cells and passage 1 (p1) hHSC and was used to assess 
the expression profile of RXFP-1, 2, 3 and 4.  RXFP-1, 3 and 4 were all 
expressed in primary HSC and LX-2 cells (figure 3.1a).  RXFP-1 had the highest 
expression and no band was detected for RXFP-2 in either LX-2 or p1 hHSC.  
H2-relaxin, H3-relaxin and INSL5 were found to have local expression in p1 
HSC (figure 3.1b).    
 
 
 
 
                
     
Figure 3.1 (A) Expression of RXFP 1-4 in primary HSC and LX-2 cells assessed by 
RT-PCR.  RXFP-2 was not expressed in p1 priamry HSC or LX-2 cells.  RXFP 1 
(314bp), 3 (288bp) and 4 (356bp) were all expressed in both primary HSC and LX-2 
cells (n=3) (B) expression of H2, H3-relaxin and INSL5 in primary HSC assessed by 
RT-PCR.  All three relaxin ligands are expressed by primary HSC (n=3).  
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3.2.2 RXFP-1 and RXFP-2 expression in activated HSC, hepatocytes (HEP) 
and a hepatocellular carcinoma (HCC) cell line HepG2 
 
RXFP-1 and 2 expression was assessed in HSC of different passage number, 
hepatocytes and HepG2 cells (hepatocellular carcinoma (HCC) cell line).  
RXFP-1 was expressed in p1, p3 and p4 HSC (figure 3.1a).  RXFP-1 expression 
peaked in p3 HSC which coincides with the highest level of α-SMA protein 
expression, a marker of activation, assessed by immunoblotting (figure 3.2b).  
RXFP-1 was also expressed in hepatocytes (HEP) and had a very weak 
expression in HCC (HepG2 cells) (figure 3.1a).  RXFP-2 expression was 
assessed in all of the cell types (figure 3.1a).  RXFP-2 was expressed in p4 HSC 
but the expression was very weak and required a higher cycle number compared 
to RXFP-1 to be able to see this low level of expression. 
 
 
 
Figure 3.2 (A) Expression of RXFP-1(317bp), RXFP-2(200bp) and GAPDH in p1, p3, 
and p4 primary HSC, human HepG2 (hepatocellular carcinoma cell line) and human 
hepatocytes assessed using RT-PCR.  RXFP-1 is expressed in p1, p3 and p4 HSC, 
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and the lowest level of expression was found in HCC (hepG2 cells) (n=3). (B) 
Expression of α-SMA and GAPDH  in P1, P3 and P4 HSC assessed by immunoblotting 
(n=3).  α–SMA expression was greatest in p3 HSC which confirms RXFP-1 expression 
increases in parallel with levels of activation.   
    
3.2.3 RXFP-1 and α-SMA cellular localisation in activated HSC 
                                               
To confirm the protein expression of RXFP-1 in activated primary HSC, 
immunocytochemistry was used.  This also tested the purity of the preparations 
of HSC.  Activated HSC are α-SMA positive in culture unlike possible 
contaminates such as macrophages and endothelial cells.  Immunocytochemistry 
was carried out on p1 cells that had been cultured on cover slips.  
Immunocytochemistry revealed activated HSC extracted from human liver were 
a single population of cells that expressed both α-SMA (figure 3.3.a and b) and 
RXFP-1 protein (figure 3.3.c and d).  
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Figure 3.3. (a) α–SMA (1/1000) antibody staining of p2 human HSC 10 x objective (b) 
α–SMA (1/1000) antibody staining of p2 human HSC 20 x objective (c) RXFP-1 
antibody staining of p2 human HSC (antibody dilution 1/200) (d) RXFP-1 antibody 
staining of p2 human HSC (antibody dilution 1/200) (e) rabbit (1/200) 10 x objective 
and (f) mouse (1/200) 20 x objective, IgG negative control staining of p2 human HSC. 
All images were taken using Zeiss Axioskop camera and software.  An n=3 was 
obtained for each antibody stain.   
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3.3 Localisation of relaxin receptors in paraffin embedded liver 
sections 
 
3.3.1 Identification of liver structures by H+E and the comparison of RXFP 
1-4 localisation 
 
Liver tissue that been removed from the normal margin of patients undergoing 
liver resection for hepatocellular carcinoma were fixed in 10% formalin and 
embedded in paraffin wax.  The fixed tissue was used to study the localisation of 
relaxin receptors.  Serial sections were cut and every tenth slide was stained with 
haematoxylin and eosin (H+E).  This was carried out by a technician in the 
histology unit (figure 3.4a).  The specimens characteristically had areas of 
scarring and areas of normal morphology within the section.  The sections were 
stained using α-SMA antibody to be able to asses the level of fibrosis, and 
localise the activated stellate cells in the sections. The α-SMA staining of the 
liver reveals the activated hepatic stellate cells to be within the scar region 
around the artery and blood vessels as well as in the Space of Disse between the 
hepatic sinusoid and the hepatocytes (figure 3.4.b v-red arrows).   Relaxin 
receptor localisation was determined by antibody staining.  RXFP-1, RXFP-3 
and RXFP-4 were localised in human liver sections (figure 3.4b).   RXFP-1 was 
found to have a relatively high expression in areas of scarring in the human liver 
sections around the arteries and blood vessels in the portal triad (black arrow).  
RXFP-1 is also localised in the hepatocytes but the expression is low compared 
to the areas of scarring (figure 3.4.b i and ii).  RXFP-3 had a similar pattern of 
expression but was not as highly expressed as RXFP-1 (figure 3.4.b iii).  RXFP-
4 was localised in areas of bile duct proliferation and around the areas of 
scarring but again compared to RXFP-1 the expression was low (figure 3.4.b iv).   
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Figure 3.4. (A) Representative image of H+E staining of human liver sections.  
Structures such as the hepatic artery, hepatocytes and the hepatic sinusoid can be 
identified (n=3) (B) Representative images of immunohistochemical staining of paraffin 
embedded human liver sections.  Antibodies for (i and ii) RXFP-1 (1/200 dilution), (iii) 
Hepatic artery surrounded by an area of 
minor scarring, which has evidence of 
excess collagen deposition. 
Normal hepatocytes, which are 
interconnected by the hepatic sinusoid 
and the space of Disse, where the stellate 
cells reside.                                                                               Chapter 3: Characterisation of RXFP 1-4 
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RXFP-3 (1/200 dilution), (iv) RXFP-4 (1/50 dilution), (v) α–SMA (1/40,000) and (vi) 
IgG isotype control (1/200), were used to localise human relaxin receptors in liver 
tissue.  RXFP-1 is strongly positive in areas of scarring (black arrow) and weakly 
positive in the hepatocytes (confirmed using RT-PCR), RXFP-3 is weakly positive 
around areas of scarring and RXFP-4 is positive in areas surrounding bile duct 
proliferation and areas of localised scarring.  All images were taken using 20x objective 
on the Zeiss Axioskop camera and software. An n=3 was obtained for each antibody 
stain. 
 
3.3.2 Serial section staining comparing RXFP-1 with sirius red and α-SMA 
 
The cellular localisation of RXFP-1 was confirmed by using serial sections 
stained using H+E, Sirius red, α-SMA, RXFP-1 and a negative control.  RXFP-1 
is localised in areas of α-SMA positive staining, suggesting RXFP-1 is up 
regulated in areas of injury where HSC have become activated (figure 3.5. iii).  
Sirius red staining revealed fibril collagen formation in areas that were also 
stained for RXFP-1 (figure 3.5. iv). 
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Figure 3.5. Representative images of paraffin embedded serial sections of human liver 
stained with (i) H+E, (ii) α-SMA (1/40,000 dilution), (iii) RXFP-1 (1/200 dilution), (iv) 
Sirius Red (fibrous collagen marker) and (v) IgG isotype control (1/200). RXFP-1 is 
clearly colocalised in an area of scarring that is also positive for α-SMA and Sirius red 
(black arrows).  RXFP-1 is also localised in hepatocytes (red arrow).  Images were 
taken with Zeiss Axioskop camera and software using 20 x objective. An n=3 was 
obtained for each antibody stain. 
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3.4 cAMP response to H2-Relaxin and relaxin-like ligands in 
HSC and LX-2 cells 
 
The measurement of cAMP is a reproducible and reliable method of detecting 
activation of a cAMP linked receptor.  cAMP is produced in cells in response to 
H2-relaxin (Halls et al., 2005a;Halls et al., 2006).  The cAMP produced in 
response to H2-relaxin, H3-relaxin, INSL3 and INSL5, in LX-2 and primary 
HSC was measured.  LX-2 cells were used to optimise the assay for the range of 
cAMP produced in response to H2-relaxin, due to difficulty in reproducibility in 
primary HSC.  A standard curve is performed each time the assay is run (figure 
3.6.a).  The cAMP assay carried out in LX-2 cells revealed a dose dependent 
increase in cAMP accumulation in response to H2-relaxin, the ligand for RXFP-
1 (figure 3.6.b).  The Log EC50 value was -9.4 and the assay gave a 1.7 fold 
window.  The log EC50 value is the point on the curve that gives 50% maximal 
response.  The concentration of H2-relaxin that gave 50% maximal response in 
LX-2 cells was therefore 3.6x10
-10 M.   A plateau or Vmax is reached between 
Log concentration -8 and -7 (which corresponds to 10 – 100 nM).  There was no 
dose dependent increase in cAMP in response to INSL3 the ligand for RXFP-2 
although at the highest dose (10 μM) there was a small increase in signal.  H3-
Relaxin and INSL5 did not increase the amount of cAMP in the cell and the only 
response observed in the initial assay was a small decrease at the highest dose 
(10 μM) of H3-relaxin (figure 3.6.c).  Activated RXFP-3 and RXFP-4 receptors 
decrease the amount of cAMP in the cell, therefore the LX-2 cells were pre-
stimulated with forskolin to induce an accumulation of cAMP before the ligands, 
H3-relaxin and INSL5 are added.  H3-relaxin and INSL5 both induced a dose 
dependent decrease in cAMP accumulation in LX-2 cells.  The activity at the 
RXFP-3 receptor was more potent then that of RXFP-4 with a Log EC50 of -8.2 
(6.016x10
-9 M) the curve was shifted to the left.  The fold window for H3-
relaxin was 1.27 and the Vmax was reached between Log concentration -6 and -
5 (1 μΜ- 10 μM).  RXFP-4 was stimulated with two INSL5 ligands, a long chain 
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essential binding domains. Both ligands elicited a similar response, the long 
chain Log EC50 was -6.017 (9.6x10
-7 M) with a fold window of 1.21 whereas the 
short chain had a Log EC50 of 6.211 (6.156 x10
-6 M) with a fold window of 1.39. 
Vmax for both ligands is reached at Log concentration -5 (10 μΜ) (figure 3.6.c).   
 
The cAMP response to relaxin ligands was then tested in primary HSC.  The top 
concentration in the dose response curve was increased by two half log 
concentrations to -6.5 due to the top of the curve not being reached in the first 
assay.  Once the assay had been optimised in primary HSC, it was found to be 
reproducible and a dose dependent response to H2-relaxin in primary HSC was 
observed.  The ligand was not as potent as in LX-2 cells as the curve shifted to 
the right with a Log EC50 of -8.7 (1.6x10
-9 M) but the fold window was greater at 
2.6.  The Vmax was reached between Log concentration -7 and -6 (100 nM- 1 
μM) (figure 3.6.d).     
 
 
 
Figure 3.6. (a) cAMP standard curve in a 384-well plate format (n=4), all assays were 
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in response to stimulation with H2-rlx (n=11), H3-rlx (n=8) and INSL3 (n=8) for 90 
minutes.  LX-2 cells increase the intracellular production of cAMP in a dose dependent 
manner in response to H2-rlx with an EC50 of 363 pM.  LX-2 cells do not increase their 
intracellular cAMP in response to H3-rlx and only respond to INSL3 at very high doses, 
which could represent cross reactivity at the RXFP-1 receptor (c) cAMP response of 
LX-2 cells when stimulated with H3-rlx (n=3), INSL5 (short chain) (n=3) and INSL5 
(long chain) (n=3) for 90 minutes after a 10 minute pre-stimulation with forskolin.  H3-
rlx decreased the intracellular production of cAMP in a dose dependent manner in LX-2 
with an EC50 of 6.016 nM. The long and short chain of INSL5 reduced the production of 
cAMP in a dose dependent manner in LX-2 cells with an EC50 of 961.5 nM and 6.16 
μM respectively, revealing the full length chain of INSL5 is required for normal 
signalling at the RXFP-4 receptor (d) Change in cAMP production in hHSC in response 
to stimulation with H2-rlx (n=6) for 90 minutes.  hHSC increase the intracellular 
production of cAMP in a dose dependent manner in response to H2-rlx with an EC50 of 
1.67 nM. 
 
3.5 In vitro model comparing expression of RXFP-1 and several 
fibrotic markers in activated vs quiescent HSC 
 
Human HSC were isolated and plated, 1 million cells per 75 cm flask.  The cells 
were grown on plastic for seven days before they were trypsinised and re-plated 
at the same density on plastic or a Matrigel 3D matrix (1 million cells per 100 
mm culture dish).  Cells were then cultured for 14 days and morphology was 
observed.  The cells grown on the 3D Matrigel matrix did not appear to become 
confluent whilst in the same time scale the cells grown on plastic continued to 
proliferate and became confluent (figure 3.7a). There were also morphological 
differences clearly evident between the two populations of cells.  The HSC 
plated on plastic remained proliferative and myofibroblast in appearance.  The 
cells plated on Matrigel remained as individual cells that did not appear to 
proliferate and grew spindle like projections to neighbouring cells (figure 3.7a).  
The cells were analysed for expression of fibrotic markers after 14 days of 
culture.  Procollagen-1 and TIMP-1 mRNA were both reduced in cells grown on                                                                               Chapter 3: Characterisation of RXFP 1-4 
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Matrigel although the procollagen-1 mRNA was reduced by a greater extent 
(figure 3.7b).  Interestingly RXFP-1 mRNA expression was considerably 
reduced in cells grown on Matrigel (figure 3.7b).  MMP-1 mRNA expression 
increases in cells grown on Matrigel but not to the extent that MMP-2 expression 
was up regulated (figure 3.7c).  TIMP-1 and α-SMA protein expression were 
both appreciably reduced (figure 3.6c) whilst pro-MMP-2 (72 kDa band) protein 
expression was to some extent upregulated in the cells grown on Matrigel, the 
cleaved/active form of the protein (68 kDa band) had been substantially up 
regulated and could now be detected on the blot (figure 3.7c).  Pro-MMP-1 (53 
kDa band) protein expression and the cleaved/active form (51 kd band) were 
both up regulated in cells grown on Matrigel (figure 3.7c).   
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Figure 3.7. (A) Representative phase contrast images of p1 hHSC after 14 days culture 
on plastic (P) or growth factor reduced Matrigel basement membrane (M). Primary HSC 
cultured on plastic are activated myofibroblasts compared to cells cultured on Matrigel 
which lose their ability to proliferate and appear to revert to a more quiescent phenotype 
(n=3). (B) Expression of fibrotic markers and RXFP-1, assessed by RT-PCR, in p1 
hHSC after 14 days culture on plastic or Matrigel.  Fibrotic markers such as 
procollagen-1 and TIMP-1 are reduced after culture on Matrigel whereas MMP-1 and 
MMP-2 expression is increased.  The most significant finding was the almost complete 
loss of RXFP-1 expression in HSC cultured on Matrigel, suggesting non-activated HSC 
do not express RXFP-1 (n=3). (C) Expression of fibrotic markers, assessed by western 
blotting, in p1 hHSC after 14 days culture on plastic or Matrigel.  Fibrotic markers a-                                                                              Chapter 3: Characterisation of RXFP 1-4 
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SMA and TIMP-1 expression where reduced in HSC after culture on Matrigel whereas 
the expression of immature (53 kDa) and mature (51 kDa) forms of MMP-1 was 
increased as well as the expression of the mature form (68 kDa) of MMP-2. 
 
 
3.6 Summary of key findings 
 
•  RXFP-1,3 and 4 were expressed by activated primary human HSC and 
LX-2 cells, assessed by RT-PCR. 
•  RXFP-1 was localised in cultured HSC by immuncytochemistry. 
•  RXFP-1 is localised to areas of scarring in the human liver. 
•  LX-2 and HSC respond to H2-relaxin by activating the accumulation of 
cAMP in a dose dependent manner.  Pre-stimulated LX-2 cells can 
respond to H3-relaxin and INSL5 by inhibiting the accumulation of 
cAMP in the cell in a dose dependent manner. 
•  HSC grown on Matrigel lose expression of RXFP-1 mRNA concomitant 
with decreased detection of mRNA for procollagen-1 and reduction in 
mRNA and protein for TIMP-1, whilst showing increased amounts of 
MMP-1 and 2 mRNA and protein. 
 
3.7 Discussion     
 
Relaxin receptor expression in activated human HSC and LX-2 cells has been 
confirmed.  Receptors RXFP-1, 3 and 4 are expressed in both LX-2 and primary 
HSC and the ligands H2-relaxin, H3-relaxin and INSL5 also have a low level of 
expression in HSC, potentially facilitating autocrine activation of the receptors.  
RXFP-1 is localised in areas of scarring in the human liver but is also expressed 
in hepatocytes.  Relaxin has various signalling mechanisms that are cell and 
tissue dependent (Bathgate et al., 2005).  Relaxin may activate different 
signalling pathways which can up or down regulate various genes such as TIMP-
1 and MMP-1 which are critical not only in HSC survival but also fibrotic 
mechanisms (Murphy et al., 2002;Iredale et al., 1992).  Relaxin has been found                                                                               Chapter 3: Characterisation of RXFP 1-4 
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to up regulate metastatic invasiveness of some forms of cancers, particularly 
breast and prostate cancer.  This may be due to the up regulation of MMPs 
(Binder et al., 2002;Feng et al., 2007).  Cells extracted from hepatocellular 
carcinoma (HCC) tissue did not express RXFP-1, therefore suggesting relaxin 
would not act directly on HCCs.  RXFP-1 expression in HSC appears to be 
activation dependent.  The expression of RXFP-1 correlated with the level of 
activation evaluated through α-SMA protein expression.  This suggests that 
relaxin receptors may have an important role in activated HSC.  This role may 
be speculated upon but H2-relaxin may contribute to the regulation of stellate 
cells in an anti-fibrotic, negative feedback capacity by activating RXFP-1.  The 
phenotype of HSC in response to H2-relaxin will be investigated in chapter 4.  
HSC become activated and lay down extracellular matrix in the normal course of 
repair in the liver.  This process only becomes pathogenic when the injury and 
inflammation becomes chronic (Iredale et al., 1998).  Therefore the HSC in a 
normal liver will need to become activated whilst repair is taking place and then 
either revert to a quiescent phenotype or undergo apoptosis once the injury has 
ceased and the normal liver architecture has been restored.  The process of 
recovery has been described by (Iredale et al., 1998) in an in vivo model of liver 
fibrosis.  It has been described that vasoactive mediators such as relaxin, 
vasopressin, angiotensin II and endothelin-1 can contribute to HSC regulation 
(Rockey and Weisiger, 1996;Reynaert et al., 2002;Wilson and Summerlee, 
1994;Morales et al., 2003).  Vasoconstrictor substances such as vasopressin and 
angiotensin II have a mitogenic affect on HSC promoting activation and 
proliferation through G-protein coupled signalling (Lo et al., 2008).  Vasodilator 
substances such as prostaglandin E2 and nitric oxide have been reported to act as 
anti-mitogenic factors reducing the proliferation of HSC (Goss et al., 
1992b;Goss et al., 1992a).  Growth factors that promote HSC proliferation such 
as PDGF require Ca
2+ influx to exert their effects.  Relaxin is a vasodilator 
substance that has been purported to not only inhibit uterine muscle contraction 
but inhibit the release of vasopressin and oxytocin (both vasoconstrictor 
substances), therefore inhibiting the release of intracellular calcium and increase                                                                               Chapter 3: Characterisation of RXFP 1-4 
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nitric oxide release through G-protein coupled signalling mechanisms (Dayanithi 
et al., 1987;Nistri and Bani, 2003).  As a potential regulator of fibrosis relaxin 
may promote the reversion of activated HSC to a quiescent phenotype or 
advance the cell into apoptosis.  H2-relaxin is also expressed by activated HSC 
which may suggest an autocrine negative feedback regulation of activated HSC.  
Regultation of HSC may also be through a paracrine mechanism if H2-relaxin 
was expressed by hepatocytes or by an endocrine mechanism through activation 
of RXFP-1 by circulating H2-relaxin.  It is also reported that marcophages 
typically THP-1 cells express relaxin receptors.  H2-relaxin induces an anti-
inflammatory and antifibrotic gene expression profile in THP-1 cells (Dschietzig 
et al., 2004;Ho et al., 2007).   
 
The Matrigel in vitro model used to compare activated with deactivated stellate 
cells had been previously described by Benyon and colleagues (Gaca et al., 
2003).  In the previous study Matrigel was used as a matrix to grow rat hepatic 
stellate cells that had been grown on plastic to activate directly after isolation 
and then re-plated on either plastic, Matrigel or collagen-1 coated plastic.  
Matrigel is a basement membrane like substance that contains laminin, collagen-
IV, entacin and heparin sulphate proteglycan and can be used as an in vitro 3-
dimensional matrix for cell attachment that is more similar to a normal liver 
basement membrane in vivo (Gaca et al., 2003).  The expression of fibrotic 
markers such as α-SMA, procollagen-1 and TIMP-1 were compared for all three 
types of matrix.  The results from Benyon and colleagues showed that cells 
grown on Matrigel, even though they were fully activated at the time of plating 
were able to revert to a more quiescent phenotype, losing their expression of α-
SMA, procollagen-1 and TIMP-1, reducing their proliferation and also becoming 
fluorescent under UV light, suggesting the cells have regained their vitamin A 
storage capacity (Gaca et al., 2003;Friedman et al., 1993).   In this study the 
same model was used, plating activated human HSC on a growth factor reduced 
Matrigel (GFR Matrigel) matrix or plastic (the collagen-1 matrix was not used in 
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et al., 2003).  Culturing HSC on Matrigel induced a reduction or loss of 
profibrogenic markers including procollagen-1, α-SMA and TIMP-1, whilst 
MMP-1 and MMP-2 expression was increased.  Interestingly this correlated with 
loss of RXFP-1, suggesting the balance was shifted to a less fibrogenic 
phenotype as the activity of the main interstitial collagenase (MMP-1) was up 
regulated and its inhibitor TIMP-1 expression was reduced and this would 
favour fibril collagen degradation (Iredale et al., 1996;Iredale et al., 1998).  
MMP-2 expression and activation was also increased, this could be due to the 
nature of the cells grown on a surface that consists of large amounts of collagen 
IV as MMP-2 is a type IV collagenase but can also degrade collagen V, VII, X, 
fibronectin, laminin and elastin and denatured collagen 1 (Hemmann et al., 
2007).  Certain cell types are dependent upon contact with one another for 
survival (Jung et al., 2005), HSC grown on different matrix have been shown to 
have various phenotypes (Priya and Sudhakaran, 2008) and certain studies have 
shown activated HSC to have invasive/migratory properties (Wang et al., 2005).  
HSC activation and survival is dependent upon autocrine and paracrine factors 
released such as TGF-β, which have a greater effect when in contact with one 
another (Gressner and Bachem, 1990).  Therefore I propose HSC grown on 
matrigel may up regulate MMP-2 to be able to migrate through the gel to be able 
to come into contact with one another.  HSC would have to degrade the collagen 
IV matrix and therefore might increase their expression of MMP-2 to facilitate 
this process.  RXFP-1 expression was increased in activated HSC and was 
localised in areas of scarring.  The cells grown on Matrigel display a less 
fibrogenic phenotype and lose their expression of RXFP-1.  This model taken 
together with the expression of RXFP-1 increasing in parallel with the level of 
activation of HSC provides further evidence that relaxin signalling through 
RXFP-1 could have a vital role in regulating the fibrogenic phenotype and 
activation of HSC.  The question is, does H2-relaxin increase the fibrotic 
phenotype and activation or does it reduce the expression of these parameters?  
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To be able to determine the properties of H2-relaxin in HSC the confirmation of 
active signalling needed to be established.  HSC and LX-2 cells exhibited a dose 
dependent increase in cAMP in the presence of H2-relaxin.  The concentration 
of H2-relaxin required to reach the EC50 (50% maximal response) and maximal 
response (Vmax) was higher in HSC then LX-2 cells.  The relative expression of 
RXFP-1 at the membrane in LX-2 cells may have been higher as LX-2 cells are 
an engineered HSC cell line that exists in the activated state (Xu et al., 2005).  
cAMP assays showed LX-2 cells also expressed active receptors for H3-relaxin 
(RXFP-3) (Liu et al., 2003) and INSL5 (RXFP-4) (Liu et al., 2005b).  RXFP-3 
and RXFP-4 are negatively coupled to cAMP and treatment with H3-relaxin and 
INSL5, their respective ligands, in pre-stimulated LX-2 revealed a dose 
dependent inhibition of cAMP accumulation.  H3-relaxin was also applied to 
non stimulated LX-2 cells to test for cross reactivity at the RXFP-1 receptor. 
There was no reaction until the highest dose when the cAMP signal decreased.  
This would not have been due to cross-reactivity with RXFP-1, as activation of 
this receptor should induce an increase in cAMP (Bathgate et al., 2005).  The 
decrease in cAMP observed may have been due to the activation of the RXFP-3 
receptor and even though the cells were not pre-stimulated with forskolin the 
inhibition of adenylate cyclase was enough to reduce the concentration of cAMP 
below the baseline.  H3-relaxin was more potent then INSL5 in pre-stimulated 
LX-2 cells.  This may be due to less RXFP-4 receptors being expressed in LX-2 
cells or just the normal pharmacodynamics of each receptor in response to their 
respective ligands.  An INSL3 dose curve was performed in LX-2 cells.  There 
was no response to the ligand until the highest dose.  PCR had shown that 
activated HSC expressed a very low level of RXFP-2, which could explain the 
small response at the highest dose was due to the activation of the RXFP-2 
receptor (Sudo et al., 2003).  The concentration of ligand to induce a maximal 
response at the RXFP-1 receptor in both HSC and LX-2 cells has now been 
quantified.  H2-relaxin can now be applied to the cells to determine any 
phenotypic changes in HSC that may indicate relaxin can regulate activated 
HSC.   
 
Chapter 4 
 
 
H2-relaxin reduces the 
expression of pro-
fibrotic markers and the 
cellular contractility of 
human hepatic stellate 
cells  
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4.1 Introduction 
 
4.1.1 Introduction  
 
Human hepatic stellate cells (hHSC) plated on plastic differentiate into a 
myofibroblast like cell.  The process under which the cells change their 
phenotype is called activation and will occur spontaneously if the cells are plated 
on either a plastic or collagen-1 matrix (Friedman et al., 1992).  The process of 
activation has been documented in rat hepatic stellate cells.  These cells were 
found to be the major source of collagen, α-SMA, TIMPs and MMPs in the 
injured liver (Friedman et al., 1985;Rockey et al., 1992;Arthur et al., 1989). This 
process requires the presence of growth factors and cytokines such as PDGF and 
TGF-β, which HSC express and utilize in an autocrine manner (Pinzani et al., 
1989).  The cells up regulate their expression of TIMPs, proinflammatory and 
profibrogenic cytokines and growth factors such as IL-1, TGF-β and begin to 
express α-SMA.  LX-2 cells are a human stellate cell line that express TIMPs, 
MMPs and α-SMA (Xu et al., 2005).  They have already undergone the 
activation process and can be passaged up to 50 times. TIMP-1 expression is 
lower in LX-2 cells than in freshly isolated activated primary hHSC but LX-2 
cells are still considered to be a good model to study possible antifibrotic 
therapies.  LX-2 cells were used to optimise the experiment before using primary 
hHSC in the cell based in vitro assays described in this chapter.  The expression 
of fibrotic markers such as TIMP-1, α-SMA, MMP-1, MMP-2 and TGF-β were 
used to evaluate any phenotypic changes in response to H2-relaxin and PARP-1 
cleavage was used to detect any increase or decrease in apoptosis. Cytokine 
arrays were carried out to detect any regulation of inflammatory or fibrotic 
cytokines by H2-relaxin in HSC. Previous studies in rat HSC have shown relaxin 
to have antifibrotic properties (Bennett et al., 2003). 
 
A gel contraction assay was designed to study the contractile properties of 
hHSC.  The mechanisms of contraction in HSC have been investigated through                                                                             Chapter 4: Functional study of H2-relaxin 
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the use of vasoactive substances such as endothelin-1 and vasopressin (Housset 
et al., 1995;Housset et al., 1993;Bataller et al., 1997).  Endothelin-1 is a potent 
vasoconstrictor when acting through the endothelin A receptor (ETA).   
Endothelin B receptors (ETB) have been found to induce an up-regulation of 
nitric oxide (NO) and therefore relaxation of the cell/tissue in which the 
receptors are found.  It has been documented that endothelin-1 is released in the 
fibrotic liver inducing contraction of the stellate cell and other structures which 
can exacerbate the injury and cause complications such as portal hypertension 
observed in the cirrhotic liver (Zhang et al., 1994;Pinzani et al., 1996).  It is 
possible that RXFP-1 not only activates NO synthesis through its own second 
messenger systems but may also induce an up-regulation in ETB expression, 
favouring relaxation over contraction in HSC.   
 
4.1.2 Hypothesis, Aims and Objectives 
 
Hypothesis 
H2-relaxin promotes an antifibrotic phenotype in cultured LX-2 and primary 
HSC in vitro. 
 
Aims 
To treat LX-2 and primary HSC with H2-relaxin and test the effect on the 
expression of markers of fibrosis, expression of inflammatory cytokines and the 
ability to contract collagen gels. 
 
Objectives 
•  Assess changes in gene expression of markers of fibrosis in hHSC after 
H2-relaxin treatment. 
•  Determine the change in protein expression of markers of fibrosis and 
apoptosis in hHSC after H2-relaxin treatment. 
•  Observe any changes in cytokine profile in hHSC after H2-relaxin 
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•  Identify a change in hHSC contractility after H2-relaxin treatment in gel 
contraction assays. 
 
4.2 Results - Evaluation of the phenotypic changes in LX-2 cells 
and primary HSC induced by treatment with H2-Relaxin 
 
4.2.1 H2-relaxin treatment of LX-2 cells, phenotypic changes observed in 
gene expression 
 
Primary HSC and LX-2 cells are both able to respond to H2-Relaxin by 
increasing the level of cAMP in the cell, as described in chapter 3.  The response 
to H2-relaxin is believed to be through the RXFP-1 receptor.  The downstream 
phenotypic effects of activating RXFP-1 in human HSC were unknown.  A 
simple assay was devised, allowing endpoint measurements using 
immunoblotting and PCR to evaluate the expression of fibrotic markers.  LX-2 
cells were used in the initial assays to determine the effective dose of H2-relaxin 
and the time point at which a significant phenotypic change may be observed. A 
time course study was set up using LX-2 cells to detect gene expression changes 
after 1, 2, 4, 6, 24, 48 and 72 hours H2-relaxin treatment.  No significant 
changes were detected throughout the time course until the 48 and 72 hour time 
point, when the greatest changes in gene expression were detected, which was 
confirmed by observing protein expression changes at 48 and 72 hours (figure 
4.2).  LX-2 cells respond to H2-relaxin after 72 hours continuous exposure, by 
reducing the gene expression of MMP-2, RXFP-1, TIMP-1 and procollagen-1 
(figure 4.1). MMP-2 is decreased by 20% in response to 1 µM H2-relaxin.  
RXFP-1 expression is reduced by 40% in response to 10 nM H2-relaxin but 
expression does not change from control levels of expression after treatment 
with 1 µM H2-relaxin.  Procollagen-1 expression is reduced by 10% by 1 µM 
H2-relaxin but is unchanged in cells treated with 10 nM H2-relaxin.  TIMP-1 
expression decreased by 20% in the 10 nM treated cells but only by 10% in the 1 
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LX-2 cells were significant and the changes observed were not dose dependent.  
Similar results regarding dosing had been observed in a clinical trial using H2-
relaxin to treat scleroderma.  The response rates were more significant in 
patients not receiving the maximum dose, therefore giving bell shaped response 
curves (Seibold et al., 2000).   
 
 
 
 
Figure 4.1. (a) MMP-2, (b) RXFP-1, (c) procollagen-1 and (d) TIMP-1 mRNA 
expression in LX-2 cells that had been treated with 10 nM and 1 µM of H2-Rlx for 72 
hours (n=3), assessed by RT-PCR. 10nM H2-rlx reduces the expression of RXFP-1 
after 72 hours but the trend is not continued with the 1 µM dose.  Results are not 
significant (p>0.1). 
 
 
4.2.2 H2-relaxin treatment of LX-2 cells, phenotypic changes observed in 
protein expression levels 
 
 α-SMA and PARP-1 protein expression in LX-2 cells were semi-quantified 
using immunoblotting.  α-SMA protein expression appeared unchanged after 48 
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hours of 1 µM H2-relaxin treatment (figure 4.2a).  Therefore H2-relaxin requires 
72 hours before gene and protein expression changes can be observed.  Both 
doses will be used to repeat the experiment in HSC but the experiment will be 
carried out over 72 hours rather then 48 hours.  The protein expression of PARP-
1 was determined after 72 hours H2-relaxin treatment (figure 4.2b).  The 
antibody used detected both cleaved and uncleaved PARP-1.  Cleaved PARP-1 
is a marker of apoptosis and therefore the ratio of cleaved to uncleaved PARP-1 
can indicate an increase in apoptosis. Uncleaved PARP-1 protein expression can 
increase in cells that are under stress conditions, this is a mechanism to prevent 
cell death through apoptosis.  LX-2 cells had increased expression of cleaved 
PARP-1 but uncleaved PARP-1 was also increased and therefore the ratio of 
cleaved to uncleaved did not indicate an increase in apoptosis.   
 
 
Figure 4.2. (A) α-SMA protein expression in LX-2 cells that had been treated with 10 
nM and 1 µM H2-Rlx for 48 and 72 hours (n=3), assessed by western blotting. α-SMA 
protein is unchanged after 48 hours but is significantly reduced after 72 hours 1 µM H2-
relaxin treatment (p<0.05).                                                                             Chapter 4: Functional study of H2-relaxin 
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Figure 4.2. (B) PARP-1 and PARP-1 cleavage protein expression in LX-2 cells that had 
been treated with 10 nM and 1 µM H2-Rlx for 72 hours (n=3). PARP-1 expression 
increased in a similar ratio to the cleaved PARP-1 band, which had been significantly 
induced by 1 μM H2-relaxin (p<0.05) and therefore there was no evidence of increased 
apoptosis.  
 
4.2.3 H2-relaxin treatment of HSC, phenotypic changes observed in mRNA 
expression levels 
 
Primary human HSC were used to continue the study as these may be a more 
representative model, RT-PCR and qRT-PCR were used to quantify gene 
expression changes.  The same dosing schedule was repeated in primary HSC as 
the responses did not appear to be dose dependent in LX-2 cells, although RNA 
and protein was extracted only at the 72 hour time point.  Primary HSC 
responded to H2-relaxin with significant changes in MMP-1 and RXFP-1 
expression, quantified by RT-PCR (figure 4.3).  MMP-1 expression was 
significantly increased by over 2 fold after 72 hours H2-relaxin treatment (figure 
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4.3ii) and RXFP-1 expression was significantly decreased by 72 hours 10 nM 
and 1 μM H2-relaxin treatment (figure 4.3v).  Other changes observed such as a 
decrease in TIMP-1 and procollagen-1 and an increase in MMP-2 expression 
were not significant when quantified by RT-PCR.   The increase in MMP-2 
expression was different from the results observed in LX-2 cells, where a small 
decrease in MMP-2 expression was observed.  Li90 cells, another HSC cell line, 
also responded to H2-relaxin showing a dose dependent decrease in TIMP-1 
expression and a dose dependent increase in MMP-2 (appendix 1).  The results 
are an n=1 and are therefore used to reinforce the similar observations in primary 
HSC, which are contradictory regarding MMP-2 in the LX-2 cell line.  A more 
sensitive technique was required to detect any subtle changes after H2-relaxin 
treatment and therefore qRT-PCR was used to confirm the results in primary 
HSC. 
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Figure 4.3. (A) Expression of fibrotic markers (i) MMP-2, (ii) MMP-1, (iii) TIMP-1, 
(iv) procollagen-1 and (v) RXFP-1 after 72 hours H2-relaxin treatment of primary 
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increased by 1 μM H2-relaxin p<0.05.  RXFP-1 expression was significantly reduced by 
both 10 nM and 1 μM H2-relaxin p<0.05. MMP-2, TIMP-1 and procollagen-1 were not 
significantly different although TIMP-1 and procllagen-1 both showed a trend to 
decrease after 1 μM H2-relaxin treatment and MMP-2 expression showed a trend to 
increase. (B) Representative images of RT-PCR products used to semi-quantify the 
expression changes (n=3). 
 
Quantitative PCR was used to confirm the mRNA changes observed in primary 
HSC after 72 hours H2-relaxin treatment.  Several additional genes were 
quantified including α–SMA, TGF-β, and CTGF, which are all markers of HSC 
activation and fibrogenesis.  The initial experiment confirmed the differential 
expression of the fibrotic markers in primary HSC activated by culture on plastic 
(figure 4.4a).  Procollagen-1 had the greatest expression in activated HSC, which 
was over 3 fold greater then TIMP-1 and α-SMA.  TIMP-1 was also nearly 3 
fold greater then α-SMA expression. Procollagen-1, TIMP-1 and α-SMA are all 
profibrotic genes which are up-regulated in activated HSC.  Surprisingly CTGF 
expression, although not significantly, was greater then TGF-β expression which 
are both up-regulated in activated HSC.  MMP-2 expression was greater then 
MMP-1 and TGF-β.  MMP-1 and TGF-β had the lowest levels of expression but 
all of these genes were expressed to a greater extent compared to RXFP-1.  After 
establishing the normal level of gene expression in activated HSC the expression 
levels were measured after 72 hours 1 µM H2-relaxin treatment (figure 4.4c). 
Results are expressed as fold changes compared to untreated activated HSC.  
H2-relaxin induces a significant decrease in gene expression of α-SMA (30%), 
TGF-β (38%), CTGF (28%) and TIMP-1 (28%) in activated HSC.  Procollagen-
1 expression decreased by over 10% but the result was not significant.  The 
greatest change was the reduction in TGF- β expression, which was reduced by 
38%.  MMP-1 expression was significantly increased by 79% compared to 
untreated HSC, whilst MMP-2 expression increased by 35% but this increase 
was not significant due to different responses observed in different primary cell 
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Figure 4.4. (A) Differential expression of fibrotic markers in human HSC, assessed by 
qRT-PCR (n=3), (B) including an example of raw data ct values (n=3). (C) Expression 
of fibrotic markers including TGF-β1 and CTGF after 72 hours 1 μM H2-relaxin 
treatment of primary HSC, assessed by qRT-PCR (n=3).  α-SMA, CTGF, and TIMP-1 
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reduction was TGF-β1 p<0.01, which is a key profibrotic cytokine. MMP-1 was 
significantly increased after 72 hours H2-relaxin treatment (p<0.05) and MMP-2 was 
increased but not in all patients tested. 
 
4.2.4 H2-relaxin treatment of HSC, phenotypic changes observed in protein 
expression 
 
α-SMA and PARP-1 protein expression was assessed in H2-relaxin treated HSC 
compared to untreated controls.   α-SMA protein expression was significantly 
reduced by over 50% after 72 hours in HSC treated with both 10 nM and 1 μM 
H2-relaxin (figure 4.5a).  PARP-1 cleavage was assessed using immunoblotting 
as a measure of apoptosis (figure 4.5b).  The ratio of PARP-1 to PARP-1 
cleaved protein expression was significantly increased by over 30% in HSC 
treated with 1 μM H2-relaxin, suggesting H2-relaxin can induce apoptosis in 
primary HSC.  To confirm these observations a cell viability assay was carried 
out (figure 4.5c).  A significant decrease in cell viability was detected after 72 
hours 1 μM H2-relaxin treatment in primary HSC.  The assay used to detect cell 
viability was a measure of the number of live cells remaining.  The results were 
normalised to untreated controls.  
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Figure 4.5. (A) α-SMA protein expression in primary human HSC treated for 72 hours 
with H2-relaxin, assessed by western blotting (n=3).  Both 10 nM and 1 μM 
significantly reduced the expression of α-SMA by over 50% (p<0.01 confidence).                                                                              Chapter 4: Functional study of H2-relaxin 
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(B) PARP-1 and cleaved PARP-1 protein expression in primary human HSC treated for 
72 hours with H2-relaxin, assessed by western blotting (n=3). The ratio of cleaved 
PARP-1 to PARP-1 expression was significantly increased by over 30% by 1 μM H2-
relaxin (p<0.05).  The increase in cleaved PARP-1 suggests that H2-relaxin increases 
the apoptosis of primary HSC.  (C) Cell viability of primary human HSC after treatment 
with 1 μM H2-relaxin for 72 hours was assessed by MTS cell viability assay (n=3).  
There was a 20% decrease in the number of viable cells after H2-relaxin treatment 
(p<0.1 confidence).   
 
4.3 Cytokine array profile of hHSC comparing H2-Relaxin 
treated with untreated control cells using cytokine antibody 
spotted membranes 
 
4.3.1 Overview of all cytokines spotted on the membranes 
 
Cytokine array membranes were used to evaluate the change in secreted 
cytokine level in H2-relaxin treated primary HSC (figure 4.6a).  A single 
concentration of 100nM H2-relaxin was used to treat the cells and the 
conditioned media from 6 different primary cell cultures was used to run the 
cytokine array experiments.  Two different membranes were used with many 
cytokines that are known to be secreted by HSC and several that have not been 
previously quantified in human HSC.  The results are presented as fold changes 
compared to untreated controls, and each of the cytokines on individual 
membrane arrays were plotted on a single graph (figure 4.6b).  The results are 
not significant due to variation between the primary cell cultures responses to 
H2-relaxin and the variability in cytokine levels in untreated controls.  Therefore 
the results suggest a trend for H2-relaxin to down regulate many profibrotic 
cytokines such as TGF-β1, TIMP-1,2 and 4, PDGF, and FGF in primary HSC.  
There was also a trend for H2-relaxin to down regulate several pro-inflammatory 
cytokines such as IL-1 α, IL-2, IL-4, IL-6 and IL-13.  H2-relaxin up regulated                                                                             Chapter 4: Functional study of H2-relaxin 
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several cytokines including Fas ligand, NT-4, VE-cadherin, and MMP-9 (figure 
4.6b).   
 
 
Figure 4.6. (A) Example of cytokine array membranes, including examples of spots 
that are down regulated in H2-relaxin treated HSC 
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Figure 4.6. (B) Fold changes in cytokine secretion after 72 hours 100nM H2-relaxin 
treatment, compared to untreated HSC, (n=6).  Cytokine array analysis of conditioned 
media reveals H2-relaxin could potentially regulate many different cytokines in primary 
HSC.  The results obtained are not significant due to large inter-patient variability, but 
show a trend in the H2-relaxin treated cells to a less fibrogenic/inflammatory but pro-
apoptotic phenotype.   
 
4.3.2 Cytokines down regulated by H2-relaxin treatment 
 
 The membrane arrays contained several closely related cytokines.  Fold changes 
in cytokines that were down regulated by more then 30%, or are a close member 
of the family of a down regulated cytokine, have been plotted on individual 
graphs (figure 4.7.a).  TGF-β1 was down regulated by over 80% in H2-relaxin 
treated HSC, although the change was not significant due to the large variation 
in the level of TGF-β1 between different primary cell cultures (figure 4.7.a i).  
TGF-β2, TGF-α, Tie-1 and Tie-2 were also down regulated by H2-relaxin, the 
greatest change observed was Tie-2, with a 30% decrease (figure 4.7.a ii).  SDF-                                                                            Chapter 4: Functional study of H2-relaxin 
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1 was down regulated by over 70% in H2-relaxin treated cells (figure 4.7.a iii) 
and SDF-1 beta was down regulated by over 30% (figure 4.7.a iv).  FGF-4, 
FGF-6, FGF-9 and Flt-3 ligand are all down regulated by H2-relaxin, the 
greatest change was in Flt-3 ligand which was down regulated by over 50%.  
There was a small increase in FGF-7 in H2-relaxin treated HSC (figure 4.7.a v).  
TIMP-1, TIMP-2 and TIMP-4 were all down regulated by over 15% in H2-
relaxin treated HSC (figure 4.7.a vi).  The decrease in TIMP-1 secretion is 
similar to the decrease in mRNA expression observed in figure 4.4.b.  PDGF 
AA, PDGF AB, PDGF R alpha, and PDGF R beta were all down regulated by 
H2-relaxin, the greatest change was PDGF R alpha which was down regulated 
by over 40% (figure 4.7.a vii).  Overall the greatest change in cytokine secretion 
was the decrease in TGF-β1, therefore the level of TGF-β1 was quantified by 
ELISA assay.  The same media samples were used to detect the changes in total 
and active TGF-β1 secreted from H2-relaxin treated HSC.  The total TGF-β1 
was reduced by over 10% whilst the active TGF-β1 was reduced by nearly 20% 
in H2-relaxin treated HSC (figure 4.7.b).   The results had to be normalised to 
control values as the starting concentration of TGF-β1 in each sample was 
extremely varied (standard deviation was not shown), results are not significant.  
The decrease of TGF-β1 quantified by ELISA assay was not as great as the 
decrease observed in the cytokine array assay.  This may have been due to freeze 
thawing of the media samples as TGF-β1 is susceptible to degradation, the 
results shown are from three experiments as not all of the conditioned media 
samples had detectable levels of TGF-β1. 
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Figure 4.7. (A) Fold changes in cytokines that were down regulated, over 50% or were 
interesting fibrosis related cytokines, by 100 nM H2-relaxin after 72 hours (n=6).  The 
interesting families of secreted proteins include (i) TGF-β, (ii) TGF-α, Tie-1, Tie-2, (iii) 
SDF-1, (iv) SDF-1 beta, (v) FGF family and Flt-3 ligand, (vi) TIMP-1,2 and 4, and (vii) 
PDGF family.  
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Figure 4.7. (B) The regulation of (i) total and (ii) active TGF-β1 by H2-relaxin was 
further investigated by ELISA analysis (n=3), using the same media samples as the 
cytokine array.  H2-relaxin down regulated active TGF-β1 by 20%. Results were 
normalized to the control samples, error bars were added to the controls and due to the 
varied concentration of TGF-β1 in the conditioned media between different patients the 
error bars are large, which is similar to the result in the cytokine arrays. 
 
4.3.3 Cytokines up-regulated by H2-relaxin treatment 
 
The secretion of several cytokines was up regulated by 100 nM H2-relaxin in 
primary HSC (figure 4.8.), NT-4 (i), VE-Cadherin (ii) and Fas-ligand (iii) were 
all up regulated by over 30%.  MMP-9 was also up regulated by over 30%, 
whilst MMP-3 and MMP-13 were unchanged (figure 4.8. iv). Changes observed 
were not significant. 
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Figure 4.8. (i) NT4, (ii) VE cadherin and (iii) Fas ligand were all up regulated by more 
then 30% (n=6). Secretion of MMP-9 was also up regulated in the H2-relaxin treated 
cells, although MMP-3 and MMP-13 were not. 
  
4.4 Investigation into the contractile properties of HSC in the 
presence of H2-Relaxin  
 
4.4.1 Endothelin-1 receptor expression in H2-relaxin treated HSC 
 
Endothelin-1 is a potent vasoconstrictor when acting through the endothelin A 
receptor (ETA) whereas endothelin B receptors (ETB) have been found to induce 
an up regulation in nitric oxide and therefore relaxation of the cell or tissue in 
which the receptors are found.  Previous studies in other cell types have reported 
H2-relaxin to increase ETB expression but this was not observed in these cells 
(Dschietzig et al., 2003).  Endothelin-1 has been shown previously to cause 
contraction of HSC (Rockey and Weisiger, 1996).  ETB has been found to 
increase the level of nitric oxide, therefore decreasing the contraction of the 
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activated HSC in order to see whether any contractility changes could be 
explained by changes in endothelin receptor expression in response to H2-
relaxin.  It was observed that ETA expression was greater then ETB expression in 
activated primary HSC, assessed by RT-PCR (figure 4.9.a).  After 72 hours 1 
μM H2-relaxin treatment the expression of ETA was reduced whereas ETB 
expression remained unchanged (figure 4.9.b).  ETB receptors have previously 
been shown to be up regulated by H2-relaxin, although this was not detected 
after 72 hours, although ETA expression is down regulated.   
 
 
 
Figure 4.9. (A) Endothelin receptor A and B expression in human heart, lung and 
activated HSC, assessed by RT-PCR and normalised to GAPDH.  ETB expression is 
50% lower in activated primary HSC compared to ETA expression (n=1).  (B) ETA and 
ETB expression in HSC treated with 1 μM H2-relaxin for 72 hours, assessed by RT-
PCR.  ETA is down regulated whilst ETB remains unchanged (n=2).   
 
4.4.2 H2-relaxin regulation of HSC contraction using gel contraction assays 
 
Activated primary HSC have contractile properties in vivo and in vitro culture 
conditions.    Activated HSC plated on a collagen-1 matrix will induce 
contraction of the matrix which allows us to measure the extent of cellular 
contraction (figure 4.10. a).  Gel contraction assays were carried out as described 
in chapter 2.  It was observed that LX-2 cells did not induce gel contraction to 
the same extent as activated primary HSC.  Activated HSC will contract with no 
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serum and serum alone was used as the control which all fold changes in gel area 
were normalised to.  Contraction of the gel was monitored by measuring the area 
of the gel at 24 and 72 hours.  Endothelin-1 and serum have a synergistic 
contractile effect, causing HSC to contract by over 10% more then in the 
presence of serum or H2-relaxin.  The increased contraction observed after 
endothelin-1 treatment was not significant but was greatest at 24 hours rather 
then the 72 hour time point (figure 4.10.b i).  HSC in the presence of H2-relaxin 
exhibited the least contraction, gel area was significantly increased by over 40% 
after 72 hours compared to serum alone.  Gel area was increased after 24 hours 
H2-relaxin treatment although at this time point the increase was not significant 
(figure 4.10.b i).  Interestingly HSC treated with H2-relaxin and then after 2 
hours treated with endothelin-1 (at the time of gel release), still exhibited similar 
contractile properties after 72 hours compared to HSC treated with just 
endothelin-1, but if HSC were treated with endothelin-1 for two hours before 
treatment with H2-relaxin (at the time of gel release) then HSC exhibited less 
contractile properties, similar to when treated with H2-relaxin alone (figure 
4.10.b ii).      
 
Figure 4.10. (A) Representative example of a gel contraction assay, 24 hours and 72 
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Figure 4.10. (B) (i) Gel area was calculated using ImageJ software.  H2-relaxin 
decreased the contraction significantly after 72 hours compared to untreated (serum), 
and endothelin-1 treated cells (p<0.05) (n=4).  Endothelin-1 caused a small increase in 
contraction compared to the untreated cells but this was not significant.  (ii) Pre-
treatment with relaxin before treating with endothelin-1 did not inhibit the contraction 
compared to endothelin-1 treated cells alone.  Pre-treatment with endothelin-1 before 
treating with H2-relaxin did not inhibit the relaxation compared to H2-relaxin treated 
cells alone (n=1). 
 
ii 
i 
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4.4.3 Secreted nitric oxide quantification in gel contraction assays 
 
Nitric oxide release from HSC during the gel contraction assays was quantified 
as described in chapter 2.  The fold change in nitrite (the stable metabolite of 
nitric oxide) after 72 hours H2-relaxin treatment was normalised to HSC in the 
presence of 10% FCS (figure 4.11).  H2-relaxin increases nitric oxide release 
from HSC by over 20%.  The changes observed were not significant but the 
mechanism of cellular relaxation in the presence of H2-relaxin may be explained 
by a combination of factors including the reduction of α–SMA, reduction in ETA 
expression, the increase in nitric oxide and the regulation of intracellular 
calcium. 
 
 
Figure 4.11. The level of nitric oxide secreted into the media over the 72 hour gel 
contraction experiment was determined. H2-relaxin treated cells increased the level of 
nitric oxide by 20% compared to untreated cells (n=3). 
 
4.5 Summary of key findings 
 
•  H2-Relaxin induced a down regulation of the pro-fibrotic factors such as 
α-SMA, procollagen-1, TIMP-1, CTGF and TGF-β in human HSC. 
•  HSC up regulated MMP-1 and MMP-2 in the presence of H2-Relaxin.                                                                             Chapter 4: Functional study of H2-relaxin 
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•  H2-Relaxin increased PARP-1 cleavage in HSC suggesting an up 
regulation of apoptosis which was supported by a down regulation in the 
number of viable cells in culture. 
•  H2-Relaxin inhibited the contraction of HSC 
 
4.6 Discussion 
 
4.6.1 H2-relaxin and specific markers of fibrosis 
 
LX-2 cells were used to initially study the effect of H2-relaxin due to their 
availability and reported similarity to primary human stellate cells (HSC).  
Before the cells were used each batch was tested for expression of α-SMA and 
TIMP-1 the two main fibrotic markers expressed by activated HSC in vitro.  LX-
2 cells have a lower expression of TIMP-1 compared to primary HSC but the 
level is still easily detectable with RT-PCR methods.  LX-2 cells were used in 
experiments between p8 and p25, after which the cells were discarded and a new 
batch grown up.  To look at gene expression changes a time course experiment 
was set up.  The mRNA was extracted from LX-2 cells treated with 1 µM H2-
relaxin after 1 hour, 2 hours, 4 hours and 6 hours.  The gene expression profile 
for TIMP-1, MMP-2 and pro-collagen-1 and RXFP-1 were assessed using RT-
PCR.  LX-2 cells revealed only small changes in mRNA expression for these 
genes over the 6 hour period and even after 48 or 72 hours of exposure to H2-
relaxin the cells did not significantly alter their gene expression pattern. The 
results for the time course are not shown as the greatest gene expression changes 
were after 72 hours.  The detection method was either not sensitive enough to 
pick up small changes in gene expression or it was possible that LX-2 cells did 
not significantly alter their gene expression patterns in response to H2-relaxin.  
This may be due to LX-2 cells being a permanently activated cell line, which 
after plating on Matrigel could not respond by reverting to an inactive 
phenotype, unlike primary HSC (Gaca et al., 2003) and therefore could resist 
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more resistant to apoptosis then primary HSC, due to their differential 
expression of p21 and p53 related genes (Xu et al., 2005).  LX-2 cells were 
initially treated for 48 and 72 hours with H2-relaxin, replenishing the ligand 
every 24 hours to look at protein expression changes.  After 48 hours of H2-
relaxin treatment LX-2 cells revealed a small decrease in α-SMA protein 
expression but after 72 hours of H2-relaxin treatment the decrease in α-SMA 
protein expression was significant.  The amount of PARP-1 cleavage protein 
present in LX-2 cells after 72 hours of H2-relaxin treatment was compared to 
non treated controls.  The PARP-1 cleavage product increased in the H2-relaxin 
treated LX-2 cells but the ratio between cleavage product and total protein did 
not increase significantly due to total PARP-1 protein expression increasing. 
Although the increase in uncleaved PARP-1 can be an indication the cells were 
trying to prevent apoptosis at this time point.    An increase in total PARP-1 
protein expression can be a sign of cellular stress.  The cells would be expected 
to increase the expression of PARP-1 to maintain genomic integrity due to the 
role of PARP-1 in genome repair, DNA replication and regulation of 
transcription (Aikin et al., 2004).  Over expression of PARP-1 can deplete the 
cell of vital energy stores which can cause energy failure and cell death through 
necrosis.  When PARP-1 is cleaved by caspase 3 the activity is lost, which 
prevents the survival of damaged DNA and releases energy which the cell can 
then use to undergo apoptosis (Aikin et al., 2004). Therefore LX-2 cells treated 
with H2-relaxin may have increased the expression of PARP-1 because the cells 
were under stress and although cleaved PARP-1 protein expression increased as 
well, H2-relaxin alone did not increase the level of apoptosis but could induce 
cell death through necrosis of LX-2 cells. If the assay had been continued there 
may have been an increase in apoptosis at later time points.  It was thought that 
primary HSC would be more dynamic in their response to H2-relaxin revealing 
greater gene and protein expression changes compared to the LX-2 cell line.     
 
The gene and protein expression profile of primary HSC was studied after 72 
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and 1 μM H2-relaxin, and the RNA and protein was extracted 4-6 hours after the 
final treatment to ensure the ligand was still active.  The gene expression profile 
was studied using RT-PCR and qRT-PCR due to the small changes observed in 
LX-2 cells, a more sensitive method was used to confirm the results.  
Procollagen-1 and TIMP-1 had the highest expression, α-SMA was detectable in 
the same range but TGF-β1 and MMP-1 were expressed the least, although they 
were still present in activated HSC. TGF-β has been studied in great detail in 
several fibrotic diseases and it is believed that the expression of TGF-β promotes 
fibrogenesis by enhancing the activation and proliferation of quiescent HSC.  
The expression of TGF-β promotes the sustained and possibly autocrine 
activation of HSC (Dooley et al., 2000;Dooley et al., 2003;Gressner and 
Weiskirchen, 2006).  Primary HSC treated with H2-relaxin significantly 
decreased their expression of α-SMA, TIMP-1, TGF-β, and CTGF after 72 
hours.  MMP-1 expression was significantly increased by 2 and 1.75 fold in both 
RT-PCR and qRT-PCR assays respectively.  Gene expression changes were 
detected for procollagen-1 (over 10% decrease) and MMP-2 (over 20% increase) 
but these changes were not significant in either RT-PCR assay.  Both PCR 
assays show good correlation but quantitative PCR was able to detect more 
significant changes in gene expression.  The changes in gene expression 
observed after 72 hours H2-relaxin treatment suggest a shift to a less fibrotic and 
increased fibrolytic phenotype in primary HSC.  
 
Primary HSC responded to H2-relaxin by significantly reducing α-SMA protein 
expression by over 50% in both 10 nM and 1 μM treatments and by significantly 
increasing the cleaved PARP-1 protein expression by 25% in the 1 µM 
treatment.  The increase in PARP-1 cleavage is indicative of increased apoptosis 
but an additional technique had to be used to confirm the result.  MTS 
proliferation assays were used to detect the cell viability after H2-relaxin 
treatment.  MTS assays utilise the cells mitochondrial machinery to induce a 
colour change and therefore the greater the colour change the greater number of 
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relaxin treated HSC, which was consistent with the PARP-1 cleavage assay.  
Therefore the data would indicate H2-relaxin induced a 20-25% increase in 
apoptosis in primary HSC after 72 hours.  Li90 cells, a human tumourgenic 
source of hepatic stellate cells, were treated with a dose response 0.1 nM – 1 µM 
of H2-relaxin for 72 hours.  There was a dose dependent reduction in TIMP-1 
and a dose dependent increase in MMP-2 expression assessed by RT-PCR.  The 
data supports the findings in primary HSC (appendix 1).  These results add to the 
evidence that H2-relaxin has antifibrotic properties in primary HSC by causing a 
decrease in activation and number of HSC and also a decrease in TIMP-1, TGF-
β and CTGF, which are all profibrotic factors.  The increase in MMP-1 
expression coupled with the decrease in TIMP-1 expression will enable the 
breakdown of scar forming collagen-1 in the liver.  The primary HSC response 
is more significant and dynamic compared to LX-2 cells in this study.  Although 
LX-2 cells are a good tool for developing new assays, primary HSC are the gold 
standard, especially concerning responses to potential antifibrotic agents that 
will be safe and effective for use in humans.  
 
4.6.2  Effect of H2-relaxin on expression of cytokines and associated 
inflammatory and fibrotic markers 
  
Cytokine arrays were carried out to show any protein changes that occur in 
primary HSC after 72 hours of H2-relaxin treatment.  Many of the proteins on 
the arrays were present in the mRNA analysis, which allowed the comparison 
between mRNA and protein expression.  Many cytokines were regulated by H2-
relaxin although the changes were not significant due to cell variation extracted 
from different patients, but the overall trend showed a reduction pro-
inflammatory and pro-fibrogenic cytokines.  The cytokines up or down regulated 
over 30% or interesting related cytokines were looked at in closer detail.  
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H2-relaxin down regulated cytokines 
H2-relaxin was shown to inhibit the protein expression and/or secretion of 
several cytokines expressed by activated HSC.  Several pro-inflammatory and 
pro-fibrotic factors were reduced including stromal derived factor 1 (SDF-1), 
members of the PDGF family, members of the FGF family, several members of 
the TIMP family, TGF-β, and TNF-α.  Transforming growth factor beta (TGF-β) 
is a one member of the transforming growth factor superfamily that consists of 
inhibins, activins, bone morphogenic proteins and other TGF proteins such as 
TGF-α.  TGF-β protein has three isoforms, TGF-β1, TGF- β2 and TGF-β3.  
These proteins are present in most cell types and have several functions 
including controlling cellular proliferation and differentiation.  TGF-β1 can act 
synergistically with TGF-α to induce cellular transformation.  TGF-β1 is 
translated as a large precursor protein which has an N-terminal signal peptide 
that is required for secretion from the cell.  This form of TGF-β1 is known as the 
latent form which requires removal of the latency-associated protein and latent 
TGF-β1 binding protein to release an active TGF-β1 protein.  The protein then 
undergoes acidification which disrupts the non covalent interactions or 
proteolytic cleavage, typically by plasmin, to become an active protein (Sato et 
al., 1990).  The mature TGF-β1 protein forms a 25 kDa homer dimer that can 
bind type II receptors.  Binding to the type II receptor initiates the recruitment 
and phosphorylation of the type I receptor.  A signal cascade then follows which 
requires the phosphorylation of small mothers against decapentaplegics 
(SMADs) which can then form a complex that translocates to the nucleus.  Once 
in the nucleus the complexed SMAD proteins can act as transcription factors 
altering the gene expression of the target cell.  There have been several SMADs 
identified, some of which are pathway specific and some that may inhibit the 
pathway specific SMADs (Heldin et al., 1997;Massaous and Hata, 1997).  TGF 
proteins and particularly TGF-β1 has been found to have a critical role in liver 
fibrogenesis.  Liver damage of any eitiology rapidly induces TGF-β1 signal 
transduction.  TGF-β1 down stream signalling pathways lead to the migration of 
neutrophils, macrophages and fibroblasts to the site of injury.  These cells in turn                                                                             Chapter 4: Functional study of H2-relaxin 
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can release more proinflammaotry and profibrogenic cytokines.  TGF-β1 is 
required for the activation and transdifferentiation of hepatic stellate cells, which 
has implicated TGF-β1 as a major player in liver fibrogenesis (Gressner et al., 
1996;Gressner et al., 2002;Gressner and Weiskirchen, 2006).   The greatest 
irrefutable evidence to support TGF-β1 as a profibrogenic factor comes from the 
transgenic mouse model which over expresses active TGF-β1 and will develop 
spontaneous liver fibrosis (Sanderson et al., 1995).  Hepatocytes respond to 
TGF-β1 by undergoing apoptosis, although more recently it has been discovered 
that hepatocytes can also differentiate into a fibroblast like phenotype in the 
presence of TGF-β1.  This process is known as epithelial mesenchymal 
transistion (EMT).  This process is relevant when considering the formation of 
cancer cells but will also contribute to the progression of fibrosis.  Microarray 
analysis revealed up regulation of genes expressed in hepatocytes that had been 
stimulated with TGF-β that were involved in EMT and fibrosis such as Snail and 
CTGF respectively (Meindl-Beinker and Dooley, 2008;Dooley et al., 
2000;Sheahan et al., 2008).  H2-relaxin down regulated TGF-β1 and TGF-β2 in 
activated HSC in this study.  A previous study has shown relaxin can inhibit 
TGF-β1 signalling by blocking SMAD 2 phosphorylation and its subsequent 
translocation to the nucleus.  TGF- β binding to the receptor was not affected by 
relaxin.  Inhibition of TGF-β1 signalling together with an up regulation of 
MMP-2 and MMP-9 expression was suggestive of a less fibrotic phenotype in 
renal fibroblasts and prevented TGF-β mediated fibroblast activation and 
function in cardiac fibroblasts (Heeg et al., 2005;Mookerjee et al., 2005b).  H2-
relaxin has been reported to increase the levels of nitric oxide, which may also 
reduce the level of TGF-β1 in the cell.  Therefore H2-relaxin may inhibit the 
activation of HSC and prevent apoptosis and EMT occurring in hepatocytes, 
which may also be a major source of activated myofibroblasts in the injured liver 
(Dooley et al., 2008).  There are hazards related to the inhibition of TGF-β1 
including increased malignancy, atherosclerosis and the deregulation of the 
immune system, although due to the importance of TGF-β1 in initiating the 
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ideal target for future therapies (Khan et al., 2005).  TNF-α is a pro-
inflammatory cytokine that is a key factor in liver diseases such as cachexia and 
cholestasis.  TNF-α induction is one of the earliest events in hepatic 
inflammation and can trigger a cascade of different cytokines that can kill 
hepatocytes, recruit inflammatory cells and initiate a would healing response 
(Tilg, 2001;Diehl, 2000).  Activation of TNF-α receptors leads to aggregation 
and recruitment of various adaptor proteins that activate downstream kinases and 
proteases.  Adaptation in the healthy liver allows hepatocytes to protect 
themselves against TNF-α and even use it to proliferate in the regenerating liver, 
but in the pre-injured liver this adaptation cannot occur.  Anti-TNF agents such 
as infliximab have been shown to reduce injury in CCl4 models.  Anti-TNF 
therapy reduces TGF-β1 levels in the liver and could be beneficial as a 
therapeutic antifibrotic (Bahcecioglu et al., 2008).  H2-relaxin down regulated 
TGF-β1 by 80% which was the greatest change observed in the cytokine array.  
The down regulation observed in the cytokine array was quantified using an 
ELISA assay to measure total and active TGF-β1.  The levels of total TGF-β1 
were not decreased as much as the active TGF-β1.  The difference in total and 
active was not significant although it does suggest H2-relaxin could have 
multiple, perhaps indirect effects, not just on gene expression but on the 
processing of growth factors and cytokines, which may be equally important as 
the total level of expression of many proteins that require proteolytic cleavage 
before secretion and/or activation/maturation is enabled.  Others have shown that 
reduction in active TGF-β1 can prevent rat hepatic fibrosis (Okuno et al., 2001).  
 
SDF-1α and SDF-1β are small cytokines that belong to the intercrine family 
(Bleul et al., 1996).  SDF-1 is also known as chemokine ligand 12 (CXCL-12).  
SDF-1α and SDF-1β are encoded by a single gene found on chromosome 10, 
and arise through alternative splicing.  The intercrine family was first described 
in 1991 to distinguish a family chemokines through their chromosomal location 
and unique structural features (Oppenheim et al., 1991).  The chemokines have 
20-50% sequence homology and are mainly located on chromosome 4 and 17.                                                                              Chapter 4: Functional study of H2-relaxin 
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They are basic, heparin binding polypeptides.  Many chemokines in the family 
can be induced by proinflammatory stimuli such as lipopolysacharide (LPS), 
TNF and IL-1.  The chemokines in the intercrine family have proinflammatory 
or reparative activities (Oppenheim et al., 1991).  Members of the intercrine 
family include IL-8, IP-10, GRO, I-309 and RANTES.  SDF-1 activates 
leukocytes and is strongly chemotactic for lymphocytes, acting in the emigration 
pathway of lymphocytes from the blood to sites of inflammation (Bleul et al., 
1996).    SDF-1 induces T-cell migration and actin polymerisation in leukocytes.  
Actin polymerisation is thought to be essential for migration of neutrophils, 
known to depend on the formation and redistribution of filamentous actin.  The 
rearrangement of the actin cytoskeleton regulates intergrin mediated adhesion, as 
well as the migration and mechanical properties of activated neutrophils (Horuk 
and Peiper, 1996;Sheikh et al., 1997).  Many leukocytes express high levels of 
CXCR4, the receptor for SDF-1.  SDF-1 knockout is lethal and thought to be 
due to its second function, which establishes hematopoieses in bone marrow 
during development.  It is thought there is a major role for SDF-1 in murine stem 
cells homing from fetal liver into the bone marrow and its repopulation during 
development (Lapidot, 2001).  Therefore if relaxin down regulates SDF-1α and 
SDF-1β, there will be a decrease in activation and migration of leukocytes from 
the blood stream into the tissue.  The liver’s resident leukocyte, the kupffer cell, 
is believed to be at least partly responsible for the initial activation of HSC.  If 
H2-relaxin can down regulate the level of SDF-1 it may reduce the activation 
and migration of kupffer cells in the liver and therefore reduce the initial and 
sustained activation of HSC. 
 
There are several forms of PDGF that make up the family of growth factors 
secreted from several different cells types to regulate cell growth and division, 
also having important functions in angiogenesis.  The PDGF ligand is a dimeric 
glycoprotein composed of two α or two β chains.  There are five different 
isoforms, including A, B, C, D, AB and two receptors PDGFRα and PDGFRβ.  
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by their respective ligands the receptors dimerise and are switched on by auto-
phosphorylation of several sites on the cytosolic domain (Matsui et al., 
1989b;Matsui et al., 1989a;Heidaran et al., 1991;Yu et al., 1995).  PDGF is a 
profibrogenic growth factor, liver fibrosis has been induced in transgenic mice 
which overexpress PDGF-B.  It was shown that PDGF-B did not up regulate 
TGF-β but did cause the activation of hepatic stellate cells marked by the 
increase in expression of α-SMA and PDGFR-β.  Collagen-1 deposition, shown 
through histological staining of liver sections, was increased in the transgenic 
mice (Czochra et al., 2006).   Other studies have found all forms of PDGF to be 
up regulated in models of liver fibrosis, and PDGFR-B is accepted as a marker 
of hepatic stellate cell activation.  PDGF-BB induces the migration of HSC, 
which is rapidly up regulated in the first two days of primary cell culture and is 
then constantly expressed.  PDGF-B expression was actually found to be rapidly 
down regulated in primary HSC undergoing activation but the other more 
recently discovered forms PDGF-C and D were strongly induced, 5 and 8 fold 
respectively.  It was postulated that PDGF-C and D may compensate for the loss 
of PDGF in hepatic fibrosis.  There were small changes in PDGF-A, but the 
changes observed were not significant in comparison to the other isoforms 
(Breitkopf et al., 2005).  H2-relaxin was shown to down regulate PDGF-AA and 
PDGF-AB, as well as both forms of the receptor.  Therefore relaxin may have an 
antifibrotic effect in human primary HSC due to the decrease in PDGF released 
from HSC, which may act in an autocrine manner.  The other forms of PDGF 
were not present on the membrane, but it would be interesting to investigate the 
effect H2-relaxin has on all of the members of the PDGF growth factor family. 
 
Fibroblast growth factors (FGFs) are a family of growth factors involved in 
angiogenesis, wound healing and embryonic development. FGFs are heparin 
binding proteins that are key players in proliferation and differentiation of cells.  
There are 23 members of the family in humans. FGF was first isolated and 
purified from bovine pituitaries by Gospodarowicz in 1974.  The growth factor 
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fibroblasts in vitro.  Growth of human fibroblasts was increased two fold in the 
presence of FGF, compared to cells cultured in fetal calf serum alone.  FGF was 
shown to increase DNA synthesis in 3T3 cells (Gospodarowicz et al., 
1977;Gospodarowicz and Moran, 1975).  More recently the effect of FGF on 
embryonic development has been studied.  FGF-7 has been shown to stimulate 
the growth of oocytes in vitro (Cho et al., 2008), FGF-7 can also induce the 
differentiation of hepatoblasts into biliary epipthelial cells (BEC’s) (Yanai et al., 
2008). H2-relaxin reduces the expression of FGF-4, FGF-6 and FGF-9.  FGF-7 
expression is slightly increased in the presence of H2-relaxin.  The implication 
of a reduction in FGF’s after H2-relaxin treatment is a reduction in a fibroblast-
like cells ability to proliferate and differentiate.  Therefore the ability for 
quiescent HSC to differentiate into activated myofibroblasts and then proliferate 
after activation would be reduced in the presence of H2-relaxin.   
 
FLT-3 is a receptor tyrosine kinase that is expressed by immature hematopoietic 
progenitor cells and is structurally related to the receptors for PDGF and colony 
stimulating factor (CSF).  FLT-3 ligand is membrane bound or can be 
proteolytically cleaved to generate a biologically active soluble ligand that is 
expressed by a variety of cells including hematopoietic and bone marrow 
stromal cells.  The activation of the FLT-3 receptor leads to tyrosine 
phosphorylation of various key adaptor proteins that are known to be involved in 
various signal transduction pathways.    FLT-3 ligand is thought to be important 
in controlling proliferation, differentiation and survival of progenitor cells but 
cannot stimulate proliferation alone (Drexler and Quentmeier, 2004).  FLT-3 
ligand synergises with CSFs and interleukins to induce growth and 
differentiation of progenitor cells that develop various cell types including 
natural killer (NK), pre-B, pre-T, monocytes and macrophages.  FLT-3 ligand is 
important in the development of lymphocytes and is therefore effective in 
promoting immunity against intracellular viral and non viral pathogens.  The 
immune response is increased in the presence of FLT-3 ligand and there is 
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express FLT-3 ligand (Juan et al., 1997). Relaxin reduces the expression of FLT-
3 ligand, which would reduce the inflammatory infiltrate in the injured liver.  A 
reduction in the infiltration of activated B and T-cells as well as macrophages in 
the liver would reduce the activation of HSC.  The immune response is vital in 
patients with Hepatitis C and an effective clearance of viral particles from the 
liver can rescue the patient from chronic damage that can lead to permanent 
fibrotic scarring and cirrhosis but in patients where damage to the liver is caused 
by other factors including alcohol and obesity the reduction of inflammatory 
mediators may reduce the fibrotic response.   
 
Tissue inhibitors of matrix metalloproteinases (TIMPs) are the cells natural 
regulators of MMP activity.  There are four known TIMPs and all known MMPs 
are inhibited by at least one of the four.  The mechanism of TIMP inhibition has 
been elucidated through studying the crystal structures of TIMP-MMP 
complexes (Gomis-Ruth et al., 1997).  TIMP-1 is believed to play a pivotal role 
in fibrosis and in particular liver fibrosis.  TIMP-1 inhibits the activity of MMP-
1, the main interstitial collagenase, therefore protecting newly formed scar 
forming collagen from MMP degradation.  TIMP-1 and TIMP-2 are expressed 
by activated HSC.  The expression of TIMP-1 correlates to the severity of liver 
disease in animal models.  TIMP-1 has also been shown to protect liver cells but 
particularly activated HSC from apoptosis (Iredale et al., 1998;Murphy et al., 
2002) and therefore the reduction of TIMPs by H2-relaxin would increase the 
degradation of scar forming collagen-1 by preventing the inhibition of MMPs 
and increase the apoptosis of HSC.   
 
Tie-1 and Tie-2 are cell surface tyrosine kinase receptors.  They possess unique 
multiple extra-cellular domains and can bind angiopoietins (Ang) which are 
protein growth factors that promote angiogenesis.  Tyrosine kinase receptors 
posses a hormone binding domain, a carboxyl terminal segment and multiple 
tyrosines for autophosphorylation.  Binding of Ang-1 to Tie-2 is believed to 
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in gene transcription. Tie-2 and Ang-1 knockout models have similar phenotypes 
(Maisonpierre et al., 1997).  Ang-2 is thought to inhibit Tie-2.   Until recently 
Tie-1 was an orphan receptor mainly found on endothelial cells.  The ability to 
purify Tie-1 and Tie-2 together lead researchers to believe the receptors formed 
a heterodimer.  The role for Tie-1 has finally been elucidated and it is believed 
that Tie-1 can modulate Tie-2 driven signalling, modulating blood vessel 
morphogenesis but they do not form a dimer.  Ang-1 induces Tie-1 
phosphorylation in endothelial cells but this is Tie-2 dependent.  Tie-2 can 
induce cell survival as well as angiogenesis.  These receptors have been 
implicated in the survival of cancer cells (Yuan et al., 2007).  H2-relaxin down 
regulates the expression of Tie-1 and Tie-2, Tie-2 is down regulated to a greater 
extent then Tie-1.  Down regulation of Tie-2 could reduce the survival of the 
cells that express the receptor, therefore in this case increasing HSC 
susceptibility to be driven into apoptosis.  
 
H2-relaxin up regulated cytokines 
H2-relaxin up regulated cytokines include, Fas ligand, VE-cadherin, 
Neurotrophin-4 (NT-4) and MMP-9, whilst MMP-3 and MMP-13 remain 
unchanged. NT-4 belongs to a family of neurotrophins including nerve growth 
factor (NGF), brain derived nerve growth factor (BDNF), neutrophin-3 (NT-3), 
and neurotrophin-5 (NT-5).    NT-4 is less conserved compared to the other 
members of the family due to a truncated pro-region and a 7 amino acid 
insertion in the mature region (Ip et al., 1992).  Neurotrophins act through 
signalling via membrane bound receptors.  There are two types of receptor that 
NT-4 will signal through, the high affinity tyrosine kinase (Trk) receptors, which 
there are three TrkA, TrkB and TrkC, and the low affinity nerve growth factor 
p75 (NTR) receptor (Samah et al., 2008).  Neurotrophins are known to promote 
neuronal survival, they are involved in brain development, nerve regeneration 
and can modulate gene expression in the nervous system.  Neurotrophins were 
traditionally thought of as mediators of the nervous system (Ip et al., 1992) but 
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peripheral tissues and cells related to the immune system such as T-cells, B-cells 
and macrophages (Samah et al., 2008).  Neurotrophins may have a role in 
modulating the critical functions of macrophages such as chemotaxis.  It has also 
been reported that NGF can enhance phagocytosis, and increase the production 
of TNF-α and nitric oxide.  Neurotrophins NGF, BDNF, NT-3, NT-4 and NT-5 
are expressed by hepatic stellate cells and their expression can be induced by pro 
and anti inflammatory agents such as TGF-β, LPS and dexamethasone although 
NT-4 was not as inducible compared to NGF and NT-3 (Cassiman et al., 2001).  
NT-4 is the least well described neurotrophin and its role in peripheral tissue is 
largely unknown but it may have a role in tissue healing mechanism by acting on 
cells involved in inflammation and the immune response (Samah et al., 2008).  
HSC are the main effector cells in liver injury but macrophages also have an 
important role in activation of HSC to a myofibroblast type cell.  Neurotrophins 
may act on kupffer cells (the livers resident macrophages) but they may also 
have a role in the regulation of HSC in the injured liver.  Previous work has 
shown NGF to be expressed by rat hepatocytes during liver injury.  Peak levels 
of hepatocyte NGF expression occurs 48 hours post CCl4 injury which coincides 
with peak HSC apoptosis and when recombinant NGF is added to rat HSC in 
vitro it causes a dose dependent increase in apoptosis (Oakley et al., 2003).  H2-
relaxin induces the expression of NT-4 in primary HSC and although the 
expression of NGF is unchanged the increase in NT-4, which will signal through 
the same receptors as NGF may induce apoptosis in an autocrine manner.  To 
confirm if NT-4 has a role in HSC apoptosis in vitro a recombinant form of NT-
4 would be added to the cultured primary HSC. 
 
Fas ligand (FasL) is a type II transmembrane protein that belongs to the TNF 
family.  Soluble FasL (sFasL) is generated by MMP-7 cleaving membrane 
bound FasL at a conserved cleavage site.  Binding to the Fas receptor, also 
known as APO-1 or CD95, induces apoptosis but there is suggestion in recent 
years that binding of the soluble form can inhibit apoptosis by blocking the 
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FasL to the FAS receptor initiates the recruitment of several other proteins to the 
intracellular death domain of Fas to form a death-inducing signalling complex, 
or DISC (Medema et al., 1997).  Of the proteins recruited the Fas-associated 
death domain (FADD) proteins acts as an adaptor that links procaspase-8 to 
stimulated Fas (Chinnaiyan et al., 1995).  Pro-caspase-8 is then activated by 
proteolytic cleavage, active caspase 8, also known as Fas linked interleukin-1β-
converting enzyme-like protease (FLICE) instigates a caspase cascade leading to 
proteolysis of protein targets that are essential for the apoptotic process (Martin 
and Green, 1995).  Apoptosis is regulated in some cell types by the expression of 
proteins such as Bcl-2, Bcl-xL, PARP-1 (inhibit apoptosis) Bax, Bak, and p53 
(promote apoptosis) (Kroemer, 1997).  Other functions of FasL include 
regulation of the immune system (O’Connell., 2001) and regulating the 
progression of cancer as described in hepatoma cells (Natoli et al., 1995).  Fas 
receptors are expressed by primary HSC and these cells have been shown to 
become susceptible to apoptosis by soluble FasL (sFasL) after activation into a 
myofibroblast like cell.  The increased sensitivity to sFasL driven apoptosis was 
believed to be at least in part due to the decrease in expression of Bcl2 and Bcl-
xL by HSC (Gong et al., 1998).  H2-relaxin increases the expression of FasL in 
primary HSC, indicating H2-relaxin is pro-apoptotic in these cells.  An increase 
in FasL could also indicate an increase in sFasL which is processed by MMP-7.  
Although there are indications that sFasL is pro-apoptotic in HSC (Gong et al., 
1998) further investigations are needed to completely understand the role of 
FasL and sFasL in liver disease.   
 
Vascular endothelial (VE)-Cadherin is a recently characterised member of the 
cadherin family (Lampugnani et al., 1992).  VE-cadherin is also known as 
cadherin-5 (Suzuki et al., 1991).  VE-cadherin is located at intercellular adheren 
junctions and has important functions in cohesion and organisation of the 
junction as well as regulating the permeability properties of the vascular 
endothelium (Bazzoni and Dejana, 2004).  VE-cadherin also has properties 
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barely detectable in sinusoidal endothelial cells in the normal liver (Scoazec et 
al., 1994;Scoazec and Feldmann, 1994) but in diseased liver, including hepatitis 
infection, cirrhosis and HCC both the mRNA and protein expression increases 
(Kato et al., 2007).  H2-relaxin induces the expression of VE-cadherin in 
primary HSC.  H2-relaxin is known as a vasoactive substance that could be 
important in maintaining the blood flow through the sinusoid of the liver and 
therefore transport of vital nutrients to the hepatocytes through the space of 
disse, especially during liver injury, particularly fibrosis, when the space of disse 
may become blocked with excess extra cellular matrix and the fenestrae of the 
endothelium are lost.  Inducing the expression of proteins such as VE-cadherin 
could implicate a role for H2-relaxin in maintaining the permeability of the 
vascular endothelium and maintaining intercellular adheren junctions that are 
important for sustaining the structure of the space of disse and the contact 
between the hepatocytes and the hepatic sinusoid through the HSC. 
 
Matrix metalloproteinase 9 (MMP-9) is a member of a family of zinc dependent 
proteolytic enzymes.  In a healthy liver the homeostasis of extracellular matrix is 
regulated by the balance of MMPs and their inhibitors TIMPs.  In chronic liver 
damage activation of HSC induces the expression of TIMPs, particularly TIMP-
1, which causes the inhibition of MMPs ultimately leading to the accumulation 
of extra-cellular matrix and fibrosis (Schuppan et al., 2001;Iredale, 1996;Iredale, 
1997).  MMPs are divided based on their main substrate for example, 
collagenases, gelatinases, and metalloelastases.  MMPs are secreted as 
zymogens and are activated by cleavage of their propeptide (Somerville et al., 
2003).  MMP-9 a 92 kDa protein is activated by the proteolytic cleavage by 
MMP-3 to an 86 kDa protein.   MMP-3 is activated by plasmin before it can 
activate MMP-9.  MMP-9, also known as gelatinase B, has similar targets to 
MMP-2, also known as gelatinase A, such as gelatins, collagen 1, IV, V, VII, X, 
fibronectin, laminin and elastin.  MMP-9 is produced by Kupffer cells in 
primary culture (Knittel et al., 1999).   During liver disease HSC, inflammatory 
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et al., 2007).  MMP-9 expression increases during the activation of HSC, 
however MMP-9 activity is not associated with the degree of fibrosis but is 
linked to tissue inflammation, consistent with earlier findings linking MMP-9 
expression to the presence of HCV infection (Lichtinghagen et al., 2001).  There 
have been inconsistent results as regards to the expression of MMP-9 in several 
different models of acute and chronic liver injury in rats.  Up regulation of 
MMP-9 at the beginning of recovery in mouse models has been observed at the 
mRNA and protein level (Knittel et al., 2000;Ueberham et al., 2003).  Disruption 
of the αvβ3  integrin and type 1 collagen interactions has been shown to induce 
apoptosis of HSC and increase the expression of MMP-9.  Active recombinant 
MMP-9 protein can promote apoptosis of HSC (Zhou et al., 2004).  It has also 
been shown that over expression of MMP-9 can reduce type 1 collagen and 
hydroxyproline content in the liver, thus MMP-9 may indirectly contribute to 
fibrolysis by accelerating HSC apoptosis (Roderfeld et al., 2006).  Antagonism 
of inflammatory cytokines through addition of IL-1 and TNF antagonists 
anakinra and etanercept, has been shown to reduce TIMP-1 mRNA levels in 
experimental toxic liver injury.  In addition to the reduction of TIMP-1 mRNA, 
MMP-9 mRNA levels increased (Roderfeld et al., 2006).  H2-relaxin increases 
the expression of active MMP-9 in HSC, which has been previously documented 
in renal fibroblasts (Heeg et al., 2005).  After reviewing the literature, an 
increase in MMP-9 could induce apoptosis of HSC and reduce their fibrotic 
phenotype, reducing the expression of TIMP-1 and ultimately the accumulation 
of type 1 collagen.  The induction of MMP-9 at the onset of fibrosis could have 
implications in allowing fibrosis to develop but due to the complexity of MMPs 
and their inhibitors in fibrosis the best model to test the affect of relaxin would 
be an in vivo model of fibrosis, where all of the cell types are present allowing 
the interactions between cell types through the levels of secreted cytokines to 
show the true response.   
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4.6.3 H2-relaxin effects on contractile properties of HSC 
 
Gel contraction assays were carried out to discover if the contractile properties 
of activated human HSC were affected by H2-relaxin treatment.  Several pro-
fibrotic agents such as endothelin-1 and vasopressin have been reported to 
increase the contraction of HSC compared to unstimulated cells.  Therefore the 
hypothesis was H2-relaxin, as an antifibrotic agent with known vasodilatory 
properties, would reduce the contraction of activated HSC.  Endothelin-1 was 
used as a positive control, although activated HSC will contract in the presence 
of serum alone.  Gel contraction assays were originally carried out using LX-2 
cells, but they did not display the same contractile properties as primary HSC.  
H2-relaxin significantly reduced the contraction of HSC compared to both serum 
and endothelin-1, which is a novel observation.  The contraction of HSC was 
measured indirectly by calculating the area of the gel after 24 and 72 hours of 
exposure to either H2-relaxin or endothelin-1, therefore the larger the gel the 
greater the relaxation.  At 24 hours HSC treated with H2-relaxin had a 20% 
increased gel area compared with untreated HSC, although the increase in gel 
area at this time point was not significant, by 72 hours the gel area had 
significantly increased to 50% above the untreated HSC and 60% above 
endothelin-1 treated HSC.   Endothelin-1 only modestly increased the 
contraction of HSC compared to untreated HSC and at no time point was the 
increase in contraction significant.  In contrast to H2-relaxin the greatest 
increase in HSC contraction by endothelin-1 was observed at 24 hours.  The 
results from a single experiment suggest that when HSC are pre-treated with H2-
relaxin for 2 hours before applying endothelin-1 the relaxation observed in H2-
relaxin alone treated HSC was significantly reduced.  HSC pre-treated with 
endothelin-1 before treatment with H2-relaxin retained the increase in gel area 
and therefore relaxation observed for H2-relaxin treatment alone.  If taken into 
account the earlier time course conducted in LX-2 cells and the delay in 
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of H2-relaxin appear to have a slow onset of action, possibly due to changes in 
gene and protein expression required for relaxation of HSC to take place. 
 
The mechanism of relaxation in HSC by H2-relaxin was investigated by 
measuring the amount of nitric oxide released into the media during the gel 
contraction assay.  Nitric oxide cannot be measured directly and therefore the 
stable metabolites nitrite and nitrate are used to compare the levels of conversion 
in treated and untreated HSC.  H2-relaxin increased the level of nitric oxide in 
the media by 20% compared to untreated HSC after 72 hours. Therefore a 
possible mechanism of relaxation of HSC after treatment with H2-relaxin may 
be through the induction of nitric oxide and several previous studies have 
proposed that H2-relaxin can induce nitric oxide through several mechanisms 
(Nistri and Bani, 2003;Sherwood, 2004b) (figure 4.12).   Activation of the 
RXFP-1 activates second messenger systems inside the cell, activating G protein 
Gs can increase the cAMP levels in the cells and induce phosphorylation of 
AKT by PI3-kinase.  Increasing cAMP initiates the activation of PKA, which 
then goes on to phosphorylate transcription factors such as NF-κB, an important 
transcription factor in the regulation of fibrosis (Oakley et al., 2005;Watson et 
al., 2008), which can induce the transcription of NOS II and therefore increase 
production of NO (Nistri and Bani, 2003;Sherwood, 2004b).  The 
phosphorylation of AKT can induce the activation of NOS III, and therefore NO.  
H2-relaxin treated HSC do not change their expression ETB, which is required 
for vasodilation in endothelial cells and signals through the induction of nitric 
oxide.  Although the expression of ETA is decreased and ETB remains 
unchanged, which confers a more vasdilatory phenotype.  Some groups have 
reported ETB expression up regulation by H2-relaxin (Dschietzig et al., 2003) 
whereas others have reported regulation of ETB protein has no role in H2-relaxin 
regulation of ETB/nitric oxide pathway (Kerchner et al., 2005).   
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Figure 4.12. Adapted from (Nistri and Bani., 2003).  Potential nitric oxide induction 
pathways used by H2-relaxin.   
 
H2-relaxin may also regulate HSC contractility through regulating intracellular 
calcium release.  It has been shown that relaxin modulates myometrial 
contractility, the mechanisms are complex and only partially understood 
(Downing and Hollingsworth, 1993;Sherwood, 2004b;Sanborn, 2001).   The 
myometrium is the middle layer of the uterine wall, consisting largely of smooth 
muscle cells but also supporting stromal and vascular tissue. The myometrium 
allow expansion and contraction of the uterine wall during pregnancy (Schofield 
and WOOD, 1964;Schofield, 1957).    It has been described that relaxin can 
regulate the contractility of vascular smooth muscle not only of the reproductive 
organs but of several different organs including the heart, kidneys and liver 
through the regulation of intracellular free calcium and/or nitric oxide levels in 
the cells (Failli et al., 2002;Bani et al., 1999).  Calcium binds to calmodulin 
which forms a complex that binds to and activates the myosin light chain kinase 
(MLCK).  Activated MLCK can phosphorylate the regulatory chain of myosin 
which will ultimately enhance its interaction with actin and actin activated 
myosin ATPase which will bring about contraction.  Phosphorylation of MLCK 
can inhibit the formation of calmodulin complexes and therefore contraction 
(Sherwood, 2004b;Sanborn, 2001).   
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There are several different mechanisms described by which relaxin may regulate 
this cascade of events (figure 4.13) but one is through the increase in 
intracellular levels of cAMP and its subsequent activation of PKA, which causes 
the phosphoylation of MLCK, reducing its affinity for myosin and therefore 
blocking the cascade (Sherwood., 2004).  It has been suggested that relaxin can 
bind to Ca
2+ making it unavailable to the contractile elements (Fields, 2005).  
Activation of PKA may also inhibit DAG + IP3 mediated release of calcium 
from intracellular stores thus reducing the available calcium (figure 4.13).  H2-
relaxin can blunt the calcium response in normotensive but not hypertensive rats.  
The levels of protein kinase G are reduced in hypertensive rats which could 
explain the difference in sensitivity to relaxin treatment (Failli et al., 2002).  
Protein kinase G (PKG) is a serine threonine specific protein kinase signalling 
molecule that is activated by increases in cGMP.  PKG has been found to play a 
pivitol role in the nitric oxide-cGMP signalling pathway, contributing to the 
regulation of not only smooth muscle relaxation but also in the pulmonary 
venous system (Lincoln et al., 1993;Walsh et al., 1995;Gao et al., 1999).  These 
studies indicate the vasorelaxant effects of H2-relaxin may be dependent upon 
the levels of protein kinase G and therefore nitric oxide levels in the cell.    
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Figure 4.13. Adapted from (Sherwood., 2004) Mechanisms by which, H2-relaxin could 
modulate intracellular calcium levels.  The bold arrows indicate known mechanisms, 
whereas the dashed arrows indicate potential mechanisms of action. 
 
Others have shown that contractility of HSC correlates with levels of activation 
and expression of α-SMA (Rockey et al., 1993).  Actin is required for cell 
migration, maintenance of morphology and contraction (Machesky and Hall, 
1997;Hinz and Gabbiani, 2003).  There are several different isoforms that are 
expressed by different cells types, but myofibroblasts (activated HSC) 
predominantly express the vascular isoform, α smooth muscle actin (α-SMA).   
Therefore a decrease in α-SMA may reduce the available actin in the cell, which 
is required for contraction (Hinz et al., 2002).  H2-relaxin decreases the 
expression of α-SMA and seems to reverse the activated phenotype, therefore 
perhaps decreasing contractility by this mechanism.  TGF-β has also been shown 
to up regulate α-SMA contraction of myofibroblasts (Meyer-ter-Vehn et al., 
2008), therefore the decrease in α-SMA expression coupled with the decrease in 
TGF-β expression by H2-relaxin may further reduce contraction of activated 
HSC.  HSC adhesion and migration is important in ECM remodelling and 
fibrosis and is dependent upon the expression of α-SMA.  An increase HSC 
adhesion and migration is profibrotic in LX-2 cells (Wang et al., 2005).  
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HSC adhesion and migration, another mechanism by which H2-relaxin could 
exert antifibrotic effects (Hinz et al., 2003).  A decrease in adhesion to collagen-
1 could affect the gel contraction assay results.  If a fewer number of HSC are 
attached to the gel, a decrease in contraction will be observed.   
 
Addition of a nitric oxide inhibitor, L-NAME, was added to the cells in the gel 
contraction assay.  The concentration of inhibitor may have been too high as no 
contraction was observed, indicating possible cell death in those wells.  
Unfortunately these experiments were not repeated and therefore mechanism of 
gel contraction by H2-relaxin remains to be fully elucidated.  The inhibition of 
contraction by H2-relaxin may be a complex sequence of events that includes 
several different mechanisms.  We now know that H2-relaxin decreases α-SMA 
and TGF-β expression, increases MMP expression, and increases nitric oxide 
levels in primary HSC.  H2-relaxin may use a combination of these factors and 
other mechanisms that we have not studied such as the inhibition of intracellular 
free calcium to inhibit contraction in activated HSC.  To determine if the effects 
of H2-relaxin observed in this chapter were through the activation of the 
receptor RXFP-1, siRNA studies were carried out.   These studies assisted in 
understanding the mechanisms by which H2-relaxin has antifibrotic and 
anticontractile effects in HSC. 
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5.1 Introduction to siRNA studies 
 
5.1.1 Introduction 
 
RXFP-1 activation is the major signalling pathway utilised by H2-relaxin. 
Studies using siRNA targeted to RXFP-1 were designed to determine whether 
the phenotypic effects described in chapter 4, after H2-relaxin treatment are 
dependent upon activation of RXFP-1.    Many of the assays carried out in 
chapter 4 were repeated after siRNA transfection and confirmation of RXFP-1 
knockdown in primary HSC.  SiRNA transfection conditions had to be 
optimised for both LX-2 and primary HSC.  The percentage knockdown was 
assessed using qRT-PCR and all the results are compared to percentage of 
expression after negative control siRNA transfection.   The toxicity of the 
siRNA oligonucleotides were assessed by MTS cell viability and LDH assays, 
which determine the number of live cells compared to the control or the number 
of dead cells compared to the total population in that well respectively.  
Transfection efficiency was determined using cAMP assays to quantify the 
knockdown of active receptor in response to H2-relaxin.  Off-target effects were 
evaluated by monitoring the expression of RXFP-3, a closely related member of 
the relaxin receptor family.  Transfection with a negative control siRNA or 
scrambeled sequence also controlled for specificity and negative off-target 
effects.   
 
5.1.2 Hypothesis, Aims and Objectives 
 
Hypothesis 
H2-relaxin exerts its phenotypic effects on HSC through the activation of relaxin 
receptor RXFP-1. 
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Aims 
To treat primary HSC with H2-relaxin and test the effect on expression of 
markers of fibrosis and the ability to contract collagen gels after knocking down 
RXFP-1. 
 
Objectives 
•  Knockdown RXFP-1 in LX-2 and primary HSC using siRNA 
•  Verify cell viability and transfection efficiency using MTS, LDH and 
cAMP assays 
•  Check the phenotype of HSC lacking RXFP-1 receptor in the presence of 
H2-relaxin. 
 
5.2 Results-Validation of siRNA oligonucleotide knockdown of 
RXFP-1 receptor in primary HSC and LX-2 cells 
 
Transient siRNA transfection was used to knockdown RXFP-1 in both LX-2 
cells and primary HSC.  Three siRNA oligonucleotide sequences were tested in 
LX-2 cells.  LX-2 cells were transfected with 50, 100 and 200 nM of all three 
RXFP-1 siRNA.  The lowest concentration with the most effective knockdown 
was RXFP-1 siRNA 1 at 100 nM (figure 5.1).  At 200 nM the negative control 
siRNA effected RXFP-1 expression suggesting toxic effects, and at 50 nM the 
knockdown was not as significant.  One sequence was found to knock down the 
receptor more efficiently and therefore RXFP-1 siRNA 1 sequence (RXFP-1 
siRNA) was used in all further studies.  Negative control siRNA was a 
predesigned sequence used for all LX-2 cell transfections.  Knockdown of 
RXFP-1 in LX-2 cells was also quantified by qRT-PCR (figure 5.2c i).  
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Figure 5.1. RXFP-1 siRNA test knockdown in LX-2 cells.  RXFP-1 expression 48 
hours post transfection assessed by RT-PCR (n=1).  RXFP-1 expression was normalised 
to GAPDH and the knockdown of the receptor was normalised to the negative control 
siRNA.  (i) 50 nM, (ii) 100 nM and (iii) 200 nM siRNA concentrations were tested, 100 
nM RXFP-1 siRNA #1 efficiently knocked down the receptor by over 80%.   
 
Primary HSC were initially transfected with 100 nM RXFP-1 siRNA, but this 
concentration was found to be toxic to the cells.  Therefore lower concentrations 
i 
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of 50 and 25 nM were tested alongside pooling all three RXFP-1 siRNA 
sequences at all three concentrations.  RXFP-1 expression was detected by RT-
PCR.  25 nM RXFP-1 siRNA was found to be effective at knocking down 
RXFP-1 expression normalised to GAPDH.  Pooling the sequences was not 
found to be more effective then the single sequence used in LX-2 cells (figure 
5.2a).  Both predesigned negative control siRNA and RXFP-1 scrambled siRNA 
were transfected at the same concentrations and neither sequences significantly 
affected RXFP-1 expression, assessed by RT-PCR (figure 5.2a).  Oligofectamine 
was the transfection reagent used in both LX-2 cells and primary HSC.  
Oligofectamine and the RXFP-1 siRNA oligo (100 nM) were added to HSC 
individually and their effect on RXFP-1 expression was also assessed by RT-
PCR (figure 5.2a).  Oligofectamine did not alter RXFP-1 expression but RXFP-1 
siRNA, despite not having any transfection reagent present, induced a small 
reduction in RXFP-1 expression.  Expression of RXFP-3 was assessed to ensure 
siRNA specifically down-regulated RXFP-1 whilst not effecting a close member 
in the relaxin family of receptors.  RXFP-3 expression was not affected by 25 
nM RXFP-1 siRNA transfection (figure 5.2b).   All the results in this study are 
normalised to negative control siRNA transfected or non-transfected cells 
depending on the appropriate control.  The negative control used in LX-2 cells 
was the predesigned sequence.  RXFP-1 scrambled sequence was found to have 
the least effect on RXFP-1 expression in primary HSC and therefore all results 
in these cells are normalised to this negative control.  RXFP-1 receptor was 
significantly knocked down by up to 90% in LX-2 cells (figure 5.2c i) and up to 
70% in primary HSC (figure 5.2c ii) when quantified by qRT-PCR.  LDH and 
MTS assays were carried out to determine the cell viability after siRNA 
transfection of primary HSC.  There was a significant difference in LDH 
released comparing each condition to triton x treated (permeablised) cells, 24, 48 
and 72 hours post transfection (figure 5.2c iii and iv).  Therefore there was no 
significant release of LDH into the media from transfected cells indicating the 
cells were still viable.  No significant change was observed in MTS cell viability 
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5.2.c vi), 48 hours post transfection.  Once the knockdown had been confirmed 
and the off target effects and toxicity of the siRNA were controlled, siRNA 
transfected HSC were used to evaluate the phenotype of cells with a reduced 
expression of RXFP-1.   
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Figure 5.2. (A) Expression of RXFP-1 in primary HSC, 48 hours after different siRNA 
transfection conditions, assessed by RT-PCR and normalised to GAPDH expression 
(n=1). (B) Expression of RXFP-1 and RXFP-3 in primary HSC, 48 hours post 25 nM 
siRNA transfection, assessed by RT-PCR (n=3). (C) (i) Expression of RXFP-1 in LX-2 
cells is significantly knocked down by 90% 48 hours post siRNA transfection (p<0.01), 
assessed by qRT-PCR (n=3). (ii) Expression of RXFP-1 in primary HSC is significantly 
knocked down by over 25% after 24 hours (p<0.05) and by 70% 48 hours (p<0.01) post 
siRNA transfection, assessed by qRT-PCR (n=3). (iii)  LDH assay at 48 hours post 
transfection of primary HSC.  The toxicity of RXFP-1 siRNA, negative control siRNA, 
oligofectamine without siRNA, and siRNA without oligofectamine were not 
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compared to triton x permeablised cells (p<0.01) (n=3). (iv) LDH cytotoxicity assays 
were carried out on primary HSC 24, 48 and 72 hours post transfection.  Neither 
negative control siRNA or RXFP-1 siRNA exhibited over 20% cytotoxicity which was 
significantly different from triton x permeablised cells for each time point (p<0.01) 
(n=3). (v) MTS cell viability of LX-2 cells 48 hours post tranfection.  Various 
conditions were compared including non-transfected, negative control siRNA, RXFP-1 
siRNA, siRNA without oligofectamine and oligofectamine without siRNA.  None of the 
conditions significantly reduced the cell viability of LX-2 cells (n=3). (vi) MTS cell 
viability of primary HSC 48 hours post transfection.  None of the conditions 
significantly reduced viability of primary HSC (n=3). 
  
5.3 cAMP assay using siRNA transfected primary HSC and LX-2 
cells, evaluation of transfection efficiency   
 
The cAMP response to H2-relaxin was abolished in LX-2 cells transfected with 
RXFP-1 siRNA (figure 5.3.a), indicating the amount of active receptor produced 
by the cells is reduced and the cells can no longer respond to H2-relaxin through 
the cAMP pathway.  This suggests that the transfection efficiency was high since 
to the amount of active receptor at the membrane must have been reduced in the 
majority of the population transfected, otherwise there would still be a cAMP 
response in the cells that remained untransfected.  The EC50 values for non-
transfected (0.12 nM) and negative control siRNA (0.41 nM) are similar (figure 
5.3.d), although the predesigned negative control used in LX-2 cells did reduce 
the Vmax or maximal cAMP response to H2-relaxin compared to non-
transfected cells (figure 5.3.a).  The cAMP response to H2-relaxin was also 
reduced in primary HSC transfected with RXFP-1 siRNA (figure 5.3.b), 
indicating the amount of active receptor produced by the cells is reduced and the 
cells therefore have a reduced response to H2-relaxin through the cAMP 
pathway.  The EC50 values for RXFP-1 siRNA (1.7 nM), RXFP-1 scrambled 
siRNA negative control (4.7 nM) and non-transfected cells (7.6 nM) are 
comparable (figure 5.3.d) but the Vmax or maximal response is significantly 
reduced in the RXFP-1 siRNA transfected cells (figure 5.3.b).  This result                                                                                         Chapter 5: RXFP-1 siRNA studies 
  201
indicates the transfection was not as efficent as in LX-2 cells, as there is some 
active receptor present in the transfected population.   This may be due to poorer 
transfection efficiency as well as a reduced percentage knockdown compared to 
LX-2 cells (figure 5.2.c ii).  Primary HSC transfected with RXFP-1 siRNA and 
negative control siRNA were still able to respond to forskolin (Forsk) by 
increasing the intracellular accumulation of cAMP compared to non-transfected 
cells (figure 5.3.c) and EC50 values were comparable (figure 5.3.d).  
 
 
 
Figure 5.3. Examining the siRNA transfected cells response to H2-relaxin in the cAMP 
accumulation assay.  (a) cAMP response to H2-relaxin in LX-2 cells transfected with 
RXFP-1 siRNA compared to non transfected and –ve control siRNA transfected cells. 
RXFP-1 siRNA transfected LX-2 cells had no response to H2-relaxin, suggesting a very 
high proportion of the cells were transfected.  The predesigned negative control used in 
LX-2 cells caused a reduced Vmax cAMP response to H2-relaxin but this did not effect 
its EC50. (b) RXFP-1 siRNA transfected primary HSC have a reduced cAMP response 
to H2-relaxin compared to –VE control siRNA transfected and non transfected cells.  
(d)EC50 (nM)     H2-relaxin       Forsk 
                            LX-2      HSC       HSC    
 
NT                        0.12        7.6         5.8 
 
neg control           0.41
             4.7         4.5 
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The EC50 in RXFP-1 siRNA transfected cells was similar to the control cells but the 
Vmax was reduced by over 5-fold compared to either control suggesting a high 
proportion of the cells were transfected bearing in mind RXFP-1 was only knocked 
down by 70% at the mRNA level.  The negative control siRNA used in this experiment 
was the scrambeled sequence of the RXFP-1 siRNA used to induce knockdown.  Cells 
transfected with the new negative control siRNA sequence have no reduction in 
response to H2-relaxin compared to non-transfected cells, therefore this sequence was 
used for the remaining experiments carried out in primary HSC.  (c) Confirmation 
through stimulation with forskolin that cells transfected with either RXFP-1 siRNA or 
the negative control siRNA do not lose their ability to accumulate intracellular cAMP in 
response to adenylate cyclase activation. (d) Table of EC50 values for the three 
conditions in both primary HSC and LX-2 cells.  
 
5.4 Evaluation of the phenotypic changes observed in human 
HSC transfected with RXFP-1 siRNA after 72 hours H2-relaxin 
treatment 
 
In chapter 4 gene expression changes were observed after 72 hours H2-relaxin 
treatment of primary HSC, the experiment was repeated comparing the 
expression of various fibrosis related genes in RXFP-1 siRNA transfected cells.  
Gene expression of pro-fibrotic genes such as α-SMA, TGF-β, CTGF, and 
TIMP-1 were all increased in RXFP-1 siRNA transfected cells after 72 hours 
H2-relaxin treatment, compared with negative controls.  Results are expressed as 
fold changes compared to negative control siRNA transfected cells.  The change 
in gene expression was significantly increased above 3-fold for α-SMA and 
CTGF, and above 2-fold for TGF-β, procollagen-1 and TIMP-1.  MMP-2 was 
also significantly increased 2 fold when RXFP-1 expression was knocked down, 
whilst MMP-1 expression was significantly decreased by over 50%.  These 
results are in contrast to H2-relaxin treated primary HSC in chapter 4, when α-
SMA, TGF-β, CTGF, TIMP-1 and procollagen-1 were all down regulated, 
whilst MMP-1 was up regulated suggesting transcriptional regulation of these 
genes by H2-relaxin is dependent upon signalling through RXFP-1.   MMP-2                                                                                         Chapter 5: RXFP-1 siRNA studies 
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was up regulated by H2-relaxin treatment but was also still up regulated in 
RXFP-1 siRNA transfected HSC in the presence of H2-relaxin.  This result 
suggests the regulation of MMP-2 by H2-relaxin is not dependent on signalling 
through RXFP-1. 
 
 
 
Figure 5.4. Gene expression profile of primary HSC transfected with RXFP-1 siRNA 
compared to negative control siRNA transfected primary HSC after 72 hours H2-relaxin 
treatment. α-SMA and CTGF were significantly up regulated by over 3 fold (p<0.01), 
TGF-β, procollagen-1 and TIMP-1 were significantly up regulated by over 2 fold 
(p<0.05), and MMP-2 was significantly up regulated by 2 fold (p<0.01).  MMP-1 was 
the only gene that was down regulated by over 50% (p<0.01).   
 
5.5 Investigation into the contractile properties of hHSC after 
transfection with RXFP-1 siRNA in the presence of H2-relaxin 
 
5.5.1 Gel contraction assay with RXFP-1 siRNA transfected HSC 
 
RXFP-1 siRNA transfected primary HSC were used in gel contraction assays to 
investigate the contractile properties of primary HSC with reduced signal 
transduction in response to H2-relaxin.  Previously we have shown that H2-                                                                                        Chapter 5: RXFP-1 siRNA studies 
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relaxin reduces the contraction of HSC when cultured on collagen-1 gel.  HSC 
contraction was measured indirectly as gel area and therefore H2-relaxin 
increases the area of the gel compared to untreated and endothelin-1 treated 
cells.  RXFP-1 siRNA transfected cells in the presence of H2-relaxin did not 
significantly reduce the contraction of HSC, in fact the increase in gel area was 
completely abolished compared to non transfected and negative control siRNA 
transfected HSC after 24 or 72 hours (figure 5.5b).  All results are normalised to 
untreated primary HSC and are expressed as fold changes.  A significant 40% 
increase in gel area was still present in non-transfected and negative control 
siRNA transfected primary HSC after 72 hours H2-relaxin treatment.  The 
siRNA knockdown of RXFP-1 was confirmed in the cells extracted from the gel 
after the completion of the contraction experiment.  Significant 70% knockdown 
was still present in primary HSC extracted from the collagen gels after 72 hours 
assessed by qRT-PCR (figure 5.5c).  H2-relaxin inhibits the contraction of 
primary HSC and the inhibition is abolished when the main receptor for H2-
relaxin is knocked down.  Therefore the anti-contractile properties of H2-relaxin 
appear to be dependent on the activation of RXFP-1.   
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Figure 5.5. Gel contraction assays carried out with siRNA transfected HSC (a) 
Representative image of collagen gels in a 24 well plate after 72 hours, comparing 
RXFP-1 siRNA transfected, negative control transfected and non transfected cells that 
have been treated with H2-relaxin with untreated cells (b) Gel area was calculated using 
ImageJ software 24 hours and 72 hours after the gel release and fold changes in gel area 
are plotted on the histogram. H2-relaxin treatment significantly increases the gel area of 
both non-transfected and negative control siRNA transfected cells (p<0.05), but there is 
no increase in gel area of RXFP-1 siRNA transfected cells compared to untreated cells 
after 72 hours. (c) SiRNA knockdown of RXFP-1 in primary HSC that have been used 
in the gel contraction assay.  To ensure the knockdown was present in cells after 72 
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the collagen-1 gels.  Over 60% knockdown of RXFP-1 was still present in the cells after 
the gel contraction assay was completed (p<0.01). 
 
5.5.2 Secreted nitric oxide determination in RXFP-1 siRNA transfected 
primary HSC 
 
The treatment of HSC with H2-relaxin had previously shown a 20% increase in 
the release of nitric oxide.  Media samples removed from RXFP-1 siRNA 
transfected primary HSC in gel contraction assays were used to measure the 
level of nitric oxide release after 72 hours H2-relaxin treatment.  Fold changes in 
nitric oxide release are normalised to non-transfected cells and compared to non-
treated RXFP-1 siRNA transfected cells.  Knockdown of RXFP-1 in primary 
HSC has abolished the increase in nitric oxide seen in H2-relaxin treated non-
transfected cells (figure 5.6). 
  
 
 
Figure 5.6. Nitric oxide level determination in gel contraction assays.  Media was 
removed from the cells after completion of the gel contraction assay and the nitrite 
released into the media (stable metabolite of nitric oxide) over the course of the 
experiment was measured in a 96 well plate based assay. Nitric oxide release was 
increased 20 % in H2-relaxin treated cells but RXFP-1 siRNA transfected cells did not 
increase the nitric oxide released, which was conversely significantly reduced by over 
20% compared to non-treated controls (p<0.05).   
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5.6 Summary of key findings 
 
•  RXFP-1 siRNA significantly reduces the expression of RXFP-1 by 90% 
in LX-2 cells and 70% in primary HSC.  siRNA transfection did not 
reduce the viability of the cells but substantially reduced the cAMP 
response to H2-relaxin in both primary HSC and LX-2 cells.  
•  The down regulation of pro-fibrotic factors such as α-SMA, pro-
collagen-1, TIMP-1, CTGF and TGF-β by H2-relaxin in human hepatic 
stellate cells is inhibited in RXFP-1 siRNA transfected cells. 
•  Primary HSC up regulate MMP-1 and MMP-2 in the presence of H2-
relaxin. The up regulation of MMP-1 is inhibited by RXFP-1 siRNA 
transfection but MMP-2 continues to be up regulated to a similar extent 
suggesting MMP-2 is not regulated by signalling through RXFP-1. 
•  H2-relaxin inhibition of HSC contractility is reversed in cells transfected 
with RXFP-1 siRNA. 
•  The increase in nitric oxide in H2-relaxin treated HSC is reversed when 
RXFP-1 is knocked down. 
 
5.7 Discussion 
 
SiRNA experiments were designed to verify the effects of H2-relaxin in primary 
HSC were through RXFP-1 signalling.  SiRNA knockdown of the receptor was 
achieved by transfecting with a transfection reagent specifically designed for 
introduction of siRNA.  Three different RXFP-1 siRNA sequences were tested 
in LX-2 cells.  Only one siRNA sequence was found to significantly knockdown 
the mRNA expression of RXFP-1.   This siRNA sequence was then used to 
determine the most effective concentration.  The most desirable concentration is 
the lowest concentration that gives the maximum knockdown, whilst having low 
toxicity.  LX-2 cells were transfected with 100nM siRNA to achieve 90% 
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at this concentration. cAMP assays were used to assess transfection efficiency.  
RXFP-1 siRNA transfected LX-2 cells do not respond to H2-relaxin, there was 
no increase in cAMP detected whilst negative control siRNA transfected cells 
had a comparable EC50 to non-transfected cells.  Negative control siRNA 
transfected LX-2 cells had a reduced Vmax response to H2-relaxin, showing the 
negative control siRNA sequence used in LX-2 cells was affecting the protein 
expression of RXFP-1.  A different negative control siRNA sequence was used 
in primary HSC (a scrambled sequence of the RXFP-1 siRNA sequence).  
Primary HSC were transfected using the same conditions used in LX-2 cells.  
This initial experiment showed that although there was good knockdown in 
primary cells the cell viability was greatly reduced at 100 nM.  Therefore the 
concentration of siRNA used to transfect primary HSC was optimised.  Again 
the lowest concentration that gave the best knockdown and the least toxicity was 
chosen for the siRNA study in primary HSC.  The same siRNA sequence that 
gave 90% knockdown in LX-2 cells was used to achieve significant 70% 
knockdown in primary HSC.  The concentration of siRNA was reduced to 25 
nM and this concentration was not toxic in primary HSC when compared to 
negative control siRNA and non-transfected cells.   Therefore before 
experiments began in primary HSC a scrambled sequence of the RXFP-1 siRNA 
was designed.  The new negative control siRNA was used in all of the primary 
HSC experiments and was shown to have very little effect on cell viability and 
off target effects.  The off target effects were tested by determining the 
expression RXFP-3 assessed by RT-PCR.  RXFP-3 is a closely related member 
of the relaxin receptor family and both the RXFP-1 siRNA and the negative 
control siRNA did not effect its level of expression.   It is difficult to say that 
RXFP-1 and negative control siRNA sequences do not cause off target effects, to 
be able to make this statement a microarray analysis on as many genes as 
possible in transfected primary HSC would have to be carried out.   These 
sequences do not reduce the cells viability and do not effect the expression of 
RXFP-3.  Other closely related relaxin receptors in the family may have been up 
regulated in response to the knockdown of RXFP-1 to compensate.  cAMP                                                                                         Chapter 5: RXFP-1 siRNA studies 
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assays were used to assess the transfection efficiency in primary HSC.  The 
cAMP response to H2-relaxin in primary HSC was reduced in RXFP-1 
transfected HSC.   
 
cAMP assays showed that in both LX-2 cells and primary HSC the knockdown 
in expression of RXFP-1 reduced the accumulation of cAMP after H2-relaxin 
treatment.  The experiment shows that a siRNA that can reduce the gene 
expression of RXFP-1 also reduces the functional protein expression and shows 
that H2-relaxin can increase the cAMP in primary HSC, specifically through the 
RXFP-1 receptor.  The original Ambion negative control was used in the LX-2 
cells and this showed a reduction in cAMP in response to H2-relaxin compared 
to non-transfected HSC.  This is why the scrambled siRNA sequence was used 
for the primary HSC experiments and in the cAMP there was little reduction in 
response compared to non-transfected cells.  To verify the reduction in cAMP 
was specific to the RXFP-1 receptor, the response to forskolin was recorded.  
Forskolin is a natural bicyclic hydrocarbon or labdane diterpene that is produced 
by the Indian coleus plant, coleus forskolin.  It is commonly used to increase the 
intracellular levels of cAMP through its activation of adenylate cyclase in intact 
cell membranes and is a known hypotensive agent (Seamon et al., 1981).  cAMP 
is important for the proper signal transduction/ biological response of many 
hormones.  In these experiments forskolin was introduced to the primary HSC 
which had been transfected with RXFP-1 siRNA to establish if the cells could 
still increase the levels of cAMP in a dose dependent manner through a 
mechanism independent upon the activation of RXFP-1.  If HSC could still 
respond to forskolin it would verify RXFP-1 siRNA transfected cells reduced the 
level of cAMP in response to H2-relaxin because of the decrease in active 
RXFP-1 at the cell membrane and not because of a loss of viability or cell 
membrane integrity.   
 
RXFP-1 siRNA transfected HSC treated with H2-relaxin for 72 hours were used 
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siRNA transfected HSC.  The expression of αSMA, TGF-β, CTGF, procollagen-
1, and TIMP-1 were all significantly increased by more then 2-fold when relaxin 
receptor RXFP-1 expression was decreased.   The up regulation of the pro-
fibrotic genes when H2-relaxin is unable to signal through RXFP-1 demonstrates 
H2-relaxin could have an important regulatory role in progression of fibrosis in 
the liver and other tissues that is dependent on the expression of RXFP-1.  Gel 
contraction assays showed that RXFP-1 siRNA transfected primary HSC lost 
their ability to inhibit contraction after 72 hours H2-relaxin treatment.  The 
increase in nitric oxide release was also inhibited by the knockdown of RXFP-1.  
RXFP-1 signalling appears to be important in inhibition of cell contraction in 
primary HSC, which may be through the increase in nitric oxide secretion.  
Therefore the suggested mechanisms of NO induction described in chapter 4 that 
were dependent upon the activation of RXFP-1, i.e. the increase in cAMP 
leading to transcriptional up regulation of NOS II and the phosphoylation of 
AKT by PI3-kinase leading to the activation of NOS III may be the mechanisms 
by which H2-relaxin induces nitric oxide secretion (Nistri and Bani et al., 2003; 
Sherwood., 2004).  The phenotype described for HSC lacking RXFP-1 is a novel 
observation.  Previous studies using RXFP-1 siRNA in different cancer cell 
types have shown that short term treatment with H2-relaxin induces cell motility 
and invasiveness, possibly due to the increased elastinolytic and ECM degrading 
phenotype.  Increases in MMP-2 and MMP-9 have been described and all these 
effects were RXFP-1 dependent.  Longer term treatment with H2-relaxin 
decreased proliferation of cancer cells and even in short term studies the 
proliferation of these cells was not increased only their invasive phenotype 
(Kamat et al., 2006;Hombach-Klonisch et al., 2006;Radestock et al., 2008).  
Reducing the expression of RXFP-1 in primary HSC reduces their collagen 
degrading/fibrolytic phenotype.  Non-transfected cells treated with H2-relaxin 
increase their expression of MMP-1 and MMP-2 which is a similar to the 
findings in endometrial cancer cells (Kamat et al., 2006). 
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Many of the observations in chapter 4 revealing a less fibrotic phenotype in 
primary HSC after H2-relaxin treatment appear to be dependent upon the 
activation of RXFP-1.  Primary HSC have a more fibrotic phenotype after 
RXFP-1 is knocked down, even in the presence of H2-relaxin.  These studies 
suggest H2-relaxin has a role in regulating the fibrosis through down regulating 
activation of hepatic stellate cells, possibly through the down regulation of TGF-
β and α-SMA (Heeg et al., 2005;Kharbanda et al., 2004).  H2-relaxin can 
decrease fibrotic markers in pre-activated HSC suggesting H2-relaxin treatment 
of patients with pre-existing liver fibrosis could benefit due to the possible 
reversion HSC to a less fibrotic/activated phenotype.   H2-relaxin also regulates 
HSC contraction, which could be through the deactivation of the cells as 
contraction seems to be dependent upon activation and expression of α-SMA 
(Rockey et al., 1993;Kharbanda et al., 2004) but also through the up regulation 
of nitric oxide (Bani et al., 2001).  H2-relaxin may have a role in the treatment of 
portal hypertension as a vasorelaxant compound able to reduce the contraction of 
HSC, and reduce the build up of scar forming collagen, which will reduce the 
pressure on the portal vein that can become constricted in the fibrotic liver due 
to distorted architecture.  Distorted architecture of the liver is due to excess 
collagen deposition originally in the space of disse, also reducing hepatic blood 
flow through the liver sinusoid which can be attributed to an increase in the 
number of activated HSC.  Further studies need to be carried out to confirm the 
down stream signalling mechanisms involved in gene expression changes and 
regulation of cellular contraction by H2-relaxin through activation of RXFP-1.  
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6.1 Introduction 
 
6.1.1 Introduction 
 
In addition to potential roles in liver disease H2-relaxin may have a vasoactive 
role in the normal kidney and potential renal antifibrotic properties (Sherwood., 
2004).  Therefore H2-relaxin may ameliorate renal damage that has already 
occurred and help prevent any future damage occurring by decreasing renal 
vascular tone, increasing GFR and clearing any fibrosis/interstitial matrix build 
up that could be a consequence or cause of poor GFR.  Its antifibrotic properties 
were initially tested in a model of scleroderma (Samuel et al., 2005c) and latterly 
using H2-relaxin knockout mice (Samuel et al., 2005b).  Interestingly the 
knockout mice develop age related fibrosis of the kidney, heart, lung and 
reproductive tract (Samuel et al.,2005).  Although there has been an interest in 
relaxin in the kidney for several years the receptor localisation profile has never 
been documented. The rationale behind the study was to map the receptor profile 
to try to gain a greater understanding and to be able to further hypothesise the 
role of relaxin and its receptors in kidney diseases.  This could shed light on 
whether relaxin receptors would be a good therapeutic target in chronic kidney 
disease (CKD).   
 
6.1.2 Hypothesis, Aims and Objectives 
 
Hypothesis 
Relaxin receptors are localised in different areas of the kidney and this 
expression pattern may change in fibrotic disease. 
 
Aims 
To establish relaxin receptor localisation in normal and fibrotic kidney 
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Objectives 
•  Localise relaxin receptors in normal and fibrotic kidney sections using 
immunohistochemistry 
•  Compare relaxin receptor localisation to markers of the specific 
structures using serial sections wherever possible. 
 
6.2 Introduction to the kidney 
 
6.2.1 Structure and function of the kidney 
 
The kidneys are located in the retroperitoneum, weighing around 140 grams 
each they are vital for the excretion of the by products of metabolism.  The 
kidneys convert over 1700 litres of blood into around 1 litre of urine everyday, 
this process is called ultrafiltration (Kumar et al., 2005; Chandrasoma and 
Taylor., 1998).  The kidneys have developed a high degree of structural 
complexity to enable them to filter out the waste products of metabolism from 
the blood, to precisely regulate the body’s concentration of salt and water, also 
maintaining the acid balance of plasma and secreting hormones such as renin 
and prostaglandins that are essential for the kidneys function.  The human 
kidney is made up of cortex and medulla (Kumar et al., 2005).  The kidneys 
have a rich supply of blood when considering they make up only 0.5% of the 
total body they receive 25% of total cardiac output.  The cortex is highly 
vascularised receiving around 90% of the total renal blood supply.  The main 
renal artery divides the anterior and posterior sections at the hilum.  The arteries 
in the kidney are usually end arteries and occlusion of any branch may cause 
infarction of the area it supplies.  The anatomical unit of the kidney is the 
nephron, composed of the glomerulus, proximal convoluted tubule, loop of 
henle, distal convoluted tubule and collecting tubule with each kidney containing 
around 1 million nephrons.  These structures can be visualised in kidney sections 
when stained with H+E (figure 6.1).  If considering the kidney from the 
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glomeruli, tubules and interstitum (Kumar et al., 2005, Chandrasoma & Taylor., 
1998).   
 
The glomerulus is composed of afferent and efferent arterioles, intervening 
capillaries that are lined by fenestrated endothelial cells (the glomerular tuft), the 
outer surface of the capillaries are lined by epithelial cells called podocytes 
which are continuous in the Bowmans Space and proximal tubule, the 
mesangium which consists of mesangial cells (the kidneys resident 
myofibroblasts), matrix and basement membrane (Chandrasoma and Taylor., 
1998).  Ultrafilatration of plasma occurs in the glomerular capillaries by the 
glomerular basement membrane (GBM).  The GBM has a thick electron dense 
central layer called the lamina densa.  The peripheral layers, called the lamina 
rara interna and the lamina rara externa are thinner electron lucent layers.  The 
GBM consists of collagen (mostly type IV), laminin, polyanionic proteoglycans 
(mostly heparin sulphate), fibronectin, entactin and several other glycoproteins.  
Collagen IV forms a suprastructure framework to which the other glycoproteins 
such as laminn and entactin attach (Timpl and Brown, 1996;Timpl, 1996).  The 
process is driven by hydrostatic pressure and the normal glomerular filtration 
membrane forms a barrier to molecules in the plasma based largely on molecular 
weight and charge of the particles.  The acidic porous nature of the GBM 
determines its permeability characteristics and the charge dependent restriction 
of the GBM is extremely important in the exclusion of molecules, such as 
albumin, due to its anionic nature (Miner, 1999).  Glomerular filtration rate 
(GFR) is around 120 ml/min, up to 80% of the ultrafiltrate is actively absorbed 
in the proximal tubule and molecules such as potassium, glucose and amino 
acids are completely reabsorbed.  The proximal tubule is particularly vulnerable 
to ischemic damage as well as being susceptible to chemical damage due to the 
toxins that it frequently has to reabsorb (Dajak et al., 2008).  
 
The tubules vary considerably at different levels in the nephron, to a certain 
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concerned with water and sodium reabsorption under the control of an 
antidiruetic hormone called ADH or Vasopressin, as it is sometimes referred, 
which is under the control of the renin-angiotensin system (Madsen et al., 
1988b).  The filtrate that passes into the loop of henle is concentrated by the 
counter current multiplier, which increases the concentration gradient allowing 
more water to passively diffuse from the Loop of Henle which then encourages 
active reabsorption of sodium ions.  Of the 120 ml/min of filtered blood only 1-2 
mls is lost as urine.  Urine is acidified and although the kidneys only excrete 1% 
of the acid excreted via the lungs as carbon dioxide and carbon monoxide 
everyday, if this mechanism fails metabolic acidosis can occur (Madsen et al., 
1988b;Madsen et al., 1988a).   
 
The entire glomerular tuft is supported by mesangial cells lying between 
capillaries.  The mesangial matrix is a meshwork where the mesangial 
mesenchymal cells are centred.  Mesangial cells are contractile, phagocytic and 
capable of proliferation, and are able to excrete ECM, including fibrilar 
collagens and biologically active mediators.  The mesangial cells are quiescent 
in the normal kidney and will become activated under pathogenic or tissue 
remodelling conditions (Sterzel et al., 1993).  They are important mediators in 
conditions such as glomerular nephritis.  Mesangial cells can be compared to the 
HSC in the liver and although they do not store vitamin A when quiescent they 
have a similar role in the life cycle of the tissue.  The interstitum is an important 
component of the normal cortex.  The interstitium space is normally compact 
and occupied by fenestrated capillaries and a small number of fibroblast like 
cells (Kaissling and Le Hir., 2008).  If there is any obvious macro or 
microscopic expansion of the interstitum this usually indicates abnormality.  
Expansion of the interstitium can be caused by oedema, inflammation and 
accumulation of chronic inflammation leading to fibrous matrix and tissue 
deposition (Kaissling and Le Hir., 2008).  Presence of proteoglycans in the 
interstitial tissue of the medulla increases with age and in the presence of 
ischemia (Sterzel et al., 1993;Sterzel et al., 1992).                                                                  Chapter 6: Localisation of RXFP 1-4 in the kidney 
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6.2.2 Chronic kidney disease (CKD) 
 
Chronic kidney disease (CKD) is characterised by severely reduced glomerular 
filtration rate.  It has many different aetiologies and an increasing worldwide 
prevalence.  Currently worldwide over 1.2 million individuals are undergoing 
dialysis treatment for end stage kidney failure, with reported annual growth rates 
of between 5-8%.  The statistics get worse when you also consider the 
population diagnosed with CKD but not undergoing dialysis.  The prevalence in 
the US is an estimated 11% of the adult population, with similar results in the 
UK and Australia.  The prevalence is much less in China with only a reported 
incidence of 2.53%.  There are obvious differences in cohort, ethnicity and 
methods of data collections but it is evident that CKD is a worldwide health 
problem with significant repercussions (Eknoyan et al., 2004). 
 
Nephrotic syndrome and renal fibrogenesis are two of the conditions that are 
included in CKD and both can be induced by several mechanisms.  Nephrotic 
syndrome is characterised by proteinuria, hypoalbuminemia, hyperlipidemia, 
oedema and in a small number of cases hypertension.  In adults the most 
common causes are membranous glomerulonephritis (MGN), focal segmental 
glomerularsclerosis (FSGS) and minimal change disease (MCD) (or lipoid 
nephrosis).  All of these diseases affect the glomeruli of the kidneys and more 
specifically the podocyte (Mathieson, 2007;Saha and Singh, 2006;Daskalakis 
and Winn, 2006;Cattran, 2003).  Podocytes (or visceral epithelial cells) form a 
crucial component of the glomerular filtration barrier, located on the outer 
epithelial membrane of the glomerular basement membrane.  They contribute to 
size selectivity and maintenance of the filtration surface (Asanuma et al., 2007).   
Adjacent podocytes interdigitate to cover the basal lamina which is intimately 
associated with the glomerular capillaries, but also leaves thin filtration slits.  
The slits formed by the podocytes are covered by a slit diaphragm, which is 
composed of many different cell surface proteins including nephrin, p-cadherin 
and podocalyxin.  This ensures that large macro-molecules such as albumin                                                                Chapter 6: Localisation of RXFP 1-4 in the kidney 
  218
remain in the blood stream.  Small molecules such as water, glucose and ionic 
salts are able to pass through, forming an ultrafiltrate that is then processed as 
urine.  Disruption of the slit diaphragm and/or disruption of the podocyte can 
lead to massive proteinuria as observed in MCD (Faul et al., 2007).  Podocytes 
have several features that indicate a high rate of vesicular traffic, many coated 
vesicles and coated pits can be observed along the basolateral domain of the 
podocytes.  Podocytes possess a well developed endoplasmic reticulum and a 
large golgi, which is indicative of a high capacity for protein synthesis and post 
translational modifications.  There is also evidence that the podocytes have 
endocytic activity due to the large number of multivesicular bodies and other 
lysosomal components seen in the cells.  Podocytes have an interesting 
morphology including pedicels or “foot processes” which extend to increase the 
surface area of the cells and can be seen using electron microscopy.  Podocytes 
are therefore critical for the maintenance of size selective diffusions barriers and 
can synthesise GBM components (Asanuma et al., 2007;Faul et al., 2007). There 
are diseases that can cause destruction of the podocyte or diseases that can drive 
them into proliferation causing them to lose their normal function.      
 
6.3 Results-Relaxin receptor localisation in normal and fibrotic 
kidney 
 
As mentioned above relaxin receptors have not been mapped in human kidney 
and therefore, antibodies to all four relaxin receptors were used to 
immunohistochemically stain normal and fibrotic kidney sections described 
below.  Lectins and antibodies that have been previously recorded to specifically 
stain structures such as the proximal tubules (lotus tetregonolobus antigen 
(LTA), distal tubules (epithelial membrane antigen (EMA)), podocytes (VEGF 
and synaptopodin) and activated fibroblasts (α-SMA) were used in series with 
the relaxin receptor antibodies to enable us to localise the staining to a particular 
structure or cell type.   
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6.3.1 H+E and Sirius red staining of normal and fibrotic kidney 
 
To carry out the study serial sections were cut from paraffin embedded 
specimens that had been graded as normal and mildly fibrotic by a consultant 
pathologist.  Tissue was collected in accordance with the human tissue act 2004.  
The sections were stained with H+E and Sirius red to ensure the different 
structures could be identified and a difference between the normal and fibrotic 
sections could be observed.   
 
 
 
 
Figure 6.1. (A) H+E stain of a paraffin embedded normal human kidney section 
detailing different parts of the nephron. (B) H+E stain of a paraffin embedded fibrotic 
human kidney section detailing inflammation and areas of scarring. 
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6.3.2 Sirius red staining of normal and fibrotic kidney sections 
 
Normal and fibrotic kidney sections were stained with sirius red to determine the 
level of collagen build up in the fibrotic sections (figure 6.2.).  Sirius red stains 
collagen and under polarised light specifically collagen-1 and collagen-III fibres 
can be detected.  The Sirius red stain detected more collagen build up in the 
fibrotic section. 
 
 
 
Figure 6.2. (a) Representative normal kidney –ve control section (b) representative 
sirius red stain of a normal kidney section (c) representative fibrotic –ve control section 
(d) representative Sirius red stain of fibrotic kidney section.  Sirius red dye will stain 
collagen and the fibrous collagen-1 and collagen-III can be detected under polarised 
light. It is apparent that the level of fibrous collagen being laid down in the fibrotic 
kidney is increased compared to the normal kidney section (n=3). All images were 
taken with an Zeiss 10x objective using Zeiss Axioskop software. 
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6.3.3 RXFP-1 localisation in normal and fibrotic kidney 
 
In the normal kidney RXFP-1 was localised most strikingly to the podocytes in 
the glomerular basement membrane (figure 6.1.).  The staining pattern was 
confirmed by a pathologist and with serial staining with VEGF-C1 and 
synaptopodin, which are both podocyte markers.  The proximal and distal 
tubules also appear to be positively stained but this was thought to be 
background staining as it was much weaker then the stain taken up in the 
podocytes. 
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Figure 6.3.  RXFP-1 localisation in normal kidney assessed by immunohistochemistry, 
in series with synaptopodin and VEGF-C1 which are both podocyte markers (a) rabbit 
isotype control of normal kidney at 20 x  objective (b) rabbit isotype control of normal 
kidney at 10 x objective (c) synaptopodin (1/20) staining of normal kidney at 20 x 
objective.  The arrow indicates positive staining of the podocytes in the glomerular 
basement membrane (d) synaptopodin staining of normal kidney at 10 x objective (e) 
RXFP-1 (1/600) staining of normal kidney at 20 x objective.  The arrow indicates                                                                Chapter 6: Localisation of RXFP 1-4 in the kidney 
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positive staining of the podocytes (f) expanded image of glomeruli stained RXFP-1 (40 
x objective), the arrow indicates positive staining of the podocytes in the glomerular 
basement membrane (g) RXFP-1 staining of normal kidney at 10 x objective (h) VEGF-
C1 (1/200) staining of normal kidney at 20 x objective, the arrow indicates positive 
staining of podocytes in the glomerular basement membrane (i) VEGF-C1 staining of 
normal kidney at 10 x objective.  All images were taken using Zeiss Axioskop software 
(n=4 different patients for all antibodies). 
 
In the fibrotic kidney RXFP-1 was again localised in the podocyte but the 
staining of the distal tubules now appears to be positive compared to the 
background staining in the proximal tubules.  Again staining was confirmed by a 
pathologist and by comparing the staining to a distal tubule (EMA) and podocyte 
(VEGF-C1) marker.  Therefore comparing normal and fibrotic kidney, RXFP-1 
is localised in the podocytes and the distal tubules begin to express more RXFP-
1 in fibrosing kidney. 
 
 
 
Figure 6.4. RXFP-1 localisation in fibrotic kidney, assessed by immunohistochemistry, 
comparing staining with a proximal tubule marker (LTA), a distal tubule marker (EMA)                                                                Chapter 6: Localisation of RXFP 1-4 in the kidney 
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and a podocyte marker (VEGF-C1) (a) LTA (1/3000) staining of fibrotic kidney, arrow 
indicates positive staining of a proximal tubule (b) EMA (1/300) staining of fibrotic 
kidney, arrow indicates positive staining of a distal tubule (c) RXFP-1 (1/600) staining 
of fibrotic kidney, red arrow indicates positive staining of podocytes and the black 
arrow indicates positive staining of a distal tubule (d) VEGF-C1 (1/200) staining of a 
fibrotic kidney, red arrow indicates positive staining of podocytes.  All images were 
taken with a Zeiss 20 x objective using Zeiss Axioskop software (n=3 for all antibodies 
in the same patient). 
 
 6.3.4 RXFP-2 localisation in normal kidney 
 
In the normal kidney RXFP-2 was localised in the proximal tubules, compared 
to proximal tubule marker LTA.   The localisation did not change in fibrotic 
kidney.   
 
 
Figure 6.5. (a) RXFP-2 (1/200) localisation in normal human kidney, assessed by 
immunohistochemistry (b) expanded image of RXFP-2 localisation.  RXFP-2 appears to                                                                Chapter 6: Localisation of RXFP 1-4 in the kidney 
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be localised in the proximal tubules when compared to LTA staining, a proximal tubule 
marker (c) LTA staining of normal human kidney section. Images were taken with Zeiss 
10 x objective using Zeiss Axioskop software (n=3 for both antibodies in different 
patients). 
 
6.3.5 RXFP-3 localisation in normal and fibrotic kidney 
 
RXFP-3 was localised in the interstitium.  Fibroblasts are the main cell type that 
occupy the intersitium which are important in maintaining the structure of the 
kidney through extracellular matrix turnover/remodelling.  α-SMA is a fibroblast 
marker and positively stains the intersitium which is comparable to RXFP-3 
staining.     
 
 
 
Figure 6.6.  RXFP-3 localisation in normal kidney assessed by immunohistochemistry, 
comparing staining with a fibroblast marker α-SMA (a) RXFP-3 (1/400) staining of 
normal kidney at 10 x objective (b) RXFP-3 staining of normal kidney at 20 x 
objective.  RXFP-3 positively stains the intersitium, which could be localised to 
fibroblasts (c) α-SMA (1/40,000) staining of normal kidney at 10 x objective (d) α-                                                               Chapter 6: Localisation of RXFP 1-4 in the kidney 
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SMA staining of normal kidney at 20 x objective.  α-SMA positively stains the 
fibroblasts in the intersitium as well as areas of smooth muscle such as arteries. Images 
were taken using Zeiss Axioskop software (n=4 for both antibodies in different 
patients).  
 
RXFP-3 was again localised in the interstitium in fibrotic kidney.  The staining 
is comparable to α-SMA which appears to have an increased expression in 
fibrotic kidney.  The increase in expression may be due to the increase in the 
number of fibroblasts which become activated in fibrosis, causing an increase in 
proliferation and therefore ECM deposition.  α-SMA was also localised in the 
glomerli, which could be the mesangial cells which are the equivalent to stellate 
cells in the liver.  Mesangial cells can also become activated in fibrosis to a 
myofibroblast-like cell, which is then positively stained by α-SMA (Sterzel et 
al., 1993).  
 
 
 
Figure 6.7. RXFP-3 localisation in fibrotic kidney serial sections, assessed by 
immunohistochemistry (a) α–SMA (1/40,000) staining of fibrotic kidney, arrows                                                                Chapter 6: Localisation of RXFP 1-4 in the kidney 
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indicate positive staining of interstitial fibroblasts which become activated in fibrosis 
(b) RXFP-3 (1/400) staining of fibrotic kidney, arrows indicate areas of positive 
staining which are comparable to α–SMA staining of activated interstitial fibroblasts (c) 
expanded image of RXFP-3 staining.  Images were taken with a Zeiss 10 x objective 
using Zeiss Axioskop software (n=3 for both antibodies in the same patient). 
 
6.3.6 RXFP-4 localisation in normal kidney 
 
RXFP-4 was localised in the distal tubules in normal kidney.  The staining was 
strongly and specifically positive in the distal tubules, which is confirmed by a 
pathologist and by comparing the expression to a distal tubule marker (EMA).  
The localisation did not change in fibrotic kidney.   
 
 
 
Figure 6.8. RXFP-4 localisation in normal kidney assessed by immunohistochemistry 
(a) rabbit isotype control (b) RXFP-4 (1/50) staining of normal kidney at 20 x objective.  
The arrows indicate RXFP-4 is localised in the distal tubules (c) expanded image of 
RXFP-4 staining (40 x objective) (d) EMA (1/300) staining of normal kidney at 20 x                                                                Chapter 6: Localisation of RXFP 1-4 in the kidney 
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objective, which is localised in the distal tubules.   Images were taken using Zeiss 
Axioskop software (n=4 for both antibodies in different patients). 
 
6.4 Summary of key findings 
 
•  RXFP-1 is localised in the podocytes of both normal and fibrotic kidney 
but is also localised in the distal tubules of fibrotic kidney. 
•  RXFP-2 is localised in the proximal tubules in both normal and fibrotic 
kidney. 
•  RXFP-3 localised to the interstitial fibroblasts in both normal and fibrotic 
kidney. The staining is more apparent in fibrotic kidney, which has 
activated fibroblasts in the interstitium. 
•  RXFP-4 is localised in the distal tubules of both normal and fibrotic 
kidney. 
 
6.5 Discussion 
 
Relaxin receptor localisation has been mapped in normal and fibrotic kidney 
using immunohistochemistry.  The most definitive findings were that RXFP-1 
localised in podocytes and RXFP-3 localisated in the interstitial fibroblasts.  
Podocytes are an important component of the glomerular filtration barrier and 
are therefore important in maintaining glomerular filtration rate (GFR).  H2-
relaxin the ligand for RXFP-1 has vasorelaxant properties.  I have found these 
properties can regulate cellular contraction in HSC and therefore a possible role 
for RXFP-1 in the podocyte, may be the regulation of cellular contraction.  This 
could alter the filtration rate through the glomerular basement membrane.  I have 
also found H2-relaxin, through the activation of RXFP-1 can up regulate HSC 
apoptosis, therefore decreasing cell viability of activated myofibroblasts.  In 
some diseases podocytes can begin to proliferate unchecked which causes the 
breakdown of the basement membrane and therefore modifies the GFR, causing 
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RXFP-1 may regulate the proliferation of podocytes, helping to regulate GFR 
and maintain homeostasis in the kidney.  It would be interesting to examine 
relaxin receptor expression patterns in specific diseases that are known to 
display glomerular cellular changes such as minimal change disease (MCD), a 
disease that affects podocytes directly, focal segmental glomerular sclerosis 
(FSGS) and membranous glomerular nephritis (MGN) (Mathieson, 2007;Saha 
and Singh, 2006;Daskalakis and Winn, 2006;Cattran, 2003).  RXFP-1 was also 
found in the distal tubules in fibrotic kidney, H2-relaxin may have a role in 
regulating fibrosis in the kidney through the activation of RXFP-1 (Samuel et 
al., 2005; Sherwood., 2004) and therefore up regulation of the receptor in 
fibrosis is an interesting finding that should be investigated further as it suggests 
that treatment with H2-relaxin could have potential as a therapeutic in the 
kidney.  
 
RXFP-3 localisation in the interstitial fibroblasts suggests H3-relaxin may have 
a role in regulating fibrosis in the kidney.  The role of H3-relaxin in fibrosis is 
undocumented and therefore we do not know if it will have a pro or anti-fibrotic 
effect.  The receptor is negatively coupled to cAMP and therefore could have an 
opposing role to RXFP-1.  An investigation into the phenotype of interstitial 
fibroblasts in culture after treatment with H3-relaxin could help to elucidate the 
role of RXFP-3 in kidney fibrosis.  RXFP-2 is localised in the proximal tubules 
and RXFP-4 is localised in the distal tubules, which could suggest a role for 
these receptors in regulating filtration in the nephron but to fully elucidate the 
function of these receptors in the kidney further work needs to be carried out.  
Primary cultures of tubule epithelial cells could be examined in their responses 
to H2-relaxin, INSL3 (RXFP-2 ligand) and INSL5 (RXFP-4 ligand).  The 
localisation of relaxin ligands could also be investigated to determine if the 
activation of the receptors is through autocrine, paracrine or endocrine sources.     
  
Chapter 7 
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7.1 Final Discussion 
 
This study has shown that relaxin could have a role in the regulation of fibrotic 
liver disease in humans (figure 7.1).  RXFP-1, 3 and 4 are expressed and 
functional in primary human HSC.  RXFP-1 expression was confirmed using 
immunocytochemistry and the receptor was found to be expressed in activated 
primary HSC at the membrane.  RXFP-2 gene expression is only detected in late 
passage HSC and the expression was very weak.  Late passage HSC may have 
changed their phenotype significantly compared to freshly isolated cells.  RXFP-
1 and RXFP-2 have previously been shown to be expressed by rat HSC (Bennett 
et al., 2007) but the expression of RXFP-3 and RXFP-4 has not been reported in 
human HSC.  The presence of functional receptors was established using cAMP 
assays and the EC50 values each relaxin ligand was determined.  The 
concentration of H2-relaxin used in the functional experiments did not cross 
react with the other relaxin receptors present in HSC.  RXFP-3 and RXFP-4 are 
negatively coupled to cAMP, unlike RXFP-1 and may have opposing effects 
when activated.  RXFP-1 expression is up regulated in activated HSC, 
expression was assessed at different passage after extraction.  The activation of 
the cells was evaluated by α-SMA protein expression.  RXFP-1 gene expression 
correlated with the increase in α-SMA protein expression.  RXFP-1 gene 
expression was also up regulated in CCl4 injured rat liver (appendix 1).  
Expression of RXFP-1 decreases when HSCs are cultured on a basement 
membrane like substrate (Matrigel).  Culture on Matrigel deactivated primary 
HSC, which was assessed by expression of fibrotic markers such α-SMA and 
TIMP-1.  Deactivation of HSC cultured on Matrigel had been shown in a 
previous study (Gaca et al., 2003).  This suggests that relaxin receptor 
expression increases in the injured liver when HSC become activated but 
expression remains undetectable in quiescent HSC.  RXFP-1 was localised to 
areas of scarring in human liver sections, suggesting protein expression is also 
up regulated in activated HSC in vivo.  Up regulation of RXFP-1 suggests a role 
for H2-relaxin in the regulation activated HSC.  Activation of HSC is required                                                                                                    Chapter 7: Final Discussion 
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for the reversal of injury in the liver, this injury may be acute or sustained.  
Acute injury is common and only when the injury is sustained does the response 
become fibrotic.  Therefore activated HSC require a signal, after activation in 
acute or sustained injury, to either revert back to quiescent cells or undergo 
apoptosis (Iredale et al., 1998).  Activation of the RXFP-1 receptor through 
stimulation with H2-relaxin in activated HSC initiated a change to a less fibrotic 
phenotype in HSC.  HSC express high amounts of TIMP-1, collagen-1 and α-
SMA when cultured on plastic.  Treating HSC with H2-relaxin for 72 hours 
caused a decrease in TIMP-1, collagen-1, α-SMA, TGF-β and CTGF, therefore 
reducing the fibrotic phenotype whilst also increasing the expression of MMP-1 
and MMP-2.  MMP-1 is the main interstitial collagenase and the increase in 
MMP-1 will facilitate the breakdown of collagen-1, the main fibril forming 
collagen in the fibrotic liver.  MMP-9 was found to be up-regulated in the 
cytokine array analysis, although MMP-3 and MMP-13 were unchanged.  MMP-
2 and MMP-9 can have pro and anti-fibrotic roles depending on the level of 
expression and time of expression during the progression of liver fibrosis.  
Induction of MMPs by relaxin has been reported by many groups.  Induction of 
MMP-1, MMP-2, MMP-3, MMP-9, MMP-12 and MMP-13 have been reported 
in various cell and animal models (Garber et al., 2001;Lekgabe et al., 
2005;Williams et al., 2001;Mookerjee et al., 2005a).  Cytokine array analysis 
identified many gene regulated by H2-relaxin in primary HSC.  The changes in 
cytokine secretion were not significant in this assay but pro-apoptotic genes such 
as Fas Ligand and NT-4 were up regulated whilst pro-fibrotic cytokines such as 
TGF-β1, FGF and PDGF and various pro-inflammatory cytokines such as IL-1α, 
IL-2, IL-4, IL-6 and IL-13 were down regulated.  Cytokine array analysis 
identified H2-relaxin as an inhibitor of TGF-β1 secretion.  The mechanism of 
inhibition was not investigated although the production of active TGF-β1 was 
inhibited to a greater extent then total TGF-β1 production assessed by ELISA 
assay (the difference was not significant).  Therefore H2-relaxin may inhibit the 
processing of TGF-β1 as well as significantly down regulating gene expression.  
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increase the level of PARP-1 cleavage after 72 hours.  This suggests the 
proliferation of HSC decreases in the presence of H2-relaxin and the cells begin 
to undergo apoptosis as PARP-1 cleavage by caspase 3 is an early marker of 
apoptosis.   A reduction in the number of activated HSC producing collagen will 
over time decrease the amount of overall collagen-1/ liver weight in vivo 
(Williams et al., 2001).  H2-relaxin through the activation of RXFP-1 may be an 
important regulator of HSC, driving the cells into a more quiescent phenotype.  
The senescence or reversion to quiescence of activated HSC has recently been 
documented as an important regulator of fibrosis, limiting the fibrogenic 
response to acute injury, as well as the apoptosis of HSC (Iredale et al., 
1998;Krizhanovsky et al., 2008). H2-relaxin also reduces the expression of 
TIMP-1 and TGF-β both pro-survival factors (Murphy et al., 2002;Gressner and 
Bachem, 1990), and eventually initiates apoptosis.   
 
The presence of relaxin receptors in activated HSC suggests a role in limiting the 
proliferation and fibrotic potential of these cells but we have also found the cells 
decrease their contractility in the presence of H2-relaxin.  This is a novel finding 
that suggests a possible role for H2-relaxin in the treatment of portal 
hypertension which can be exacerbated by the contraction of HSC around the 
portal blood supply in the cirrhotic liver.  It has been previously suggested that 
relaxin has vasoactive properties and these properties are controlled by the 
induction of nitric oxide.  It has been proposed that relaxin can induce nitric 
oxide through several mechanisms (Nistri and Bani et al., 2003; Sherwood., 
2004).  In this study the inhibition of contraction of HSC was measured using a 
collagen-1 gel contraction assay.  Relaxin was found to inhibit the contraction of 
HSC significantly after 72 hours.  The level of nitric oxide was also determined 
and it was found that nitric oxide levels were increased after relaxin 
administration.  The inhibition of contraction may be due to several actions of 
relaxin, the decrease in α-SMA levels, the increase in MMP levels, the increase 
in nitric oxide levels, the inhibition of intracellular free calcium or a combination 
of all of these.  The decrease in α-SMA in the presence of H2-relaxin may affect                                                                                                    Chapter 7: Final Discussion 
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contraction in HSC.  Actin fibres are important in cell contraction and inhibition 
of α-SMA expression has previously been reported to reduce cellular contraction 
in myofibroblasts (Hinz et al., 2002).  As previously reported the down 
regulation of TGF-β may also contribute to the decrease in α-SMA induced 
contraction in H2-relaxin treated HSC (Meyer-ter-Vehn et al., 2008).  In the late 
1990’s MMP-2 was found to increase the cleavage of big ET-1, producing ET1-
32, a novel ET-1 agonist.  ET1-32 was found to have activity at both ETA and ETB 
receptors (Fernandez-Patron et al., 1999).  The increase in MMP-2 by H2-
relaxin in HSC may increase the production of ET1-32, this coupled with the 
down regulation of ETA receptors by H2-relaxin may increase the production of 
nitric oxide through ET1-32 activation of the ETB receptor.  The increase in MMP 
expression may also affect the collagen-1 gel that it used to measure HSC 
contraction.  An increase in MMP secretion can enhance the breakdown of 
collagen and therefore reduce the area of the gel.  An inhibitor of nitric oxide, L-
NAME, was used in the gel contraction assay but there was not enough time to 
optimise the concentration.  No contraction was seen in L-NAME treated HSC 
in either in H2-relaxin treated or controls.  The concentration of inhibitor may 
have been too high and has subsequently killed the cells.  The ability of relaxin 
to inhibit intracellular free calcium levels was not investigated but may have a 
significant role to play in the action of H2-relaxin in regulating HSC 
contractility. 
 
Many of the phenotypic changes observed in H2-relaxin treated HSC, including 
the increase in cAMP, were found to be dependent upon the expression and 
activation of RXFP-1.  A significant reduction in RXFP-1 gene expression by 
over 70% in primary HSC using siRNA, reversed the antifibrotic effects of H2-
relaxin on HSC gene expression profile.  Significant increases in TGF-β, TIMP-
1, α-SMA, CTGF and procollagen-1 and a significant decrease in MMP-1 were 
observed in the presence of H2-relaxin in cells with reduced RXFP-1 expression, 
when compared to cells with a normal level of RXFP-1 in the presence of H2-
relaxin.  The expression of MMP-2 was significantly increased by 2-fold in                                                                                                    Chapter 7: Final Discussion 
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RXFP-1 siRNA transfected HSC, which is similar to the change in expression 
for H2-relaxin treated non-transfected cells.  This result suggests the increase in 
MMP-2 by H2-relaxin is not through the activation of RXFP-1 but through an 
independent mechanism.  It has been suggested that H2-relaxin can influence 
gene expression by activating glucocorticoid receptors (GR).  To signal through 
GR, H2-relaxin must cross the cell membrane and activate GR at the nuclear 
membrane (Dschietzig et al., 2004;Bathgate et al., 2005).  Investigations into the 
mechanisms of MMP-2 up regulation by H2-relaxin would further the 
understanding in H2-relaxin signalling.  H2-relaxin inhibition of HSC 
contractility is also dependent upon RXFP-1 expression.  The increase in nitric 
oxide released from H2-relaxin treated HSC was completely reversed in RXFP-1 
siRNA transfected HSC.  There was a significant 20% decrease in nitric oxide 
compared to non-transfected cells in the presence of H2-relaxin.  This result 
suggests H2-relaxin signals through RXFP-1 mechanisms to increase nitric 
oxide in the cells.  Activation of G protein Gs will not only increase cAMP, but 
can also increase the phosphorylation of AKT though PI3-kinase, both pathways 
have been suggested as possible mechanisms in H2-relaxin induction of nitric 
oxide (Nistri and Bani., 2003).  Therefore HSC contractility may be dependent 
upon the expression of α-SMA and TGF-β as well as the regulation of nitric 
oxide secretion.  Relaxin has a direct role in maintaining blood volume and 
circulation in the kidney (Sherwood., 2004) and I hypothesise from the findings 
in this thesis and from others that relaxin could also play an important role in 
circulation through the liver at the sinusoidal level (Bani et al., 2001), which is 
particularly important in the fibrotic liver. 
   
H2-relaxin and RXFP-1 knockout mice demonstrate age related fibrosis of the 
kidney (Samuel et al., 2005b;Samuel et al., 2005a).  The relaxin receptor 
localisation in normal and fibrotic kidney has now been established.  An 
interesting pattern of expression was found, including RXFP-1 in the podocytes 
and RXFP-3 in the interstitial fibroblasts, which has implications for relaxin to 
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relaxin is a vasoactive hormone that is thought to regulate blood pressure during 
pregnancy through regulation of blood volume in the kidneys (Sherwood., 
2004).  Therefore expression of RXFP-1 in the podocytes indicates a role for 
regulation of GFR at the site of the epithelial glomerular basement membrane.   
The mechanism of GFR regulation could be through the regulation of podocyte 
contraction and/or proliferation.   
 
7.2 Limitations 
 
The limitation of the gel contraction assay is that it is not a direct measurement 
of cellular contraction and other factors such friction and adhesion of the gel to 
the culture vessel can result in incomplete contraction and distorted shaped gels 
(Vernon and Gooden, 2002).  An assay designed to either directly measure HSC 
contraction or reduce the friction and adhesion of the gel would help confirm the 
results observed in the collagen-1 gel contraction assays.  One group has 
monitored individual cell contraction using photomicrographs at different time 
points after addition of vasoactive compounds (Pang et al., 1993).  This method 
would reduce the uncertainty of using an indirect measurement when using a 
compound such as H2-relaxin over a relatively long time period as it may alter 
the behaviour of the collagen-1 gel.  The problem with using this method is that 
it requires more sophisticated equipment and therefore may not be possible to 
carry out in many labs.  An alternative method which would reduce the friction 
of the gel in the culture vessel is an oil supported collagen retraction (OSCR) 
assay (Vernon and Gooden et al., 2002).   This method still utilises collgen-1 
lattices but in a low friction environment.  The usual method of measurement for 
gel contraction assays is to measure the diameter of the gel and then calculate 
the gel area from this measurement.  At the beginning of the study this method 
was used.  It quickly became apparent that distorted gel shapes made 
measurement of contraction difficult to quantify and therefore pictures were 
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gel rather then calculating the area from the diameter.  This method improved 
the reproducibility of the results.    
      
7.3 Suggestions for future Work 
 
To continue this work the mechanism of HSC relaxation by H2-relaxin should 
be fully elucidated through the use of nitric oxide inhibitors, signalling 
mechanism inhibitors/inducers and intracellular calcium modifying agents.  
Chemical agents such as L-NAME, a nitric oxide inhibitor, could show that 
actions of H2-relaxin regulating cellular contraction are nitric oxide dependent.  
In this study we have shown that many of the actions of H2-relaxin in HSC are 
through the activation of RXFP-1 and therefore studying the down stream 
pathways of this receptor will help understanding of the mechanisms of action in 
these cells.  Previous groups have shown that the increase in cAMP in response 
to H2-relaxin is biphasic and is linked initially to the Gs-adenylate cyclase 
pathway and the delayed response switches to a Gi linked PI3-kinase pathway 
(Bathgate et al., 2005;Halls et al., 2006).  Possible downstream molecules 
include PKC, PKA, Erk 1/2 and transcription factors such as NF-κB (Bathgate et 
al., 2005).  Inhibitors of PI3-kinase such as LY294002 and wortmannin have 
been shown to inhibit the second phase of response to H2-relaxin (Halls et al., 
2006).  These inhibitors could be used alongside PKC, PKA (PKA inhibitor 5-24 
(calbiochem)) and Gi (pertussis toxin (PTX)) inhibitors to determine the 
pathways responsible for the phenotypic changes observed in HSC.  Several 
PKC inhibitors are available that are designed to target specific isoforms such as 
PKCζ pseudosubstrate inhibitor myristoylated (calbiochem) or non-selective 
potent inhibitors such as protein kinase C inhibitor peptide 19-36 (calbiochem) 
can be used.  H2-relaxin PKCζ activation and translocation to the membrane has 
been reported in a number of cell lines (Dessauer and Nguyen, 2005), therefore 
specifically targeting isoforms of PKC may identify the signalling pathway in 
HSC.  Phosphoylation of proteins such as Erk1/2, AKT and JNK could be used 
determine the pathways that are activated by H2-relaxin and also to establish if                                                                                                    Chapter 7: Final Discussion 
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the inhibitors used are targeting the correct pathways.  H2-relaxin activation of 
NF-κB can be studied through the electromobility shift assays (Takahra et al., 
2004), and an inhibitor such as BAY 11-7082 (calbiochem) can confirm if NF-
κB activation is essential for the phenotypic changes observed.  Agents that 
target a potential relaxin pathway that regulates the intracellular calcium 
concentration such as an intracellular calcium chelator BAPTA-AM or 
calcium/calmodulin kinase II inhibitor KN62, could also be used to study the 
effect on cellular contraction in the presence of H2-relaxin.  A CCl4 rat model 
has already been used to study the effects of relaxin in vivo (Williams et al., 
2001) but relaxin knockout mice have not been used to study liver fibrosis.  H1-
relaxin (the equivalent to H2-relaxin in humans) knockout animals could be 
given CCl4 induced liver injury.  The initial observation could establish if relaxin 
knockout mice develop liver fibrosis at an earlier stage or if the grade of fibrosis 
is more severe.  A fibrosis recovery model could be set up to look at recovery 
rate after acute or sustained CCl4 injury in the knockout model to determine if 
relaxin knockout animals recover more slowly from injury and finally the re-
administration of relaxin to mice with fibrosis to establish if relaxin can hasten 
recovery.           
 
Due to the vasorelaxant properties of H2-relaxin and our findings that H2-
relaxin reduces the contraction of HSC, a model of portal hypertension could be 
set up using normal and relaxin knockout mice.  There are several different 
models of portal hypertension, including portal vein ligation, bile duct ligation 
induced cirrhosis and CCl4 induced cirrhosis (Geerts et al., 2008;Abraldes et al., 
2006).  Portal vein ligation induces portal hypertension independently from 
cirrhosis whereas the other models rely upon the development of cirrhosis to 
induce portal hypertension (Geerts et al., 2008;Abraldes et al., 2006).  H1-
relaxin knockout mice could be used in the portal vein ligation model to 
independently study the effects of relaxin on portal hypertension but a model 
that studies portal hypertension as a result of CCl4 induced cirrhosis may be 
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portal hypertension in humans.  Therefore if H1-relaxin knockout mice were 
given sustained CCl4 injury to induce cirrhosis, the development of portal 
hypertension could be monitored using hemodynamic studies comparing relaxin 
knockouts to controls.  H1-relaxin knockouts could then be treated with H2-
relaxin to monitor the effect on portal hypertension.  Studies carried out on mice 
would be advantageous due to the amount H2-relaxin required to reach dosing 
concentrations would be reduced compared to studies in rats, and the H1-relaxin 
knockout mouse could be used.       
 
The kidney is a complex structure with many different cell types, the localisation 
of the relaxin receptors in the kidney has highlighted possible roles for relaxin in 
normal and fibrotic kidney.  An in depth study utilising podocytes and interstitial 
fibroblasts to elucidate the phenotype in the presence of relaxin would contribute 
to the understanding of the role of relaxin in the kidney. 
 
             7.4 Final comments 
 
The recognition of H2-relaxin as a regulator of HSC activation and contractility 
has contributed to the understanding of relaxin as a regulator of fibrosis in the 
liver.  RXFP-1 has been identified as a marker of HSC activation.  A schematic 
representation of the findings has been constructed (figure 7.1).  The finding that 
HSC contractility can be regulated by H2-relaxin has uncovered a new area of 
interest in relaxin as a potential therapy for portal hypertension.  Additional 
studies using animal models will help to reveal the potential role for H2-relaxin 
as an antifibrotic therapy and possibly in the treatment of portal hypertension.  
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Figure 7.1. Schematic representation of the findings in this thesis.  H2-relaxin drives 
HSC into a less fibrotic phenotype and after time a certain proportion will be driven into 
apoptosis. 
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Appendix 1 - Supporting data 
 
In vivo model of liver injury in rats  
 
Liver injury is induced using CCl4 as described previously (Iredale et al., 1998).  
Cohorts of 12 Sprague Dawley rats were given CCl4 injury for 4 weeks to 
generate an early reversible fibrosis and another cohort of 12 were given injury 
for 12 weeks to be given advanced micronodular cirrhosis, which undergoes 
only partial resolution over one year of follow up.  Three rats were sacrificed at 
4 weeks and 12 weeks from the cohorts and three rats were in each group of 
follow up time points showing resolution in the rats given only 4 weeks fibrosis.  
The control rats were injected with olive oil twice a week.  The rats were 
sacrificed and the liver was dissected.  The whole liver from each rat was used 
for protein and RNA extraction.  The RNA was then used to look at the mRNA 
expression of the RXFP-1 comparing whole liver from rats of the same age and 
species that were not given injury and at two different time points of injury (4 
and 12 weeks).   
 
RXFP-1 expression in CCl4 model of liver injury 
 
RXFP-1 mRNA expression was induced during CCl4 rat liver injury in a whole 
liver extraction.  A 4000-fold induction of RXFP-1 occurred after four weeks of 
injury compared to normal controls.  4 weeks CCl4 induces mild fibrosis.  The 
fold induction is so high due to the very low expression of RXFP-1 in normal rat 
liver.  The peak induction of RXFP-1 to 5000-fold above controls was observed 
in the animals with twelve weeks CCl4 injury, which have peak fibrosis and non 
reversible cirrhosis in some cases (figure 1.) 
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Figure 1. (A) Expression of RXFP-1 in CCL4 injured rat whole liver, assessed by RT-
PCR and normalised to GAPDH. (B) Fold change in RXFP-1 expression in normal 
whole rat liver compared to four weeks fibrosis and twelve weeks cirrhotic liver injury.  
RXFP-1 expression is induced after 4 and 12 weeks CCL4 injury.  A significant up 
regulation of RXFP-1 coincides with peak induction of injury after 12 weeks (p<0.01).   
     
 
Li90 cells as a model of human fibrotic liver disease 
 
Li90 cells are a tumourgenic hepatic stellate cell line (Murakami et al., 1995).  
They have not been immortalised but their lifespan in culture is up to twenty five 
passages.  They have been isolated from the liver near a region of hepatocellular 
carcinoma and therefore these cells resist apoptosis and have longer life-span 
then primary cells isolated from normal areas of the liver (Murakami et al., 
1995).  Li90 cells appear very similar in morphology to primary hepatic stellate 
cells when cultured on plastic until later passage when a change in morphology 
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was observed, proliferation decreased and it was decided Li90 cells were not the 
best model to continue the studies.  
 
It was decided that hHSC and LX-2 cells would be used for the rest of the 
experiments.  LX-2 cells are a readily available HSC cell line which maintain 
their phenotype after many passages and are therefore useful for optimising 
assays and primary human HSC are still the gold standard for in vitro studies of 
human liver fibrosis.    
 
H2-Relaxin treatment of Li90 cells 
 
The treatment of Li90 cells (passage 15) with a dose response for H2-relaxin for 
72 hours caused a dose dependent reduction in TIMP-1 and an increase in MMP-
2 expression.  The most significant reduction in TIMP-1 was after 1 nM 
treatment which reduced the expression by over 30%.  MMP-2 expression was 
increased by nearly 2-fold at the lowest dose of 0.1 nM H2-relaxin.  The greatest 
increase was observed after 72 hours 1 nM H2-relaxin, higher doses did not 
augment this effect.  The overall effect is a shift in the fibrotic balance to a more 
collagen degrading phenotype.   
 
 
Figure 2.  (A) Expression of TIMP-1 in Li90 cells that have been treated with a dose 
response for H2-relaxin for 72 hours, assessed by RT-PCR (n=1).  TIMP-1 expression is                                                                                                  Appendix 1: Supporting data 
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reduced, in a dose dependent manner, by over 30% after 72 hours 1 μM H2-relaxin 
treatment. (B) Expression of MMP-2 in Li90 cells that have been treated with a dose 
response for H2-relaxin for 72 hours, assessed by RT-PCR (n=1). MMP-2 expression 
increases in all of the treatment groups and dose not appear to be dose dependent.  The 
greatest increase was after 72 hours 1 nM H2-relaxin treatment which induced a 2-fold 
increase in expression.   
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Appendix 2 - Buffers and reaction components 
 
Western Buffers 
 
Western running Buffer 
20x NuPAGE SDS Running Buffer MOPS (Invitrogen) was diluted to prepare 
1x NuPAGE SDS Running Buffer.  50 ml NuPAGE SDS Running Buffer 20x 
MOPS was added to 950 ml of Ultra-pure Water making a total volume of 1000 
ml.  600 ml of the 1x NuPAGE SDS Running Buffer was needed in the outer 
buffer chamber.  Immediately prior to loading the samples, 500 µl of the 
NuPAGE Antioxidant (Invitrogen) was added to the remaining 200 ml of the 1x 
NuPAGE SDS Running Buffer and mixed thoroughly.  This was for use in the 
inner running chamber.  
 
Western Transfer Buffer 
1 litre of 1x NuPAGE Transfer Buffers was prepared as follows: 
 
Contents  Amount 
Ultrapure Water 
20X NuPAGE Transfer Buffer 
NuPAGE Antioxidant 
Methanol 
749 ml 
50 ml 
1 ml 
200 ml 
 
Table 9. Contents of western transfer buffer (because there was transfer of two gels 
within a blot unit, the methanol content was 20% (200 ml) to ensure even and efficient 
transfer of both gels; it was reduced to 10% if only one gel was transferred). 
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Immunohistochemistry/immunocytochemistry buffers 
 
Tris buffered Saline 
Sodium chloride (sigma)  80 grams 
Tris                     6.05 grams 
1M hydrochloric acid (sigma)                      38 ml 
Distilled water                 10 Litres 
 
The buffer salts and acid were mixed in 1 litre of distilled water.  The pH was 
then adjusted to pH 7.65 and then the remaining 9 litres of water was added, 
which gave a final pH of 7.6. 
 
Endogenous peroxidise inhibitor-paraffin 
Methanol (romil)                 5.9 ml 
Hydrogen peroxide                 0.1 ml 
 
Blocking culture media (gibco) 
Dulbecco’s modified Eagles medium                80 ml 
Fetal calf serum                20 ml 
Bovine serum albumin              1 gram 
 
BSA was dissolved in the DMEM and FCS then aliquoted and stored at -20˚C 
until required. 
 
0.01M Citrate buffer formula 
Citric Acid crystals                      2.1grams 
Distilled water                            1000 ml 
 
Mixed and pH adjusted to pH 6.0 with 1M sodium hydroxide (approximately 25 
ml) 
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RT-PCR primer sequences 
 
RXFP-1- 317bp  
Sense: 5’-CAGCTTGTAGGATCTTTGGCC-3’ 
Antisense: 5’- GCGGCCAAATTAATACCAAG-3’ 
 
RXFP-2- 200bp  
Sense: 5’-AGATATTGGAAGCAAAGGGT-3’ 
Antisense: 5’-TGGCATCAGAGAACACTATA-3’ 
 
RXFP-3 - 288bp  
Sense: 5’-CGGAGACTGTCGAAGGTCAC-3’ 
Antisense: 5’-GCTGGTGATCGAAGGAGACG-3’ 
 
RXFP-4 - 356bp  
Sense: 5’-CCTTTGCCTGCTGCGTTTCC-3’ 
Antisense: 5’-GCACAGGGTTGAGGCAGCTA-3’  
 
Procollagen-1- 651bp 
Sense: 5’-AACATGACCAAAAACCAAAAG-3’ 
Antisense: 5’-CATTGTTTCCTGTGTCTTCTGG-3’ 
 
MMP-2 - 514 bp 
Sense: 5’-GCTGGCCCTGGCTCCCACAGG-3’ 
Antisense: 5’-ATACAAAGCAAACTGCTAATG-3’ 
 
MMP-1 -243 bp 
Sense: 5’-ATGCTGAAACCCTGAAGGTG-3’ 
Antisense: 5’-CTGCTTGACCCTCAGAGACC-3’ 
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TIMP-1 - 656 bp 
Sense: 5’-TGTTGTTGCTGTGGCTGATAG-3’ 
Antisense: 5’-CGGAAGAAAGATGGGTGTGGG-3’ 
  
H2-relaxin- 247bp 
Sense: 5’-CCTGGAGCAAAAGGTCTCTG-3’ 
Antisense: 5’-CTTCAGCTCCTGTGGCAAAT-3’ 
 
Endothelin-1 receptor A- 233bp 
Sense: 5’-TATCCTGGCCATTCCTGAAG-3’ 
      Antisense: 5’-TTCTCAAGCTGCCATTCCTT-3’  
 
Endothelin-1 receptor B- 231bp 
Sense: 5’-TCCCGTTCAGAAGACAGCTT-3’ 
Antisense: 5’-CAGAGGCAAAGACAAGGAC-3’ 
 
GAPDH-240bp 
Sense: 5’-GGAGTCAACGGATTTGGTCGTA-3’ 
Antisense: 5’-CTTGATTTTGGAGGGATCTCGC-3’ 
 
β-actin- 674bp 
Sense: 5’-ACCAGGGCGTGATGGTGGGCATGGGTCAGAA-3’ 
Antisense: 5’-TCCATAGGCTGGAAGAGTGCCTCAG-3’ 
 
qRT-PCR primer sequences 
 
RXFP-1- 99bp 
Sense: 5’-GCTGTATGCCATGTCAATCATT-3’ 
Antisense: 5’-TCTCCACGAAACTTTAGGTCAA-3’ 
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TIMP-1- 81bp 
Sense: 5’-GCAATTCCGACCTCGTCATC-3’ 
Antisense: 5’-TCTTGATCTCATAACGCTGGTATAA-3’ 
 
MMP-1- 127bp 
Sense: 5’-GCACTGAGAAAGAAGACAAAGG-3’ 
Antisense: 5’-CTAAGTCCACATCTTGCTCTTG-3’ 
 
TGF-β1- 83bp 
Sense: 5’-CACTCCCACTCCCTCTCTC-3’ 
Antisense: 5’-GTCCCCTGTGCCTTGATG-3’ 
 
α-SMA- 76bp 
Sense: 5’-AAGCACAGAGCAAAAGAGGAAT-3’ 
Antisense: 5’-ATGTCGTCCCAGTTGGTGAT-3’ 
  
MMP-2- 90bp 
Sense: 5’-CATACAGGATCATTGGCTACAC 
Antisense: 5’-TCACATCGCTCCAGACTTG 
 
Procollagen-1- 130bp 
Sense: 5’-AGACAGTGATTGAATACAAAACCA-3’ 
Antisense: 5’-GGAGTTTACAGGAAGCAGACA-3’ 
 
CTGF- 113bp 
Sense: 5’-CCCAGACCCAACTATGATTAGAG-3’ 
Antisense: 5’-AGGCGTTGTCATTGGTAACC-3’ 
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Short interfering RNA (siRNA) sequences 
 
RXFP-1 siRNA (1) 
Sense: 5’-GCCUAGAAGGGAUUGAAAUtt-3’ 
Antisense: 5’-AUUCAAUCCCUUCUAGGCtg-3’ 
 
RXFP-1 siRNA (2) 
Sense: 5’-GGAUGUUUAGACCUCUUAUtt-3’ 
Antisense: 5’-AUAAGAGGUCUAAACAUCCtt-3’ 
 
RXFP-1 siRNA (3) 
Sense: 5’CCACAAGACCAUUUAAAGAtt-3’ 
Antisense: 5’-UCUUUAAAUGGUCUUGUGGtc-3’ 
 
-ve control scrambled 
Sense: 5’-AAGCAUGGAUGCUGAAGUAtt-3’ 
Antisense: 5’-UACUUCAGCAUCCAUGCUUtg-3’ 
 
Ambion predesigned –ve control #1 
Commercial product no sequence available 
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